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ABSTRACT
Role of Nitric Oxide and Reactive Oxygen Species in Apoptotic,
Inflammatory and Migratory Signaling Pathways in Cancer
Siera Jo Talbott

Cancer represents over 200 different diseases of different cell and tissue
type origins. The heterogeneity of tumors presents challenges in finding effective
treatments for the different diseases. Therefore, understanding the molecular
events that promote tumorgenesis can assist in the development of better
targeted treatments and therapies. Reduction/oxidation (redox) biology has
become increasingly important as high levels of nitric oxide (NO) and reactive
oxygen species (ROS) are reported in both the development of cancer and in
response to treatment. In addition to their known potential biotoxic effects on
DNA, proteins and lipids, NO and ROS are recognized as secondary
messengers within the cell that mediate specific signaling events. The
microenvironment can additionally be a source of NO and ROS that promote
chronic inflammation and tumorigenesis. Additionally, tumor cells are reported to
function with higher levels of oxidative stress indicating the signaling effects of
NO and ROS are of even higher importance. We are primarily interested in how
NO and ROS can mediate signaling changes and participate in the advancement
of cancer.
Death receptors (DR) are transmembrane receptors that mediate cytokine
signaling via cognate ligands to determine the fate of the cell. DR signaling can
lead to cell survival and proinflammatory responses or apoptotic cell death. DR
ligands such as Tumor Necrosis Factor alpha (TNF-α) and Fas Ligand (FasL) are
abundant during infection and pathogenesis and are an important factor in both
tumorigenesis and cancer treatment. DR-mediated apoptotic resistance is a
major problem in effective cancer treatments and is usually marked by cancer
cells upregulating intracellular antiapoptotic proteins.
In the first study, we examine the effects of S-nitrosylation on antiapoptotic
protein FLICE Inhibitory Protein (FLIP) which is highly expressed in
chemotherapeutic-resistant tumors. We performed apoptosis assays using
fluorescence microscopy and report that FLIP antiapoptotic activity is dependent
on S-nitrosylation at cysteines 254 and 259. By using dual-luciferase reporter
assays we demonstrate that S-nitrosylated FLIP mediates potent
proinflammatory transcription factor Nuclear Factor kappa B (NF-κB). Receptor
Interacting Protein 1 (RIP1) and Tumor Necrosis Factor Receptor-associated
Factor 2 (TRAF2) are two essential adaptor proteins upstream of NF-κB
activation. Upon coimmunoprecipitation and confocal microscopy we were able
to determine FLIP interaction with RIP1 and not TRAF2 was dependent on Snitrosylation status and most likely mediates NF-κB activity. Additionally through

standard Western blotting, we show that FLIP processing and cleavage is
dependent on S-nitrosylation status. Taken together, our results indicate the Snitrosylation posttranslational modification of FLIP is a potent mediator of cell
fate. It can allow cancer cells apoptotic resistance while signaling for
inflammation and proliferation. This deleterious combination could promote
tumor survival selectivity in chemotherapeutic resistant cancers.
Cellular migration is a necessary component of invasion and metastasis in
cancer. Caveolin-1 (Cav-1) is the essential constituent of cholesterol enriched
lipid raft invaginations known as caveolae. Cav-1 is polarized in migratory cells
indicating a role in motility and it has been reported to affect migration. Cav-1
can act as a scaffolding protein and has been reported as both a tumor promoter
and suppressor determined mostly by protein binding partners.
In the second study, we examine the effects of different ROS species on
migration in non-small cell lung cancer (NSCLC) cells. By using wound healing
and Transwell assays we determined O2- and H2O2 have an inhibitory effect
whereas OH⋅ promotes NSCLC migration and invasion. Through Cav-1
knockdown and overexpression experiments we were able to determine the
ROS-mediated migration and invasion occurs in a Cav-1-dependent manner.
Furthermore, we show the inhibitory roles of O2- and H2O2 on Cav-1 expression
are mediated through the ubiquitin-proteosome pathway. Our laboratory and
others have shown Cav-1-mediated migration occurs through PI3K/Akt signaling.
Therefore, we confirmed the ROS-mediated Cav-1-dependent migration affected
Akt phosphorylation consistent with the known migratory process. This is the first
report linking OH⋅ and Cav-1-dependent migration and invasion.
In summary, these studies examine the effects of NO and ROS on
important signaling pathways in cancer progression. Specifically we show how
NO and ROS can selectively target apoptotic, proliferative and migratory
processes which could dramatically enhance tumorigenesis in vivo. With an
abundance of NO and ROS reported in the tumor and the supporting
microenvironment, this research further expands on the limited knowledge of
implications of redox biology in cancer signaling.
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Chapter 1. Literature Review

Cancer as a NO and ROS signaling disease

Cancer is a class of diseases that are characterized by normal cells
undergoing malignant transformation. These diseases are commonly lethal to
the carriers with vast differences in prognosis due to the immense disparity in
genetic profiles of the many types of cancer. Cancer development is often
described in three classically distinct categories: initiation, promotion and
progression. This classical view dissects the disease into pre-cancerous
hyperproliferative growth (initiation), cancerous development and growth
(promotion) and metastasis of tumor cells and advancement of disease
(progression). The development of each of these stages is the result of specific
changes in the normal cellular signaling profiles resulting in aberrant cellular
behavior. Overall, this aberrant behavior can be more specifically
subcategorized into six areas of protein signaling that were characterized by
Hanahan and Weinberg in 2000. These six categories have been widely
accepted throughout the molecular cancer biology field to describe the type of
changes a normal cell must make in order to undergo malignant transformation.
Study 1 in this dissertation addresses two of Hanahan and Weinberg’s
categories; the ability of cells to: circumvent cell death and promote cell growth
through examination of a potent anti-apoptotic protein in the Death Receptor
pathway. Study 2 in this dissertation addresses a third category: how cells gain
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motility and invade surrounding tissues via examination of how Reactive Oxygen
Species alter Caveolin-1-dependent migration. Overall, the events that prompt
tumorigenesis can be largely environmental including infection, toxin exposure,
radiation and other cellular stressors such as oxidative stress.
The reductive/oxidative (redox) balance in signaling function has become
increasingly important in the context of disease since the pathological
microenvironment and cellular homeostasis readily has imbalances. Changes in
the normal redox state of the cell can damage proteins, lipids and DNA.
Chemical species derived from oxygen (reactive oxygen species) and nitrogen
(reactive nitrogen species) are examples of molecules that can perturb the
cellular redox balance leading to oxidative and nitrosative stress. Reactive
oxygen species (ROS) and nitric oxide (NO) that are readily found throughout the
cell in low concentrations are vital for cellular processes. Several cellular
signaling pathways have been shown to be regulated by redox status (Kamata
and Hirata 1999; D'Autreaux and Toledano 2007; Hancock 2009); however at
high concentrations, both ROS and NO surpass threshold toxicity leading to cell
death and abnormality.

Reactive Oxygen Species
ROS are naturally found in the cell as a result of cellular metabolism and
respiration (Casteilla, Rigoulet et al. 2001). Superoxide anion (O2-) is a
byproduct of oxidative metabolism that is scavenged by the superoxide
dismutase (SOD) family to produce another ROS, hydrogen peroxide (H2O2), in
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both the mitochondria and cytosol. H2O2 can additionally participate in the
Fenton reaction resulting in the generation of one of the most cellular damaging
ROS, hydroxyl radical (OH⋅) (Goldstein, Meyerstein et al. 1993; Galaris, Skiada
et al. 2008). The mitochondria are the primary site for ROS generation and
therefore are equipped with many catabolizing enzymes (such as MnSOD) to
manage levels of ROS. Mitochondria are not the only source for ROS. NADH
oxidases, cyclooxygenase, xanthine oxidase, cytochrome P450s and
peroxisomes are also responsible for ROS production (Ignarro 2000; Salganik
2001).
When the generation of cellular ROS exceeds the capacities of
catabolizing enzymes and electron-donating antioxidants, they can damage
surrounding proteins, lipids and DNA by oxidation (Barbouti, Doulias et al. 2002;
Sallmyr, Fan et al. 2008). This damage can result in cell cycle arrest (Yang, Wu
et al.), apoptosis (Simon, Haj-Yehia et al. 2000) and the development of disease
(Lambeth 2007). Elevated levels of oxidation have long been reported in
numerous diseases including cardiovascular disease, neurodegenerative
disorders and cancer. NO and ROS are widely considered in terms of tissue and
cellular damage. They have recently been noted for their participation in specific
protein signaling within the cell. ROS can aid in growth factor, cytokine and
hormone signaling (Lambeth 2007) as well as in cellular processes of adhesion,
movement (Ushio-Fukai 2006), apoptosis (Wong, Iskandar et al.) and gene
transcription (Dhar, Young et al. 2002). Because ROS can promote genetic
instability through DNA oxidation and it is reported to be involved in multiple
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signaling pathways, it is not surprising that elevated levels of ROS are associated
with an increased risk in cancer development (Toyokuni 2004; Gius and Spitz
2006). Additionally, unrelenting cell growth can result in tumor development that
exceeds the capacity of existing vasculature resulting in nutrient and oxygen
shortages that put the cell under selective pressures. Hypoxic conditions alone
can lead to transcriptional changes and overall increases in ROS (Kim and
Chung 2007). Multiple contributing factors such as increased metabolic activity
and mitochondrial dysfunction (Carew and Huang 2002; Pelicano, Xu et al. 2006)
can all contribute to the overabundance of ROS seen in pathology (see figure 1).
The high level of ROS seen in cancer has been pursued as a mechanism
to specifically target tumor cells for cell death. Because cancer cells have
elevated levels of ROS they have a high dependence on ROS-eliminating
agents. Zhou et al. showed that 2-methoxyestradiol induces ROS-mediated
apoptosis in leukemia cells by inhibiting SOD (Zhou, Hileman et al. 2003).
Additionally, tumor cells are reported to have high innate ROS levels (Burdon
1995) making them vulnerable to toxic thresholds, therefore additional ROS
insults induced by exogenous agents can promote cell death in tumor cells. For
example, chemotherapeutic agent, bortezomib induces apoptosis via ROS
generation in NSCLC cells and is currently used in the treatment of multiple
myeloma (Ling, Liebes et al. 2003). One potential problem with these prooxidant treatments is the oversight of ROS effect on protein signaling at sublethal levels. Since it has been established that ROS can implement signaling
changes in targeted molecules these types of therapies could have ample
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unwanted effects. Additionally, due to the inherent oncogenic nature of ROS,
treatments that increase overall ROS levels should be proceeded with caution.
The alternative approach of antioxidant therapies for cancer has
demonstrated success in anticancer treatments. Anitoxidant treatments of
vitamin E and pyrrolidone dithiocarbamate in combination with
chemotherapeutics 5-fluorouracil and doxorubicin were shown to induce
apoptosis in colorectal cancer in vivo (Chinery, Brockman et al. 1997). Vitamin E
decreases proliferation in cervical, lung and ovarian carcinoma (Jha, Bedford et
al. 1999). Enhancement of ROS clearance also shows similar results. For
example, the overexpression of SOD inhibits cell growth in breast cancer
(Weydert, Waugh et al. 2006). Basal ROS levels are heterogenous among the
human population suggesting that although antioxidant therapy may be
advantageous for patients with a high level of ROS, it may be detrimental to
people with a low level of ROS by decreasing the activity of ROS-dependent
protective mechanisms (Salganik 2001). Production of ROS is essential for a
number of biochemical reactions and modulating cellular processes such as
antimicrobial phagocytosis and apoptosis (Johnson, Yu et al. 1996). H2O2 and
O2- are indicated to play a crucial role in mechanisms underlying proliferative
responses via transcription factors: c-fos, c-myc and NF-κB (Burdon 1995).
Additionally, antioxidant therapies have been reported to inhibit the specific
therapeutic activity of anticancer drugs in patients (Labriola and Livingston 1999).
Much of the evidence that antioxidant therapy can be anti-tumorigenic has been
done in the context of healthy individuals where ROS profiles are considerably
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lower than in cancer (Seifried, McDonald et al. 2003). A more detailed
understanding of how ROS modulates cancer protein signaling is necessary to
better assess whether pro- or antioxidant therapy is beneficial.

Figure 1. Multiple stimuli lead to the production of ROS and RNS which mediate
many redox-dependent signaling pathways. ROS/RNS have been noted to
induce MAPK activity and tyrosine kinases (i.e. src, Ras, PI3K) and inhibit
tyrosine phosphatases. They can also enhance transcription factor activity.
ROS can stimulate ion channels (i.e. plasma membrane Ca2+ and K+) leading to
overall changes in cation balance. Adapted from (Pelicano, Carney et al. 2004;
Aruoma, Grootveld et al. 2006).

Nitric Oxide
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NO is primarily produced intracellularly from L-arginine by a family of four
nitric oxide synthases (NOS) that are differentially expressed. Neuronal NOS
(nNOS or NOS1) is constitutively expressed and involved in cell communication.
Inducible NOS (iNOS or NOS2) can be induced by lipopolysaccharides (LPS),
cytokines, and other immunomodulatory compounds and its expression is
modulated by proinflammatory transcription factor nuclear factor kappa B (NFκB) and the mitogen-activated protein kinase (MAPK) pathway (Lowenstein and
Padalko 2004). It is the only family member that has calcium-independent
activity and is the most frequent isoform associated with tumorigenesis.
Endothelial NOS (eNOS or NOS3) is constitutively expressed in many cell types
and generates NO in blood vessels to regulate vascular function. eNOS
produces lower levels of NO than iNOS, however, it has been a suggested target
in cancer therapy due to its role in angiogenesis, mobility and invasiveness (Ying
and Hofseth 2007). Mitochondrial NOS (mtNOS) is thought to be a variant of
nNOS and contributes to redox-dependent signaling in the mitochondria
(Finocchietto, Franco et al. 2009).
NO is a highly diffusible pleiotropic molecule that is short lived and
therefore exhibits localized effects. The direct interaction of NO with a target
protein occurs via formation of a disulfide bond with a cysteine residue on the
target protein. Nitrosylation (or nitrosation) of a target protein can alter its
function and interactions; therefore it is a post-translational modification
regulating protein function. These effects can be either activating or inhibitory.
The knowledge of how many proteins are sensitive to NO signaling only became
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known after Jaffrey and Snyder developed the Biotin Switch Method in 2001
(Jaffrey and Snyder 2001). NO has already been reported to react with more
than a hundred proteins to form S-nitrosothiols (SNO) (Paige, Xu et al. 2008).

S-nitrosylation
The posttranslational modification, S-nitrosylation, is considered to be
selective and specific; although, the regulation of the SNO system is not yet well
understood. It has been proposed that proximity of iNOS to a target protein
regulates the ability for it to be nitrosylated (Bredt 2003). For example,
cyclooxygenase-2 has been shown to be S-nitrosylated after
coimmunoprecipitation with iNOS following inflammatory stimulation (Kim, Huri et
al. 2005). Alternatively, Mitchell et al. demonstrated thioredoxin transnitrosylates
caspase-3 through domain recognition; thereby regulating caspase activity
(Mitchell and Marletta 2005). This type of protein-protein interaction with SNO
could mimic the specificity of SH2 domains within the context of tyrosine
phosphorylation (Tannenbaum and White 2006). This is not the first time that
thioredoxin has been shown to have a role in SNO. Thioredoxin was first
reported to act as a protein disulphide reductase in plants (Schurmann and
Jacquot 2000). More recently, S-nitrosoglutathione reductase (GSNOR), an
enzyme ubiquitously expressed, has emerged as an important factor in
governing the S-nitrosylation of SNO proteins (Benhar, Forrester et al. 2009).
The increasing number of reports describing enzymes involved in oxidative

8

signaling further indicates the specificity and importance of NO in protein
signaling.
NO has been widely attributed to promote tumor formation and metastasis
(Fukumura, Kashiwagi et al. 2006). NO has been reported to interact with HIF1α to regulate metastasis, invasion and chemoresistance in human gastric and
breast cancer cells (Maccarrone and Brune 2009). Additionally, increases in
iNOS activity are definitively associated with tumorigenesis in many types of
cancer (Jenkins, Charles et al. 1995; Crowell, Steele et al. 2003) and numerous
selective inhibitors of iNOS show a reduction in tumor growth (Thomsen, Scott et
al. 1997). Elevated iNOS expression is reported in tumor cells (Siedlar, Mytar et
al. 1999; Takahashi, Kitahashi et al. 2008) and in the tumor microenvironment
(Hussain, He et al. 2008). The high levels of NO produced by iNOS are normally
used by macrophages for antimicrobial phagocytosis (Babior 1978; Nussler, Di
Silvio et al. 1992), however tumor-associated macrophages can be part of a
chronic inflammatory microenvironment that promotes tumor growth rather than
targeting the cells for death. In contrast, there have been some reports that high
levels of NO and iNOS overexpression suppress tumorigenesis (Harada,
Supriatno et al. 2004). However, Edwards et al. reported that NO inhibits cell
growth in vitro but stimulates tumorigenesis and metastasis in vivo (Edwards,
Cendan et al. 1996) potentially explaining the discrepancies between pro- and
anti-cancer effects. Additionally, in vitro experiments fail to incorporate any
paracrine effects from the stroma which contains cells that both express iNOS
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and are responsive to NO and inflammatory stimuli thereby representing a
different environment.

Reactive Nitrogen Species
RNS are a family of molecules that are generally derived from NO; for
example, O2- and NO react rapidly to form peroxynitrite (ONOO-) (Wiseman and
Halliwell 1996). Although RNS such as ONOO- and dinitrogen trioxide (N2O3)
are more commonly noted for toxicity they also demonstrate effects on specific
signaling pathways. Wu et al. demonstrated RNS treatment leads to JNKmediated non-apoptotic cell death (Wu, Zhang et al. 2008). Cells that are
recruited to sites of injury and infection secrete high levels of NO leading to an
overall increase in RNS (Patel, McAndrew et al. 1999). Like ROS, RNS have
also been shown to moderate growth factor, cytokine and environmental stress
signaling (Lander 1997; Suzuki, Forman et al. 1997).
During chronic inflammation, activated inflammatory cells release RNS
and ROS that can promote tumorigenesis in the initiated cell. The complexity of
ROS and NO effects on cellular fate lies both in the signaling potential as well as
the cumulative total dose and cell type (Kawanishi, Hiraku et al. 2006).
Therefore, understanding how ROS and RNS mediate changes in protein
signaling and which cellular pathways involved in cancer are affected is
increasingly important.
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Death Receptor Signaling – Apoptotic

Inflammation, proliferation and apoptosis are tightly regulated cellular
processes that are regulated in part by a family of transmembrane receptors
called Death Receptors (DR). There are at least eight members of the DR family
including: Fas, Tumor Necrosis Factor Receptor 1 (TNFR1), TNFR2, DR3, DR4
(also known as TRAIL-R1), and DR5 (also known as TRAIL-R2) (Lavrik, Golks et
al. 2005). DRs are members of the TNFR superfamily which includes CD40 and
lymphotoxin β receptors that are important in immune cell signaling. In addition
to the cysteine-rich extracellular domain found in all TNFR superfamily members,
DRs contain a homologous cytoplasmic sequence of 80 amino acids termed the
Death Domain (DD) (Tartaglia, Ayres et al. 1993). Signals are propagated by
extracellular trimeric cytokines (also known as DR ligands) that bind DRs and
initiate the formation of oligomeric signaling platforms such as a DISC (or Death
Inducing Signaling Complex) which can lead to apoptosis.
Apoptosis is a type of cell death that is required for development and
cellular homeostasis that is frequently dysregulated in disease. It was originally
characterized by Kerr et al. in 1972 when cells exhibited distinct and consistent
morphological changes preceding cell death. This process appeared necessary
for embryogenesis, development and cell turnover (Kerr, Wyllie et al. 1972).
Apoptosis can be signaled by two converging pathways: the extrinsic pathway
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and the intrinsic pathway. Both pathways are dependent on cysteine–aspartate
proteases called caspases (Li and Yuan 2008). The extrinsic pathway is a
ligand-mediated process that occurs through DRs such as Fas, resulting in the
activation of initiator caspases (i.e., procaspase-8, procasase-10) leading
ultimately to the activation of effector caspases (i.e., procaspase-3, procaspase7) and cell death. The intrinsic pathway (also known as the mitochondrial
pathway) is initiated inside the cell in response to DNA damage, hypoxia,
irradiation, abnormal cell cycle, changes in growth factors and other acute stress
signals. The initiation of the intrinsic pathway is contingent on the balance of proand anti-apoptotic proteins of the Bcl-2 family which maintain the integrity of the
mitochondrial membrane. Cytochrome c and Second Mitochondria-derived
Activator of Caspases (SMAC, also referred to as DIABLO) are maintained in the
mitochondrion. Following stimulation of the intrinsic pathway, proapoptotic Bcl-2
proteins, Bax or Bak can insert into the mitochondrial membrane initiating
Mitochondrial Outer Membrane Permeabilization (MOMP) (Chipuk, BouchierHayes et al. 2006). Proapoptotic proteins released from the mitochondrion
stimulate the formation of the apoptosome complex; consisting of cytochrome c
clustered with Apaf-1 and caspase-9 (Zou, Li et al. 1999). Simultaneously,
SMAC/DIABLO bind and inhibit cellular Inhibitors of Apoptosis Proteins (cIAP) in
the cytosol that negatively regulate caspase-9 under resting conditions. The
mitochondrial release of pro-apoptotic factors is considered an irreversible signal
for cell death (Green and Amarante-Mendes 1998). The final stage of apoptosis
via both pathways involves chromatin condensation, DNA fragmentation, cell

12

shrinkage and membrane blebbing. This phenotype is distinctive of apoptosis
and unlike other types of cell death, such as necrosis and autophagy.

Fas
Fas (also known as CD95 and Apo-1) is the most classically studied DR.
It was identified in 1989 (Trauth, Klas et al. 1989) and immediately recognized for
its importance in T and B cell homeostasis (Ju, Panka et al. 1995; Krammer
2000). Defective Fas signaling is involved in Autoimmune Lymphoproliferative
Syndrome (ALPS) (Fisher, Rosenberg et al. 1995), Graft-versus-Host Disease
(GVHD) (Via, Nguyen et al. 1996) and many types of cancer (Houston and
O'Connell 2004).
Fas receptor is activated and trimerizes when bound by Fas Ligand (FasL)
leading to conformational changes of the cytoplasmic tail of the protein. Figure 2
illustrates conventional signaling of how Fas commonly signals for apoptosis
through formation of a DISC. Fas can also form signaling complexes that result in
proliferation and inflammation (Wajant 2002). Fas-Associated protein with Death
Domain (FADD) is an adaptor molecule that is recruited to the cytoplasmic tail of
Fas through Death Domain (DD) homotypic interaction following receptor ligation
(Chinnaiyan, O'Rourke et al. 1995). FADD then recruits effector proteins such as
caspase-8, caspase-10 and FLICE-inhibitory protein (FLIP) through binding of
Death Effector Domain (DED) interactions. FADD is recruited for classical
apoptotic signaling. When two or more molecules of procaspase-8 bind FADD to
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form the DISC, they are catalytically cleaved by autoactivation (Chang, Xing et al.
2003) leading to initiation of the caspase cascade and subsequent apoptosis.

Figure 2. FLIP concentration alters DISC-dependent apoptosis, inflammation
and proliferation signaling through other complexes. When highly expressed,
FLIP competes with caspase-8 for FADD binding at the DISC preventing
activation of the apoptotic caspase cascade. Adapted from (Mathew and White
2006; Lamkanfi, Festjens et al. 2007).
Most Cells are categorized into two types based on their response to Fas
ligation and DISC assembly (Scaffidi, Fulda et al. 1998). In type I cells, Fasmediated caspase-8 activation of caspase-3 is sufficient for inducing cell death.
Fas has been reported to cluster in lipid rafts providing ample oligomerization to
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robustly activate caspase-8 (Muppidi and Siegel 2004). In type II cells, cell death
requires amplification of the apoptotic signal which requires mitochondrial
involvement. In these cells, caspase-8 cleaves Bid which inactivates
antiapoptotic protein Bcl-2 and destabilizes the mitochondrial membrane leading
to the release of cytochrome c and formation of the apoptosome. Both cell types
share the same apoptotic result through final activation of effector caspase-3.

FLIP
FLIP is another DED-containing protein that is an integral component of
the DISC. Cellular FLIP is expressed in mammalian cells as two splice variants,
FLIP short (FLIPS) and FLIP long (FLIPL). Both FLIPS and FLIPL contain two Nterminal DEDs. FLIPL contains the additional C-terminal Caspase-Like Domain
(CLD). FLIPL is structurally homologous to caspase-8 with the exception of an
active cysteine residue in caspase-8 substituted by a tyrosine residue, lending it
proteolytically inactive to cleave caspase substrates (Irmler, Thome et al. 1997).
Viral expressed FLIP (vFLIP) consist of only the two N-terminal DEDs
(homologous to cFLIPS) and are expressed by γ-herpesviruses and the
tumorigenic molluscipoxvirus, (Thome, Schneider et al. 1997).
FLIP is most notably an inhibitor of apoptosis and is implicated in many
types of cancer resistant to FasL-mediated apoptosis (Irmler, Thome et al. 1997).
FLIPL has been implicated as both a pro- and antiapoptotic protein at the DISC.
At high concentrations, FLIPL competes with procaspase-8 for FADD binding at
the DISC thereby preventing all autoprocessing and caspase activation. At low
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and physiological levels, FLIPL can promote apoptosis when at the DISC through
allosteric interactions with procaspase 8 (see figure 2) (Scaffidi, Schmitz et al.
1999; Micheau, Thome et al. 2002). Additionally, the different isoforms of FLIP
have been reported to have distinct protein-protein interactions and signaling
capacities. FLIPL can activate Raf1 and Erk and is shown to recruit TRAF1,
TRAF2 and RIP to Fas complexes (see figure 2) (Kataoka, Budd et al. 2000).
FLIPL also contains a Nuclear Localization Sequence (NLS) which mediates
interaction with MAPK-independent AP-1 activation (Zhang, Chen et al. 2009).
FLIP has been shown to be a substrate of caspase-8 and cleaved at D376
which promotes TRAF2 binding (Kataoka and Tschopp 2004) and RIP1
recruitment to the DR membrane complex (Dohrman, Kataoka et al. 2005).
FLIPL has also been reported to be cleaved at D198, generating a protein
fragment of only the two N-terminal DEDs, equivalent to FLIPS that activates NFκB (Golks, Brenner et al. 2006). There is good indication that vFLIP also
activates NF-κB through interactions with IKKγ, supported by molecular modeling
studies (Bagneris, Ageichik et al. 2008).

TRAIL
TNF-related apoptosis-inducing ligand (TRAIL, also known as Apo-2L) is a
cytokine in the TNF superfamily that binds DRs: TRAIL Receptor 1 (TRAIL-R1,
also known as DR4) and TRAIL-R2 (also known as DR5). It also binds Decoy
Receptor 1 (DcR1), Decoy Receptor 2 (DcR2) and osteoprotegerin (OPG).
DcR1 lacks a cytoplasmic domain preventing propagation of a cellular signal and
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DcR2 has a truncated cytoplasmic domain which leads to incomplete activation.
OPG is a soluble and possible additional decoy receptor (Emery, McDonnell et
al. 1998). TRAIL induces apoptosis similarly to FasL stimulation (Pitti, Marsters
et al. 1996) and is constitutively expressed in numerous tissues (Wiley, Schooley
et al. 1995). TRAIL ligation of TRAILR1/R2 results in formation of a DISC.
TRAIL apoptotic signaling also involves mitochondria apoptotic involvement
through Bid signaling (Werner, de Vries et al. 2002).

Non-apoptotic Death Receptor Signaling

TNFR1/2
Not all DRs primarily signal for cell death (Budd 2002). DRs can signal for
cell survival, differentiation, inflammation and proliferation through pathways
involving NF-κB, Jun N-terminal Kinase (JNK), MAPK and p38 MAPK (Aggarwal
2003). The most distinguished DRs that promote inflammation and proliferation
are TNFR1 and TNFR2. TNFR1 (also known as p55) is ubiquitously expressed
across most cell types, whereas TNFR2 (also known as p75) is primarily
expressed on haemopoietic cells (Chen, Subleski et al. 2008). Their cognate
ligand, TNF-α, is a 17kDa potent inflammatory cytokine that is secreted by
macrophages, neutrophils, T- and NK-cells following their infection as part of an
inflammatory immune response or as an acute stress response to facilitate tissue
repair (Balkwill 2002).
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Following receptor ligation, TNFR1 leads to the formation of two distinct
signaling complexes (see figure 3). Complex I is rapidly formed at the membrane
consisting of TNFR1-Associated Death Domain (TRADD), TNF receptorassociated factor 2 (TRAF2), Receptor Interacting Protein 1 (RIP1) and cIAP1.
This complex leads to pro-survival responses in the cell through NF-κB and
MAPK signaling (Micheau and Tschopp 2003). Complex II subsequently forms
when RIP1, TRAF2 and TRADD disassociate from TNFR1 (and the membrane)
and either RIP1 or TRADD recruit FADD and/or procaspase-8 through DED
homotypic interaction leading to DISC formation and subsequent apoptosis (Li
and Yuan 2008) (Micheau and Tschopp 2003). TNF-α ligation results in
Complex I formation within 2 minutes (Natoli and Austenaa 2008) and only leads
to Complex II formation after prolonged signaling (+24 hours). In the formation of
Complex II, cIAP1/2 are autoubiquitinated and degraded resulting in the
deubiquitination of RIP1, thereby allowing DISC recruitment (Nastiuk and
Krolewski 2008).
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Figure 3. TNFR1/2 signaling results in two complexes. Complex I, assembled
instantly following TNF-α ligation results in non-degradative ubiquitination chains
linked at lysine 63 (illustrated in yellow) attached to RIP1 and results in
downstream degradative ubiquitin chains linked at lysine 48 (illustrated in green)
attached to phosphorylated IκB. Adapted from (Silke and Brink; Wertz and
Dixit).

TNFR1 classically signals for activation of the potent proinflammatory
transcription factor NF-κB via complex I through TRAF2 and RIP1. Both these
proteins have been reported to interact with components of the IKK complex
leading to activation of NF-κB. NF-κB is a transcriptional regulator that is
activated by various stimuli including cytokines (such as TNF-α), chemokines,
adhesion molecules and immune responses to regulate inflammation, cell
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survival and proliferation.

NF-κB transcription factors are homo- or

heterodimers of the Rel family proteins that bind specific DNA sequences called
κB sites in the promoter region of target genes. Most NF-κB dimers contain RelA (p65) or c-Rel and are regulated by Inhibitor of kappa B (IκB) proteins.

NF-κB
NF-κB can be activated via the canonical or non-canonical pathway.
Under resting conditions, IκB binds NF-κB and conceals the nuclear localization
sequence resulting in cytosol sequestration. TNFR1/2 ligation classically leads
to canonical activation of NF-κB. Figure 3 illustrates when TNF-α binds TNFR1,
TRADD is recruited to the receptor which binds TRAF2 and RIP1. Together this
leads to the activation of IκB kinase (IKK) complex which phosphorylates IκB.
The phosphorylated IκB is ubiquitinated and degraded by the proteosome
allowing a free NF-κB to translocates into the nucleus to function as a
transcription factor upregulating numerous target genes. The IKK complex
contains three subunits, IKKα, IKKβ, IKKδ or NEMO. The α and β subunits
contain kinase activity to phosphorylate IκB. NEMO is the regulatory subunit
mediating binding to upstream activators of IKKα and IKKβ. Recently IKK
subunits have been implicated in IκB- and NF-κB-independent signaling effects
(Perkins 2007) indicating IKK activation effects may be more widespread than
initially thought. The non-canonical activation of NF-κB is only stimulated by a
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small number of stimuli and results in NF-κB Inducing Kinase (NIK) to activate
IKKα.
Canonical signaling depends on two proteins upstream of IKK activation
TRAF2 and RIP1. Classically it has been reported that TRAF2 is necessary to
recruit NEMO to the receptor complex and RIP1 is necessary for IKK activation,
giving each a distinctive role in NF-κB activation (Devin, Cook et al. 2000).

TRAF2
TRAF2 is a member of the TRAF protein family, which are all
intermediates in NF-κB signaling. TRAFs have a 150 amino acid TRAF domain
in the C-terminus which enables oligomerization between TRAFs and facilitates
receptor binding. TRAFs 2-7 have a RING domain near the N-terminus enabling
them to exhibit ubiquitin ligase activity. TRAF2 is the most extensively studied
family member and its overexpression has been correlated with invasiveness and
poor prognosis of cancer patients (Trauzold, Roder et al. 2005; van Galen, Muris
et al. 2008). Although TRAF2 dependent NF-κB activation has been clearly
demonstrated, TRAF2 knockout mice have deficient JNK signaling but still
demonstrate proper NF-κB activation (Yeh, Shahinian et al. 1997). Tada et al.
discovered TRAF2/TRAF5 double knockout mice had impaired NF-κB signaling
(Tada, Okazaki et al. 2001) suggesting that TRAF5 can compensate for TRAF2
deficiencies. This type of signaling overlap is evident in multiple protein families.
Interestingly, not all TRAF members promote NF-κB activation, for example,
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TRAF 3 has been reported as an inhibitor of NIK-dependent non-canonical
signaling (He, Saha et al. 2007).

RIP1
RIP1 is in the RIP family proteins and is constitutively expressed in most
tissues. RIP1 has a DD facilitating interactions with DD-containing proteins: DR
receptors, TRADD and FADD. RIP1 has been reported to be mandatory for NFκB activation in numerous studies (Kelliher, Grimm et al. 1998; Poyet, Srinivasula
et al. 2000; Jackson-Bernitsas, Ichikawa et al. 2007). It has been shown to
interact with IKKγ (NEMO) to activate IKK (Kelliher, Grimm et al. 1998). RIP can
interact in both the TNFR1 prosurvival signaling complex as well as the DISC
and has therefore been proposed as a link between the two. Specifically the
hinging component of promoting cell proliferation or cell death is determined by
RIP ubiquitination state (Festjens, Vanden Berghe et al. 2007; Declercq, Vanden
Berghe et al. 2009). Following TNFR1 ligation, RIP1, TRAF2 and cIAP1/2 are
recruited to the receptor complex. cIAP1/2 target RIP1 for ubiquitination with
chains linked through lysine 63 (Varfolomeev, Goncharov et al. 2008). This is a
non-degradative posttranslational modification that promotes complex I formation
and the downstream activation of MAPK and NF-κB (see figure 3). Inhibition or
degradation of cIAPs allows deubiquitination of RIP1 thereby promoting FADD or
procaspase-8 binding through DED interactions, resulting in DISC formation.
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Divergent Death Receptor Signaling

Although TNFR1 is classically implicated in pro-survival and inflammatory
responses, it can additionally lead to apoptosis through TRADD recruitment of
FADD and subsequent assembly of a DISC (Lavrik, Golks et al. 2005) (see figure
3). This signaling is much less frequent than the inflammatory signaling
(Ashkenazi and Dixit 1998). Crosstalk between receptors has also been widely
reported. Fotin-Mleczek et al. reported that TNFR2 can enhance TNFR1mediated apoptotic signaling. They indicate that TNFR2 downregulates cIAPs
and promotes TRAF2 degradation leading to enhanced activation of caspase-8
(Fotin-Mleczek, Henkler et al. 2002).
Other DRs and ligands signal for inflammation and proliferation aside from
TNFR1/2. Fas signaling can result in caspase-8 mediated NF-κB activation
through RIP1 recruitment (Shikama, Yamada et al. 2003). Fas and TRAIL-Rs
are also reported to recruit the TRADD adaptor protein and activate NF-κB
(Schneider, Thome et al. 1997; Tang, Wang et al. 2009).

Additionally TRAIL

has been reported to activate NF-κB through Protein Kinase C (Ehrhardt, Fulda
et al. 2003) and induce proliferation through Akt and Erk pathways (Secchiero,
Milani et al. 2003). FLIPL can recruit TRAF1, TRAF2 and RIP to the DISC
(Kataoka, Budd et al. 2000) and FLIPS can bind and activate IKKγ (Golks,
Brenner et al. 2006) (see figure 2). Gene knockouts of any member of the DISC
(FADD, caspase-8 and FLIP) are embryonically lethal due to incomplete heart
development and T-cell proliferation (Kennedy, Kataoka et al. 1999; Yeh, Itie et
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al. 2000; Chun, Zheng et al. 2002) further indicating the importance of these
proteins in proliferative pathways.
Many components of the DR pathway undergo PTM that mediate their
function. FADD phosphorylation is required for its compartmentalization
(Osborn, Sohn et al. 2007). The Fas cytosolic domain can be phosphorylated
and ubiquitinated to modulate signaling (Voss, Lettau et al. 2008). Components
of NF-κB have been shown to be a target of S-nitrosylation leading to inhibition of
transcriptional activation (Marshall and Stamler 2001; Marshall, Hess et al.
2004). We have previously shown that FLIP can be S-nitrosylated
(Chanvorachote, Nimmannit et al. 2005). Other groups have shown caspase-3
can also be S-nitrosylated leading to its inactivation of enzyme activity (Mannick,
Schonhoff et al. 2001). Further understanding of the PTMs that modulate
proteins in the DR pathway can potentially provide insights for future targeted
therapies.

Death Receptor Signaling in Disease

Tumor cells frequently gain apoptotic resistance via mutation of the
signaling proteins within either the intrinsic or extrinsic apoptotic pathways.
Deficiencies in apoptosis as described by Hanahan and Weinberg is one of the
hallmarks of cancer (Hanahan and Weinberg 2000) that we are primarily
interested in throughout Study 1. Apoptotic resistance has also been described
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as a crucial characteristic of metastasis (Mehlen and Puisieux 2006). Mutations
in the apoptotic DR-pathway further assist tumor cell survival by providing
escape from immune surveillance. Specifically, many tumor cells express sFas
or TRAIL to eliminate infiltrating T-cells and lymphocytes in addition to common
antiapoptotic mutations within the DR-pathway (Hahne, Rimoldi et al. 1996;
Stewart and Abrams 2008). Chemotherapy and radiation are conventional
therapies in cancer treatment that rely on DR-pathways to induce cell death in
tumor cells. Chemotherapy-resistant tumor cells are increasingly formidable
since they have gained safeguards against apoptosis whereas the normal cells
have not, potentially providing an environment that will allow for survival of the
tumor cell.
TRAIL has emerged as a promising therapeutic target for adjuvant cancer
therapies for its ability to target cancer cells for apoptosis with relatively low
toxicity in normal cells (Ashkenazi, Pai et al. 1999; Falschlehner, Ganten et al.
2009). The decoy receptors are widely expressed in normal tissues and offer
putative resistance to TRAIL induced apoptosis (Sheridan, Marsters et al. 1997).
Additionally, many cancer types have shown elevated levels of TRAIL-R1/R2
resulting in an increased sensitivity to TRAIL-induced apoptosis (Oikonomou,
Kosmidou et al. 2009). Chemotherapy and radiation treatment induces p53dependent apoptosis, however, many cancers obtain p53 mutations which
provide resistance to these treatments. TRAIL signals for apoptosis regardless
of p53 activation and therefore is an advantageous adjuvant therapy (Wang
2008). Recombinant TRAIL therapy induces apoptosis in many cancers
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including prostate (Yu, Mandlekar et al. 2000), breast (Keane, Ettenberg et al.
1999), glioma (Rieger, Naumann et al. 1998), multiple myeloma (Gazitt 1999) to
name a few. Additionally, antibodies that stimulate TRAILR1/R2 have also
shown success in vivo (Chuntharapai, Dodge et al. 2001; Ichikawa, Liu et al.
2001). Unfortunately, the success of TRAIL therapy has not been seen in all
cancers.
Mutations in TRAIL-R1/R2 can translate to insensitivity to TRAIL-mediated
apoptosis in metastatic breast cancer (Shin, Kim et al. 2001). Similar mutations
have been reported in bladder and ovarian cancers (Kim, Fisher et al. 2000).
Elevated levels of antiapoptotic proteins Bcl-2, survivin and XIAP all demonstrate
TRAIL-mediated apoptotic resistance (Chawla-Sarkar, Bae et al. 2004).
The most universally reported mechanisms of chemotherapy resistance are with
elevated expression of FLIP and cIAPs. At high expression levels, FLIP is a
potent inhibitor of DISC-mediated apoptosis. Many cancer cells have highly
active DR-signaling and targeted FLIP silencing alone can lead to DRindependent cell death in breast cancer cells (Day, Huang et al. 2008) and
NSCLC cells (Chen, Liu et al. 2007; Wilson, Redmond et al. 2009).
Fas and FasL frequently contribute to apoptotic resistance in cancer.
Different tumor types have been shown to express FasL, targeting immune cells
for apoptosis thereby allowing them to escape immune surveillance (Walker,
Saas et al. 1998).

Pancreatic adenocarcinomas express FasL and are immune

to Fas-mediated apoptosis by alterations in the Death Receptor signaling pathay
(Ungefroren, Voss et al. 1998). Both SCLC and NSCLC cell lines have been
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shown to express FasL (Niehans, Brunner et al. 1997). Furthermore, acute
leukemia and chronic myelogenous leukemia that express FasL have been
shown to have a poorer prognosis (Lickliter, Kratzke et al. 1999). With the
combination of loss of function mutations in proteins in the Fas pathway or
upregulation of antiapoptotic proteins (cIAP, FLIP, Bcl-2) cancer cells become
immune to autocrine effects of FasL.
TNF-α is an critical part of an effective immune system and is involved in
inflammatory signaling. High levels of TNF-α secretion have been reported in
numerous autoimmune disorders such as Crohn’s Disease, rheumatoid arthritis,
psoriasis, lupus and multiple sclerosis (Atzeni, Del Papa et al. 2004). It is also
involved in the pathogenesis of diabetes, sepsis and cancer (Chen and Goeddel
2002). TNF-α is major component of proinflammatory signaling and is an
indicator of both acute and chronic inflammation. The implications of inherent
inflammatory signals are a major component in the tumor microenvironment.
Acute high doses of TNF-α can aid the immune surveillance and cancer cell
clearance (Watanabe, Niitsu et al. 1988; Lejeune, Ruegg et al. 1998). Chronic
TNF-α exposure contributes to tumorigenic signaling through regulation of
angiogenic factors, MMPs, cytokine and chemokine release (Balkwill and
Mantovani 2001).
Although TNF-α can play a paradoxical role in tumor development, TNF-α
antagonists and anti-inflammatory treatments in combination with cancer
treatments are beneficial to halt tumorigenesis (Coussens and Werb 2002).
TNF-α signaling antagonists such as Enbrel®, Infliximab®, Adalimumab® and
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Entanercept® have been widely successful in the management of numerous
diseases with chronic TNF-α signaling (Heilig, Fiehn et al. 1993; Feldmann and
Maini 2001). These are designed either as receptor antagonists or soluble
receptor mimics and neutralize the effects of overabundant TNF-α.
The association between chronic inflammation and cancer has long been
established. NF-κB has been presented as the main component in this junction
due to its transcriptional control over key inflammatory cytokines (Karin 2008).
NF-κB is frequently constitutively expressed in cancer (Bharti and Aggarwal
2002). In addition to deregulation of the signaling pathways, mutations in NF-κB
member proteins resulting in constitutive activation have also been reported and
correlated with an incidence of cancer (Gilmore, Gapuzan et al. 2002).
Additionally, NF-κB has been shown to be essential for epithelial to
mesenchymal transition, a hallmark in carcinoma development towards a
metastatic tumor (Huber, Azoitei et al. 2004). Further research has implicated
signaling to matrix metalloproteinases (MMPs) (Mehlen and Puisieux 2006),
which are necessary for extracellular matrix degradation during invasion.
NF-κB activity can regulate and be regulated by ROS, however, the exact
effects are controversial (Bubici, Papa et al. 2006). This is probably due to the
fact that both ROS and NF-κB mediate so many different effects within the cell.
Individually, the connection between ROS and cancer as well as the cohort of
inflammation/NF-κB activity and cancer cannot be denied (Ohshima and Bartsch
1994; Tamir and Tannenbaum 1996; Felley-Bosco 1998).
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In normal physiology the chronic signaling of TNF-α to NF-κB is
terminated by the switch from prosurvival signaling complex (complex I) to the
formation of a DISC (complex II). In aberrant signaling or unlimited cytokine
provisions, the prosurvival signaling prevails leading to a constant positive
feedback loop promoting inflammation. For example, IAPs which have been
repeatedly reported to be upregulated in cancer (Vucic 2008) are induced by NFκB activation and then further promote NF-κB activation through RIP-1
ubiquitination and the stabilization of complex 1 (Gyrd-Hansen and Meier). This
abiding positive feedback loop would further promote the chronic inflammatory
environment and tumorigenesis.
Alterations in protein signaling within the DR pathway of tumor cells are
not the only oncogenic promoting force. The stroma surrounding a tumor has
been shown to contribute to matrix remodeling, proliferation and angiogenesis
(Condeelis and Pollard 2006). Tumor associated macrophages (TAMs), which
play a significant role in DR-signaling, can provide an chronic inflammatory
environment, rich in growth and angiogenic factors that support the growth of
hyperproliferative cells (Coussens and Werb 2002). High levels of NO and large
amounts of circulating TNF-α are frequently reported (Mantovani, Allavena et al.
2004). Additionally, fibroblasts can profoundly enhance carcinoma tumor
formation through secreted growth factors such as transforming growth factor
(TGF-β) and hepatocyte growth factor (HGF) (Bhowmick, Neilson et al. 2004).
Additionally, abnormal or irradiated stroma can serve as a carcinogen to normal
cells (Bissell and Radisky 2001).
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Cell Migration

Cellular migration is a complex signaling process that involves multiprotein
organization and coordination. It is a vital component of embryogenesis,
infection, inflammatory responses and wound healing (Horwitz and Webb 2003).
In order to migrate, cells undergo molecular rearrangements to polarize
(distinguishing between the front and rear of the cell) resulting in membrane
extensions that abet movement (Lauffenburger and Horwitz 1996).
In the pathology of cancer, migration is one component of the metastatic
cascade that results in advanced disease and poor prognosis (Weigelt, Peterse
et al. 2005). Tumor cells must manipulate migratory processes for successful
invasion and metastasis resulting in the establishment of tumor cells in distant
organs. This is the major cause of death in most cancers (Inamura and
Ishikawa; Weigelt, Peterse et al. 2005).
ROS are implicated in tumorigenesis and have been shown to contribute
to migratory signaling. Long term oxidative stress is known to increase the
invasive potential in mammary epithelial cells (Mori, Shibanuma et al. 2004).
ROS has been reported to contribute to prolonged activation of promigratory
signaling. ROS production has been shown to activate Erk1/2, JNK and NF-κB
resulting in TGF-β-dependent astrocyte (Hsieh, Wang et al.) and glioblastoma
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(Chiu, Shen et al.) migration. ROS from the tumor microenvironment have also
been shown to participate in tumor cell migration. Tobar et al. demonstrated that
stromal mammary cells mediate MCF-7 breast cancer cells migration through
NADPH oxidase 4 (Nox4) production of ROS (Tobar, Guerrero et al.).
Additionally Nox4-produced ROS has been shown to lead to migration in other
cell types as well (Nam, Park et al.). With many cellular and tissue sources of
ROS, these signaling intermediates could be key amplifiers for sustained
signaling events involved in cell migration (see figure 1).

Caveolin-1

Caveolin-1 (Cav-1) is a multifunctional scaffolding protein that is the
signature protein of a lipid raft subtype known as caveolae. These cellular
membrane invaginations are especially prominent in endothelial cells, however,
they are also formed in fibroblasts, adipocytes, smooth and skeletal muscle
(Parton and Simons 2007). Caveolae are highly enriched in sphingolipids and
cholesterol, a binding partner of Cav-1 (Parton, Hanzal-Bayer et al. 2006).
Caveolae compartmentalize proteins and signaling pathways to initiate cell
migration (Isshiki, Ando et al. 2002). Many proteins have been detected within
caveolae including eNOS and VEGF receptor.
Cav-1 is part of the three protein Caveolin gene family. Caveolins are 2124 kDa membrane proteins with characterizing hairpin structure (Parton, Hanzal-
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Bayer et al. 2006). Cav-1 and Cav-2 are expressed in most cell types including
epithelial, endothelial, mesenchymal and neuronal cells (Burgermeister,
Liscovitch et al. 2008). Cav-3 is only found in muscle cells (Salanueva, Cerezo
et al. 2007). Cav-1 has been reported to regulate many cellular processes
involved in cancer including angiogenesis, migration, metastasis, proliferation
and drug resistance (Goetz, Lajoie et al. 2008). Knockdown of Cav-1 in
endothelial cells has been shown to inhibit cell polarization, migration and
invasion (Galvez, Matias-Roman et al. 2004; Beardsley, Fang et al. 2005).
Additionally, Cav-1 knockout MEFs are reported to have atypical morphology and
migratory behavior due to changes in Rho GTPases and Src signaling (GrandeGarcia and del Pozo 2008).
In endothelial cells, caveolin is polarized within the cell during migration.
Sun et.al. determined the 10 amino acid residues in the N-terminus responsible
for Cav-1 localization in the rear of the cell and rear polarization (Sun, Flynn et al.
2007). PTM of Cav-1 also helps determine its localization within the cell. Cav-1
is predominantly localized at the rear of a migrating cell. A subpopulation of Cav1 phosphorylated at tyrosine residue 14 are found at the leading edge and
regulate focal adhesion (Beardsley, Fang et al. 2005). This Src-dependent
phosphorylation mediates interleukin-6 and insulin-like growth factor signals
through PI3K and STAT3 (Podar and Anderson 2006). Additionally, VEGFmediated migration in multiple myeloma is Cav-1 dependent (Podar,
Shringarpure et al. 2004).
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Cav-1 has both tumor suppressor and oncogenic activities and has been
implicated in cancer progression and metastasis. Cav-1 contains a scaffolding
domain (CSD) that binds proteins to exert tumor promoting or suppressive
effects. For example, binding of NOS and cytosolic tyrosine kinases are inhibited
through Cav-1 interaction whereas insulin receptor and adhesion proteins are
kept active to support migration and angiogenesis (Williams and Lisanti 2005).
The reported contradictory roles in migration could be dependent on cell specific
differences in genotype and phenotype (Grande-Garcia and del Pozo 2008).
Cav-1 inhibits migration in metastatic rat mammary adenocarcinoma (MTLn3)
cells (Zhang, Razani et al. 2000).
Elevated expression of Cav-1 is highly correlated with poor prognosis in
many types of cancer including gastrointestinal, esophageal, bladder, thyroid,
brain, liver and renal cell (Burgermeister, Liscovitch et al. 2008). However, the
tumorigenic role of Cav-1 may still vary by cell type. In prostate cancer, Cav-1
overexpression is associated with disease progression through interactions with
Akt and angiogenic signaling (Thompson, Tahir et al.; Yang, Truong et al. 1999;
Tahir, Yang et al. 2001). In pancreatic cancer, Cav-1 tissue expression positively
correlates with tumor aggressiveness (Tanase 2008). Alternatively, Cav-1
overexpression in breast cancer cells inhibits anchorage-independent growth,
matrix invasion and proliferation implicating Cav-1 expression as a tumor
suppressor (Fiucci, Ravid et al. 2002). Additionally, it has been identified as a
tumor suppressor in HER2/EGFR positive breast cancer (Park, Kim et al. 2005),
mucoepidermoid carcinoma (Shi, Chen et al. 2007) and extrahepatic bile duct
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carcinoma (Murakami, Miyamoto et al. 2003). The conflicting reports of Cav-1
function also extend to drug sensitivity and treatment. It has been implicated in
drug-resistant colon and breast cancer (Lavie, Fiucci et al. 1998; Yang, Truong et
al. 1999) although also reported to restore chemosensitivity to cisplatin in oral
cell carcinoma (Nakatani, Wada et al. 2005).
Cav-1 can clearly play a role in tumorigenesis. The variance of the
contribution depends on the cell type and genetic signature of the cancer.
Further mechanistic understanding of Cav-1 as both a tumor suppressor and
promoter can potentially identify manageable targets within disease treatment
and increase the patient prognosis. PTMs and redox can additionally modify
Cav-1 signaling and should be investigated. NADPH oxidases have been
identified in caveolae and lipid rafts (Zhang, Yi et al. 2006) indicating ROS are
potentially prevalent near Cav-1. In Study 2 we examined the role of ROS on
Cav-1 signaling in H460 lung adenocarcinoma cells to determine a pro- or antimigratory effect. We were particularly interested if different ROS species
conferred a similar effect on Cav-1-dependent migration.
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Impact and implications
Currently, drug resistance and therapeutic selectivity are major issues in
available effective cancer treatments. Understanding the differences between
normal biology and cancer pathology will help determine potential targets for
directed therapies. The signaling pathways that control apoptosis and cellular
migration are important components in the progression of cancer. ROS and NO
are noted to be key players in the advancement of pathology and disease not
only as markers of toxicity but also by mediating specific signaling events (refer
to figure 1). ROS, NO and DR-ligands are excessively produced in the tumor
microenvironment and contribute to tumorigenesis (Maeda and Akaike 1998;
Coussens and Werb 2002).
We are interested in how NO and ROS mediate protumorigenic effects
such as developing mutations that are classified as the “Hallmarks of Cancer”
(Hanahan and Weinberg 2000). Loss of tumor suppressors in combination with
gain of function mutations can lead to apoptotic resistance, unlimited proliferation
and migration and metastasis which are all seen in the advancement of cancer.
Upregulation of antiapoptotic protein FLIP has been noted in multiple types of
chemotherapy-resistant cancers. It has recently been associated with
proliferative DR-pathways (Hyer, Samuel et al. 2006). The details of this
association and the underlying mechanisms are not yet clear. In Study 1 we
were interested in DR-mediated apoptosis and specifically examined how Snitrosylated FLIP, an antiapoptotic and proinflammatory protein, regulates
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downstream signaling. We show that S-nitrosylation of FLIP at residues 254 and
259 modulate potent transcription factor NF-κB through the redistribution of
RIP1. We further show that S-nitrosylation of FLIP mediates protein processing
into smaller protein fragments which could potentially alter signaling in pathways
that classically recruit splice variant FLIPS.
Migration is a key component in tumor invasion and metastasis. A full
understanding of the proteins mediating cell movement in the context of the
tumor environment is necessary to effectively treat disease. In Study 2 we
examined how ROS contributes to migration in NSCLC cells. We demonstrate
that different ROS species mediate specific changes in migration and invasion in
a Cav-1-dependent manner. We further show ROS-mediated Cav-1 expression
reduces phosphorylated Akt. We additionally confirmed our results in melanoma
cells.
Current literature indicates the importance of ROS and NO in the
development and progression of cancer. Cancer cells and the supporting
microenvironment are exposed to hypoxic and chronic inflammatory conditions
that modulate ROS and NO production in vivo. These redox changes can
dramatically alter cellular signaling and processes that control the fate of the cell.
The functional implications of redox changes have only recently started to be
dissected. Overall, this work will aim to decipher how ROS and NO can
specifically alter known pathways in apoptosis and migration relevant in cancer
progression.
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Abstract
Death receptor (DR) ligation can lead to divergent signaling pathways
causing either caspase-mediated cell death or cell proliferation and inflammation.
These variations in cellular fate are determined by adaptor proteins that are
recruited to the DR signaling complex. Flice inhibitory protein (FLIP) is an
established inhibitor of caspase-8-mediated apoptosis, and it is also involved in
NF-κB activation. However, the molecular mechanism that regulates FLIP within
this complex is unknown. In this study, we provide new evidence for the
regulation of NF-κB by FLIP through S-nitrosylation which involves covalent
modification of the protein’s cysteine thiol by nitric oxide to form S-nitrosothiol.
Point mutations of FLIP at cysteine residues 254 and 259 prevent FLIP Snitrosylation and its ability to activate NF-κB. The mechanism by which FLIP
nitrosylation regulates NF-κB activity involves RIP1 binding and redistribution,
whereas TRAF2 binding and distribution are unaffected. We further show that
FLIP processing and cleavage is dependent on its nitrosylation status.
Collectively, our study reveals a novel pathway for FLIP regulation of NF-κB
through protein S-nitrosylation, which is a key posttranslational mechanism
controlling DR-mediated cell death and survival. Since increased expression of
FLIP and nitric oxide are frequently observed in chemotherapy-resistant tumors,
S-nitrosylation of FLIP could be a key mechanism of chemoresistance and tumor
growth.
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Introduction
Cellular proliferation, inflammation and apoptosis are highly regulated
cellular processes important in homeostasis. Dysregulation of these processes
can cause a multitude of human diseases including cardiovascular disease,
autoimmune disorders and cancer.

This occurs frequently in response to

aberrant signaling initiated by death receptors (DRs). DRs belong to the tumor
necrosis family receptor (TNFR) superfamily, which includes TNF receptors
(TNFRs), Fas and TNF related apoptosis inducing ligand receptors (TRAIL-Rs)
(Baker and Reddy 1998). DRs have been widely noted to play an important role
in cancer development and metastasis (Debatin and Krammer 2004).

DR

ligands are pleiotropic cytokines that initiate the formation of signaling complexes
on the cytoplasmic tail of the receptors. Contrary to their name, DRs can signal
both for cell survival and cell death (Budd 2002). Receptor ligation results in
receptor oligomerization and recruitment of adaptor proteins to the receptor
complex, which determines the fate of the cell. Regulation of proteins that are
recruited to the signaling complex is equally important in determining the
outcome of DR stimulation. An example of a signaling complex that forms at the
membrane is the death inducing signaling complex (DISC), where the adaptor
protein FADD and procaspase-8 are recruited, resulting in caspase activation
and subsequent cell death. DR-mediated cell survival however is mediated by
an alternate complex that involves proteins upstream of nuclear factor kappa B
(NF-κB), mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3kinase (PI3K) pathways.
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Many cancer cells constitutively express DRs resulting in an increased
sensitivity to ligands such as Fas and TRAIL (Gibson, Oyer et al. 2000). This
increased sensitivity was thought to provide a selective opportunity to target
cancer cells for apoptosis sparing normal cells with basal DR expression levels.
This has led to the current exploration of adjuvant TRAIL therapies alongside
chemotherapy in a wide variety of cancer treatments (Falschlehner, Ganten et al.
2009). However, many advanced cancers have gained resistance to apoptotic
signaling via the upregulation of apoptotic inhibitor proteins such as cellular
inhibitors of apoptosis (cIAPs) and Flice inhibitor protein (FLIP) (Scaffidi, Schmitz
et al. 1999). FLIP, originally noted for its importance in lymphocyte proliferation
and development (Thome and Tschopp 2001), is a known inhibitor of DRmediated apoptosis (Krueger, Baumann et al. 2001) Multiple isoforms of FLIP
mRNA have been identified, but two protein forms, FLIPL (long) and FLIPS (short)
are most readily observed, each having distinct signaling effects at the DISC
(Wajant 2003).

FLIPL is a 55kDa protein that is a substrate of caspase-8

resulting in truncation from the C-terminal end into a 43kDa protein which has
been noted to be more active (Kataoka and Tschopp 2004; Dohrman, Kataoka et
al. 2005). FLIPS is a 22kDa isoform consisting only of the two N-terminal death
effector domains (DEDs). Both isoforms of FLIP inhibit apoptosis via their ability
to form heterodimers with procaspase-8, preventing activation of the caspase
cascade (Irmler, Thome et al. 1997; Wajant 2003). Elevated FLIP expression
levels are directly associated with chemotherapy-resistant cancers as an
acquired

mechanism

to

evade

DR-mediated
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apoptosis

(Wajant

2003).

Additionally, FLIP has been reported in other DR pathways, including the
activation of the potent pro-inflammatory transcription factor NF-κB (Kataoka,
Budd et al. 2000; Sun, Zachariah et al. 2003). FLIP can interact with multiple
proteins important in TNF-mediated NF-κB activation including receptor
interacting protein kinase 1 (RIP1) (Chaudhary, Eby et al. 2000), TNFRassociated factor 2 (TRAF2) (Kataoka and Tschopp 2004), and inhibitor kappa B
kinase gamma (IKKγ) (Golks, Brenner et al. 2006), indicating the multiple roles
for FLIP in NF-κB signaling. Furthermore, NF-κB promotes FLIP expression in a
positive feedback loop (Kreuz, Siegmund et al. 2001). These high levels of FLIP
can potentially enhance a chronic inflammatory response and promote tumor
growth.
Abundant concentrations of DR-ligands are produced in response to
infection, inflammation and in response to chemotherapeutic drugs. NF-κB is
sequestered by NF-κB Inhibitors (IκBs) in the cytosol under normal conditions.
Proinflammatory cytokines and DR-ligands activate NF-κB by targeting IKK for
activation leading to phosphorylation and subsequent degradation of IκB, thereby
allowing NF-κB to translocate to the nucleus to function as a transcription factor.
TNFR-mediated activation of NF-κB is initiated by the formation of a cytoplasmic
complex containing TNFR superfamily 1A-associated via death domain
(TRADD), RIP1, TRAF2 and cIAPs.

During TNFR signaling, RIP1 is

polyubiquitinated by cIAPs promoting the formation of a pro-survival complex
upstream of NF-κB activation (Varfolomeev, Goncharov et al. 2008).

RIP is

essential for activation of IKKs by this complex (Devin, Cook et al. 2000).
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Inhibition or loss of cIAPs, as well as the deubiquitination of RIP, causes
apoptosis via RIP recruitment to the DISC (Geserick, Hupe et al. 2009).
Therefore, RIP is a pivotal signaling protein in DR-stimulated complex formation.
By regulating both cell death and proliferation it is not surprising that RIP
overexpression has also been associated with poor prognosis in cancer (Park,
Hatanpaa et al. 2009).
Reactive nitrogen and oxygen species are commonly found in pathologies
such

as

chronic

inflammation,

cardiovascular

disease

and

advanced

tumorigenesis. Activation of inducible nitric oxide synthase (iNOS) and elevated
levels of nitric oxide (NO), lead to rapid increases in the S-nitrosylation of
proteins. S-nitrosylation is the covalent addition of NO to the thiol side chain of a
cysteine residue. This post-translational modification (PTM) can regulate protein
interactions and modify downstream signaling. Other PTMs have been reported
to significantly alter FLIP stability and function (Higuchi, Yoon et al. 2003;
Kaunisto, Kochin et al. 2009). We have previously shown that S-nitrosylation of
FLIP can prevent its ubiquitination and subsequent degradation making it a more
potent inhibitor of Fas-mediated apoptosis (Chanvorachote, Nimmannit et al.
2005).
Here we demonstrate the effects of FLIP S-nitrosylation of residues 254
and 259 on NF-κB activation. The underlying mechanism of changes in NF-κB
activation is due to the ability of S-nitrosylated FLIP to bind RIP1 following TNF-α
stimulation. Additionally, we demonstrate that S-nitrosylation of FLIP regulates
its cleavage into shorter forms. Determining the regulation of FLIP signaling is
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fundamental to understanding its role in disease and is imperative for the future
development of effective therapeutic strategies in chemotherapy-resistant
cancers.
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Experimental procedures
Cell lines and reagents: HEK 293, MCF-7, and A549 cells were cultured in
Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) containing 10%
fetal bovine serum, 2 mM L-glutamine, 20 mM HEPES, 100 units/ml penicillin,
and 100 μg/ml streptomycin in a 5% CO2 environment at 37 °C. Recombinant
FasL (SuperFasL), monoclonal antibody against FLIP (Dave-2), and the NO
donor DPTA NONOate were purchased from Alexis Biochem (San Diego, CA).
The NO donor sodium nitroprusside (SNP), NO inhibitors amino-guanidine (AG)
and 2-(4-carboxy-phenyl)-4,4,5,5 tetramethylimidazoline-1-oxy-3-oxide (PTIO),
and Hoechst 33342 were from Sigma (St. Louis, MO). The transfection agent
Lipofectamine Plus was purchased from Invitrogen (Carlsbad, CA). Monoclonal
anti-cfp (3E6) antibody was purchased from Invitrogen (Carlsbad, CA). Anti-myc
antibodies were purchased from Millipore (Billerica, MA) and SCBT (Santa Cruz,
CA). Polyclonal antibody against GAPDH was purchased from BD Transduction
(San Jose, CA). Polyclonal antibody against FLAG (OctA) was purchased from
SCBT (Santa Cruz, CA). Polyclonal antibody against TRAF2 was purchased from
Cell Signaling Technology (Danvers, MA). Commercial protease inhibitor mixture
was purchased from Roche Applied Science (Indianapolis, IN). pRL and pGL
vectors were purchased from Promega (Madison, WI). pcDNA3-FLIP plasmids
were made as described previously (Chanvorachote, Nimmannit et al. 2005).
pECFP-TRAF2 was made as described previously and provided as a kind gift
from J. Schmid (Medical University Vienna, Austria) (Birbach, Gold et al. 2002).
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S-nitrosylation assay: HEK 293 cells were transfected with pcDNA3-FLIP. The
following day cells were treated as indicated in figure legend. S-Nitrosylated
protein detection assay kit was commercially obtained from Cayman Chemical
Company (Ann Arbor, MI) and was used according to the manufacturer’s
instruction. Briefly, cell pellets were lysed under the protein free thiols blocking
condition. Protein S-nitrosothiols were then reduced to yield free thiols which
were covalently labeled with maleimide-biotin. Lysate protein (500 µg) was
subjected to the immunoprecipitation as described earlier. Subsequent analysis
for S-nitrosylated protein was determined by Western blotting using Snitrosylation detection reagent I (HRP) and by fluorescence reading using Snitrosylation detection reagent II (fluorescein). For Western blot analysis, protein
samples were prepared in Laemmli buffer and were resolved under denaturing
conditions. For fluorescence reading, immune complexes were further incubated
with

fluorescein

detection

agent

overnight

following

the

standard

immunoprecipitation step. Complexes were rinsed with wash buffer three times,
resuspended in colorless Laemmli sample buffer, and boiled for five minutes.
Clear lysates were loaded onto the fluorescence plate and analyzed for
fluorescence intensity using a fluorescence plate reader at a 485-nm excitation
and a 520-nm emission (FLUOstar OPTIMA, BMG Labtech, Durham, NC).

NF-κB gene reporter assay: 1.5 × 105 HEK 293 cells/well were seeded on 0.02%
gelatin coated 24-well plates. Cells were transfected the following day with 600
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ng of empty pcDNA3 vector, the indicated amount of pcDNA3-FLIP plasmids,
100 ng of a multimeric NF- B pGL2 luciferase vector and 5 ng of the Renilla pRLTK vector. Transfections were performed using Lipofectamine 2000 (Invitrogen).
Expression of proteins was verified by immunoblotting. Media was changed 6
hours after transfection and cells were grown overnight. Luciferase activity was
determined using a dual-luciferase reporter assay system kit (Promega, San Luis
Obispo, CA). The activity of the NF- B reporter luciferase was standardized to
that of Renilla luciferase.

Within the same experiment, each transfection was

performed in quadruplicate, and where necessary, empty control plasmid was
added to keep each transfection receiving the same amount of total DNA. Data
shown are representative averages and standard deviations from one of three
separate experiments performed.

Apoptosis assay: MCF-7 cells were transfected with FLIP wildtype or FLIP 2CM
using Amaxa Nucleofector (Lonza, Walkersville, MD) using the recommended
manufacturer protocol. Transfected cells were seeded at 15,000 cells per well in
a 96 well plate and allowed to recover for 24 hours. Cells were treated with 200
ng/mL FasL or 100 ng/mL TNF-α for 12 hours. Apoptosis was determined by
Hoechst 33342 DNA fragmentation assay. Briefly, cells were incubated with 10
μg/mL of Hoechst 33342 for 30 min and were visualized under a fluorescence
microscope (Leica Microsystems, Bannockburn, IL). Cells having intensely
condensed and/or fragmented nuclei were considered as apoptotic.
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Immunoblotting: Cells were lysed in RIPA lysis buffer containing 1 mM sodium
orthovanadate, 100 mM phenylmethylsulfonyl fluoride, and a commercial
protease inhibitor mixture (Roche Applied Science, Indianapolis, IN) for 20 min
on ice. After insoluble debris was pelletted by centrifugation at 14,000 x g for 10
min at 4 °C, the supernatants were collected and determined for protein content
using the Bradford method (Bio-Rad). Proteins (60 µg) were resolved on a
reducing 10% SDS-polyacrylamide gel and transferred onto PVDF membranes.
The transferred membranes were blocked for 1 hour in 5% nonfat dry milk in
Tris-buffered Tween (25 mM Tris-HCl, pH 7.4, 125 mM NaCl, 0.05% Tween 20)
and incubated with the appropriate primary antibodies.

Membranes were

washed 3 times with Tris-buffered Tween for 10 min and incubated with
horseradish peroxidase-coupled isotype-specific secondary antibodies for 1 hour
at room temperature. The immune complexes were detected by enhanced
chemiluminescence (ECL) detection.

Immunoprecipitation: Cells were lysed in lysis buffer containing 20 mM Tris-HCl,
pH 7.5, 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM sodium
orthovanadate, 50 mM sodium fluoride, 100 mM phenylmethylsulfonyl fluoride,
and a protease inhibitor mixture for 20 min on ice. Immunoprecipitation
experiments were carried out using Dynabeads (Invitrogen, Carlsbad, CA) and
the recommended protocol. Immunoblotting was carried out as described above.
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Immunofluoresence: Cells were seeded on rat type I collagen coated coverslips
(5 µg/cm2), fixed with 3.7% paraformaldehyde for 15 min, incubated in 50 mM
glycine for 5 min, and permeabilized and blocked with 0.5% saponin, 1.5% BSA,
and 1.5% normal goat serum for 30 min. FLIP was immunostained with anti-myc,
RIP1 was immunostained with an antibody against FLAG (OctA). TRAF2 was
immunostained with antibody against CFP.

Secondary Alexa Fluor 405,

488, 546,

and

and

647-conjugated

antibodies,

phalloidin

were

used

from Invitrogen (Carlsbad, CA). Cells were washed with PBS containing 0.5%
saponin,

and

coverslips

were mounted

using

Fluoromount-G

(Southern

Biotechnology Associates, Birmingham, AL). Cells were viewed with a Zeiss
LSM 510 confocal on an AxioImager Z1 microscope using a 63x objective lens.

Statistics: The differences between treatment groups were analyzed using an
unpaired Student’s t-test and were considered significant when P < 0.05. Error
bars display standard deviation.
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Results
FLIP is S-nitrosylated at residues 254 and 259
The antiapoptotic role of FLIP in DR-mediated apoptotic signaling is firmly
established. We have previously reported that FLIP S-nitrosylation prevents its
ubiquitination and subsequent degradation, thereby making it a more potent
inhibitor of Fas-mediated apoptosis (Chanvorachote, Nimmannit et al. 2005).
Since DR signaling can also lead to cell survival we tested the hypothesis that Snitrosylation of FLIP modulates its role as an NF-κB activator. We used our
previously described double cysteine mutant of FLIP (2CM), where single point
mutations of cysteine residues 254 and 259 to alanines in the caspase-like
domain

(CLD)

of

FLIP

prevent

S-nitrosylation

(Chanvorachote, Nimmannit et al. 2005).

of

FLIP

(Figure

1a)

Transiently transfected FLIP 2CM

showed impaired responsiveness to pharmacological NO modification, as evident
by the lower overall S-nitrosylation of FLIP 2CM compared to wild type FLIP, with
S-nitrosylation levels comparable to those detectable following the treatment with
the iNOS inhibitor amino-guanidine (AG) (Figures 1b and c).

We do not see a

complete reduction in S-nitrosylation levels since there are additional cysteine
residues within the FLIP protein sequence that could potentially be Snitrosylated.
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S-nitrosylation of FLIP modulates NF-κB activation
It is well established that FLIP can promote NF-κB activation (Chaudhary,
Eby et al. 2000; Kataoka and Tschopp 2004; Golks, Brenner et al. 2006). While
transient transfection of wildtype FLIP activates NF-κB in a dose dependent
manner compared to empty vector control (Figure 2a), FLIP 2CM completely
lacks any detectable activation of NF-κB (Figure 2c). This result suggests that
the S-nitrosylation of FLIP at residues 254 and 259 is necessary for FLIPLmediated activation of NF-κB. The expression of all FLIP constructs has been
verified by immunoblot (Figures 2b and d). In agreement with previous results,
transient expression of the two N-terminal DEDs, representative of FLIPS, but not
one N-terminal DED alone, independently activates NF-κB (Figure 2c) (Kataoka
and Tschopp 2004; Golks, Brenner et al. 2006). These results indicate that Snitrosylation of FLIP at cysteine residues 254 and 259 represents a distinct
mechanism to activate NF-κB, compared to the DED-mediated response
previously reported. To further examine the role of S-nitrosylation of FLIP on NFκB activation, we performed experiments using NO modifying reagents. Cells
were transiently transfected with wild type FLIP expression constructs, followed
by treatment with the NO donor DPTA NONOate (NONO) and sodium
nitroprusside (SNP). NO supplementation using either NONO or SNP treatment
caused a decrease in FLIP-mediated NF-κB activation, which was independent
on the expression level of FLIP, while FLIP 2CM was not affected by NO
supplementation and failed to activate NF-κB (Figure 2e). Although we expected
to observe an increase in NF-κB activation, the subunits of NF-κB are also
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targets for S-nitrosylation, which results in an overall inhibition of its activation by
preventing translocation to the nucleus and interfering with DNA binding
(Marshall, Hess et al. 2004). However, we show the FLIP-mediated induction of
NF-κB remains statistically significant compared to control cells (Figure 2e).
Additionally, NF-κB activation promoted by transient transfection of FLIP, but not
FLIP 2CM was significantly increased upon global NO inhibition using the NO
scavenger

2-(4-carboxy-phenyl)-4,4,5,5

tetramethylimidazoline-1-oxy-3-oxide

(PTIO) and the selective iNOS inhibitor amino-guanidine (AG) (Figure 2f). Thus,
our results show that the S-nitrosylation of FLIP is upstream of NF-κB activation
and is another S-nitrosylation-mediated mechanism to modulate NF-κB
activation.
Since DRs signal for NF-κB activation and apoptosis, we also determined
the effect of S-nitrosylation of FLIP on apoptosis. Cells were transfected with
either an empty vector, FLIP or FLIP 2CM, followed by treatment with the DR
agonist TNF-α or FasL and quantification of apoptosis. Treatment of the cells
with TNF-α and FasL causes increased cell death shown by an increase in
fragmented nuclei, which is inhibited by FLIP, but not FLIP 2CM (Figures 3a and
b). These results indicate that the S-nitrosylation of FLIP is important in both
proliferative and apoptotic signaling originating from DRs.

S-nitrosylation of FLIP modulates RIP1 binding and localization
To further delineate the molecular mechanism by which S-nitrosylation of
FLIP mediates NF-κB activation, we investigated its interaction with upstream
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adaptor RIP1, which is a crucial signaling protein upstream of NF-κB activation
and known binding partner of FLIP (Irmler, Thome et al. 1997). We transiently
transfected cells with FLIP or FLIP 2CM and tested the interaction with
endogenous RIP1. FLIP or FLIP 2CM was immunoprecipitated and the immune
complexes were probed for RIP1. FLIP binds to RIP1 in the absence of any DR
stimulation, and the interaction is disrupted following TNF-α treatment (Figure
4a). In contrast, FLIP 2CM retained its ability to interact with RIP1 even in cells
that were treated with TNF-α (Figure 4a) at the same level as observed in cells
not stimulated by TNF-α (data not shown). This differential binding indicates that
the S-nitrosylation of FLIP at residues 254 and 259 inhibits binding to RIP1.
Furthermore, FLIP, but not FLIP 2CM is cleaved upon TNF-α treatment, also
indicating that S-nitrosylation is necessary for FLIP processing.

We next

examined the cellular localization of FLIP and RIP1 by confocal microscopy in
HEK 293 cells, which express very low levels of endogenous FLIP (data not
shown). We observed that in resting cells, RIP1 is distributed in the cytoplasm
however it is recruited to the membrane in response to TNF-α stimulation. This
translocation to the membrane is impaired, when the FLIP 2CM mutant is coexpressed (Figure 4b). These results suggest that the S-nitrosylation of FLIP is
essential in regulating its interaction with RIP1, thus affecting localization of RIP1
to the DR complex following receptor ligation, thereby modulating DR signaling.

TRAF2 localization and FLIP binding is not dependent on FLIP S-nitrosylation
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TRAF2 is another DR signaling complex adaptor protein, which is
essential for NF-κB activation (Devin, Cook et al. 2000).

Since the S-

nitrosylation of FLIP affects its interaction with RIP1, we also examined the
interaction of FLIP with TRAF2. We transiently transfected cells with either FLIP
or FLIP 2CM, immunoprecipitated FLIP and analyzed the immune complexes for
the presence of endogenous TRAF2.

However, in contrast to the FLIP

interaction with RIP1, its interaction with TRAF2 was not affected, when
comparing FLIP and FLIP 2CM, either in the presence or absence of TNF-α
(Figure 5a). Additionally, we examined the localization of TRAF2 in HEK 293
cells following TNF-α stimulation. We found that TRAF2 is distributed in the
cytoplasm in resting cells and translocates to the membrane following receptor
stimulation with TNF-α regardless of the presence of FLIP or FLIP 2CM (Figure
5b). Thus, our results indicate that S-nitrosylation of FLIP at residues 254 and
259 does not affect its interaction with TRAF2 and therefore is expected to not
cause the effects on NF-κB activation.

S-nitrosylation of FLIP causes processing into shorter forms
FLIP protein levels and the ratio of FLIPL and FLIPS vary in different cell
types.

It is also known that FLIPL is rapidly converted into a p43 fragment

through proteolytic cleavage (Neumann, Pforr et al.; Kataoka and Tschopp 2004;
Dohrman, Kataoka et al. 2005).

Since different forms of FLIP show distinct

effects on NF-κB activation (Figure 2c), we next tested whether DR ligation
causes proteolytic processing of FLIP, which could also impact activation of NF-
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κB. We used a human lung adenocarcinoma A549 cell line, which expresses a
high level of FLIP, and either mock treated the cells, or treated the cells with the
DR-ligands TNF-α and FasL for different times in the absence or presence of the
proteasome inhibitor MG132.

We then probed the lysates for expression of

endogenous FLIP. We found that the 55 kDa FLIPL is partially converted in
resting cells into the 43 kDa, C-terminally truncated FLIPL (Figure 6a). Treatment
with MG132 also revealed presence of p22 FLIP, which is proteasomally
degraded. However, treatment with either TNF-α or FasL enhanced expression
or stability of FLIPS, with FasL also promoting further processing of p43 into the
p39 version, which is yet another C-terminal processing event. We next tested
whether S-nitrosylation could impact proteolytic processing of FLIP.

We

transiently transfected HEK 293 cells with either FLIP or FLIP 2CM, treated cells
with FasL or TNF-α, and probed cell lysates for FLIP. While FLIP is partially
converted into p43, as observed for endogenous FLIP, FLIP 2CM is protected
from processing and remains as p55 FLIPL (Figures 6b and c). Additionally FLIP
processing is enhanced by NO supplementation by treatment with NONO
comparable to FasL treatment (Figure 6d). This increased processing is also
consistent with S-nitrosylation fragments seen in Figure 1c.

Thus, our data

indicate that S-nitrosylation at residues 254 and 259 is required for the ability of
FLIPL to act as a substrate and its proteolytic conversion into p43.
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Discussion
In this study we demonstrate that S-nitrosylation of FLIP at cysteines 254
and 259 mediate RIP1 binding to induce NF-κB activation. This mechanism is
distinct from previously reported FLIP-mediated NF-κB activity, thus FLIP Snitrosylation provides a novel molecular mechanism of FLIP-mediated NF-κB
regulation (Kataoka and Tschopp 2004; Golks, Brenner et al. 2006). FLIP can
interact with multiple proteins upstream of NF-κB and therefore it is not surprising
to discover that differences in FLIP signaling and nitrosylation state can lead to
the activation of NF-κB via multiple avenues. An increasing number of studies
have been reported examining the inhibition of FLIP using small molecule
inhibitors, chemicals or siRNA techniques (Bijangi-Vishehsaraei, Saadatzadeh et
al.; Sanchez-Perez, Ortiz-Ferron et al.; Luo, Wang et al. 2008; Wilson, McEwan
et al. 2009), however, additional regulation may be found within the cell by PTMs.
FLIP PTMs have been shown to be involved in changes in its stability,
binding partner interactions and localization.

FLIP phosphorylation prevents

localization to the DISC in TRAIL-mediated DR5 signaling and leads to an
increase in TRAIL mediated apoptosis (Higuchi, Yoon et al. 2003). We have
previously reported that FLIP S-nitrosylation prevents ubiquitination and
subsequent degradation (Chanvorachote, Nimmannit et al. 2005). S-nitrosylation
has gained increasing importance as a PTM that affects protein interactions and
signaling pathways. The tumor environment frequently has elevated NO levels
due to constitutive iNOS activity and redox imbalances, leading to an overall
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increase in protein nitrosylation. In this study, we demonstrate NF-κB induction
by wildtype and nitrosylable FLIP in a dose-dependent manner. However, NF-κB
activation is completely abrogated, when testing a mutant of FLIP that cannot be
nitrosylated at residues 254 and 259.

Rescue of NF-κB activity by FLIPS (FLIP

2DED) indicates there are at least two separate mechanisms for FLIP-mediated
NF-κB activation in agreement with previous reports that FLIP isoforms have
distinct signaling, because the nitrosylation sites we investigated map within the
caspase-like domain and not the DED (Krueger, Schmitz et al. 2001; Wajant
2003). NO supplementation results in an increase in overall protein nitrosylation,
however we observed a decrease in NF-κB activity, contrary to the expected
increase from additionally S-nitrosylated FLIP.

Others have shown NF-κB

activity is inhibited when subunit p50 is S-nitrosylated due to its inability to bind
DNA (Marshall and Stamler 2001).

Interestingly, our results show FLIP

significantly induces NF-κB activation even with NO inhibition. FLIP has most
notably been reported as an inhibitor of apoptosis by binding procaspase-8
thereby preventing its activation (Irmler, Thome et al. 1997; Krueger, Baumann et
al. 2001). We further demonstrate that S-nitrosylation at residues 254 and 259
are necessary to confer this resistance to apoptosis.
It has been previously reported that FLIP interacts specifically with TRAF2
to activate NF-κB (Kataoka and Tschopp 2004). We were unable to demonstrate
that the S-nitrosylation of FLIP at residues 254 and 259 alters the interaction with
TRAF2, indicating that this interaction is not responsible for the change in Snitrosylated FLIP-mediated NF-κB activation. RIP1 is another essential signaling
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protein for TNFR-mediated NF-κB activation (Kelliher, Grimm et al. 1998). The
ubiquitination state of RIP is mediated by cIAPs, which determine the formation
of the DISC or NF-κB signaling complex (Geserick, Hupe et al. 2009).

Our

results demonstrate that the S-nitrosylation of FLIP at residues 254 and 259
mediate RIP binding and localization.

Our results indicate that the altered

interaction between FLIP and RIP1 as a consequence from S-nitrosylation,
contributes to the mechanism for FLIP-mediated NF-κB activation. With nonnitrosylable FLIP retaining RIP binding, thus preventing RIP1 recruitment to DRs,
NF-κB is unable to be canonically activated. Protein sequestration is a common
means for controlling signal transduction. For example, compartmentalization by
lipid rafts changes the makeup of TNFR1 and Fas signaling complexes (Schutze,
Tchikov et al. 2008).
Varying FLIP mRNA transcripts correspond to FLIPL and FLIPS and have
been reported to have varying affinity in binding partners and distinctive
downstream signaling, in addition to the classical anti-apoptotic function through
caspase-8 inhibition (Park, Kim et al. 2001; Kim, Park et al. 2008). FLIPL has
been shown to be a caspase-8 substrate resulting in a 43kDa protein with more
robust NF-κB activation (Kataoka and Tschopp 2004; Dohrman, Kataoka et al.
2005). We identified in FasL and TNF-α treated A549 cells, which express high
levels of FLIP, additional cleavage fragments. Additionally, we demonstrate that
FLIPL is being cleaved into smaller fragments by using a myc-tagged expression
construct that includes only the exon regions of the coding sequence thereby
preventing the smaller fragments from being mRNA splice variants. Given that
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different forms of FLIP have different signaling capabilities, this could have
dramatic implications in chemotherapy-resistant cancer cells that have elevated
levels of FLIP in conjunction with high levels of caspase-8.

Ligand-induced

cleavage and multiple cleavage truncations of FLIP have not been previously
reported, and it is currently unknown if caspase-8 is responsible for the additional
cleavage fragments. Additionally, the increases in NO associated with disease
could further impact this signaling pathway, since FLIP is subject to nitrosylation.
The S-nitrosylation status of FLIP likely affect proteolytical processing of FLIP,
since we were unable to detect cleavage in our FLIP 2CM transfected cells.
Our data could suggest that S-nitrosylation of FLIP leads to an increase in
NF-κB activity in two distinct ways. First, S-nitrosylation of FLIP results in an
increase in FLIP processing thereby generating a p22 fragment which is a known
inducer of NF-κB (Golks, Brenner et al. 2006). The FLIP 2CM was unable to be
processed into the p22 fragment and therefore would be unable to induce NF-κB
through this mechanism.

Second, FLIP S-nitrosylation could lead to the

disassociation of binding with RIP1 potentially promoting RIP1’s activation of NFκB.

The FLIP 2CM retained RIP1 binding potentially interfering with RIP1-

mediated NF-κB activation. However, there is still a signaling paradox in this
system of NO-signaling as TNF-α-stimulation results in an overall decrease in Snitrosylation of FLIP as well as an overall decrease in NO production (data not
shown). The specific details of S-nitrosylation are reported to be exceedingly
complex and the mechanisms of targeted specificity still remains unclear
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(Tannenbaum and White 2006). We clearly demonstrate S-nitrosylation of FLIP
affects FLIP function, however it probably does not affect all FLIP interactions.
In summary, many chemotherapy-resistant tumors are insensitive to cell
death through elevated levels of FLIP and consequently elevated NF-κB activity.
Targeted FLIP silencing has been shown to restore sensitivity to DR-mediated
apoptosis (Sharp, Lawrence et al. 2005). Studies on FLIP regulation by PTMs
and resulting interactions are imperative to better understand its role in normal
physiology and pathogenesis of cancer and inflammation. Specifically our results
suggest that developing strategies to interfering with FLIP S-nitrosylation could
have potential for future targeted therapies for chemotherapy-resistant tumors.
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Figures

FIGURE 1.

FIGURE 1. S-nitrosylation of FLIP A) A schematic of the domain structure of
FLIP isoforms and expression vectors is shown. FLIP wt, FLIP 2DED (Death
Effector Domains), FLIP 2CM. B) HEK-293 cells were transiently transfected with
myc-FLIP wt or myc-FLIP 2CM and treated with media alone (no txt), 300 μM
AG, 400 μM NONOate for 12 hours or 50 ng/mLTNF-α for 30 min. Analysis for
S-nitrosylation was determined by fluorescence described in Materials and
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Methods. C) HEK-293 cells were transiently transfected with myc-FLIP or mycFLIP 2CM. myc-FLIP expressing cells were treated as in B). Lysates were
coimmunoprecipitated using anti-myc antibodies and assayed for S-nitrocysteine
by streptavidin using an S-nitrosylation kit. Membranes were stripped and
reprobed with anti-myc antibodies to detect FLIP. Total cell lysates (TCL) were
also probed with anti-GAPDH antibodies to control for loading. Error bars
represent standard deviation. * indicates a statistical significance from no
treatment (no txt) control (p < 0.05). Experiments were repeated three times.
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FIGURE 2.

FIGURE 2. FLIP-mediated NF-κB activation HEK-293 cells were transiently
transfected with an NF-κB-luciferase and Renilla-luciferase reporter and
expression constructs for the FLIP domains, as indicated. Luciferase activity was
determined by the dual-luciferase reporter assay. A) Cells were transiently
transfected with increasing amounts of FLIP and an NF-κB luciferase reporter
plasmid. NF-κB activity was determined by luminescence according to Materials
and Methods. B) Total cell lysates were also analyzed by Western blot using an
anti-myc antibody to verify the increasing expression levels of FLIP. C) Cells
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were transiently transfected with empty vector (EV), FLIP, FLIP 2CM, FLIP 2DED
or FLIP 1DED and analyzed for NF-κB activity as noted in (A). D) Total cell
lysates were also analyzed by Western blotting as above to verify expression of
all constructs. E) Cells were transiently transfected with EV, FLIP, FLIP 2CM or
FLIP 2DED. Cells treated with media alone, 400 μM NONOate or 500 μM SNP
for 12 hours to supplement nitric oxide and analyzed for NF-κB activity as noted
in (A). F) Cells were transiently transfected with empty vector (EV), FLIP wt or
FLIP 2CM, and cells were treated with media alone, 300 μM AG or 300 μM PTIO
for 12 hours to inhibit NO production. Lysates were analyzed for NF-κB activity
as noted in (A). Error bars represent standard deviation. All luciferase
experiments were repeated at least three times. * indicates statistical significance
from EV transfected cells. # indicates statistical significance from no treatment
(no txt) control (p < 0.05).
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FIGURE 3.

FIGURE 3. S-nitrosylation of FLIP modulates its anti-apoptotic activity.
MCF-7 cells were transiently transfected with FLIP or FLIP 2CM expression
constructs. 24 hours post-transfection, cells were treated with media alone, 50
ng/mL TNF-α or 200 ng/mL FasL for 16 hours. Cells were assayed by Hoechst
33342 staining to determine the percentage of apoptotic cells. A) Examples of
Hoechst staining. B) Graphical representation of 15 fields of view analyzed. *
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indicates statistical significance from control and ‡ and ^ indicate statistical
significance compared to treated EV (p < 0.05).
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FIGURE 4.

FIGURE 4. S-nitrosylation of FLIP modulates its interaction with RIP1 and
localization of RIP. A) HEK-293 cells were transiently transfected with myc-FLIP
or myc-FLIP 2CM expression constructs. 36 hours post-transfection, cells were
either left untreated or treated with 50 ng/mL TNF-α for 30 min. Lysates were
coimmunoprecipitated with anti-myc antibodies to purify FLIP and probed for
endogenous RIP. Membranes were stripped and reprobed with anti-myc
antibodies. Lysates were also probed with anti-myc antibodies to detect FLIP,
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anti-RIP1 and anti-GAPDH antibodies. B) HEK-293 cells were transiently
transfected with myc-FLIP, myc-FLIP 2CM and FLAG-RIP1 expression
constructs as indicated, left untreated or stimulated with 50 ng/mL TNF-α for 10
or 15 min. Cells were fixed, immunostained with anti-myc and anti-FLAG
antibodies and fluorescently labeled secondary antibodies and phalloidin to
visualize actin and analyzed by confocal microscopy. White arrows indicate RIP
localization to the membrane.
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FIGURE 5.

FIGURE 5. TRAF2 binding to FLIP is not dependent on FLIP S-nitrosylation
A) HEK-293 cells were transiently transfected with myc-FLIP or myc-FLIP 2CM
expression constructs. 36 hours post-transfection, cells were left untreated or
treated with 50 ng/mL TNF-α for 30 min. Lysates were coimmunoprecipitated
with anti-myc antibodies to purify FLIP and probed for endogenous TRAF2.
Membranes were stripped and reprobed with anti-myc antibodies to detect FLIP.
Total cell lysates (TCL) were also probed for myc-FLIP, TRAF2 and GAPDH to
demonstrate equal loading. B) HEK-293 cells were transiently transfected with
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myc-FLIP, myc-FLIP 2CM and CFP-TRAF2 expression constructs as indicated,
left untreated or stimulated with 50 ng/mL TNF-α for 10 or 15 min. Cells were
fixed, immunostained with anti-myc and anti-CFP antibodies and fluorescently
labeled secondary antibodies and phalloidin to visualize actin and analyzed by
confocal microscopy. White arrows indicate TRAF2 localization to the membrane.

93

FIGURE 6.

FIGURE 6. S-nitrosylation of FLIP promotes protein processing into shorter
forms A) A549 cells were analyzed for endogenous FLIP expression. Cells were
treated with media alone (txt), pretreated with 1 μM MG132 for 24 hours, 50
ng/mL TNF-α for 30 min or 100 ng/mL FasL for 4 and 6 hours. B) HEK-293 cells
were transiently transfected with empty vector (EV), myc-FLIP or myc-FLIP 2CM
expression constructs. 36 hours post-transfection, cells were left untreated or
treated with 50 ng/mL TNF-α for 30 min or 200 ng/mL FasL for 4 hours and
analyzed by Western blot using anti-myc antibodies to detect FLIP. Membranes
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were stripped and reprobed with anti-GAPDH antibodies to control for equal
loading. C) MCF-7 cells were transiently transfected as in B, and left untreated or
treated with 50 ng/mL TNF-α for 30 min. Total lysates were analyzed by
Western blot with anti-myc and anti-GAPDH antibodies. D) MCF-7 cells were
transiently transfected with EV or myc-FLIP. 36 hours post-transfection, cells
were left untreated or treated with 200 ng/mL FasL, 600 μM AG or 400 μM
NONOate for 4 hours. Total lysates were analyzed by Western blot with anti-myc
and anti-GAPDH antibodies.
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Abstract
Acquired capability of tumor cells to migrate and invade neighboring
tissues is associated with high metastatic potential and advanced stage of
cancers. Recently, signaling molecules such as reactive oxygen species (ROS)
and caveolin-1 (Cav-1) have been implicated in the aggressive behavior of
cancer cells. However, the role of specific ROS in cancer cell migration and Cav1 regulation are unclear. We demonstrate here that Cav-1 plays an important
role in the migration and invasion of human lung carcinoma H460 cells and that
these effects are differentially regulated by cellular ROS. Using various known
inhibitors and donors of ROS, we found that different ROS have different effects
on Cav-1 expression and cell migration and invasion. Superoxide anion and
hydrogen peroxide down-regulated Cav-1 expression and inhibited cell migration
and invasion, while hydroxyl radical up-regulated the Cav-1 expression and
promoted cell migration and invasion. The down-regulating effect of superoxide
anion and hydrogen peroxide on Cav-1 is mediated through a transcriptionindependent mechanism that involves protein degradation via the ubiquitinproteasome pathway. These results indicate the essential role of different ROS
in cancer cell motility and through Cav-1 expression, which may provide a key
mechanism controlling tumor progression and metastasis. The up-regulation of
Cav-1 and cell motility by hydroxyl free radical suggests an important role of this
ROS as a positive regulator of tumor progression.
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Introduction
Cancer cell migration and invasion are initial steps in metastasis which is
a primary cause of cancer-related death. During metastasis, primary tumor cells
migrate and invade neighboring tissues and enter the circulation to establish new
or secondary tumor sites (Friedl and Wolf 2003; Gupta and Massague 2006;
Bacac and Stamenkovic 2008). Increasing evidence suggests that signaling
molecules presenting in the tumor microenvironment have a significant impact on
the migratory properties of cancer cells (Laurent, Nicco et al. 2005; Kopfstein and
Christofori 2006). For example, increased ROS in the tumor micro-environment
has been associated with increased aggressiveness of cancer cells (Droge
2002). While several studies have investigated the effects of ROS on cell
migration and invasion, variable results have been reported depending on the
type of ROS, dose, and production site, as well as the tissue type of cells
(O'Toole, Goel et al. 1996; Urbich, Dernbach et al. 2002; Novo, Marra et al. 2006;
Kumar, Koul et al. 2008). Several mechanisms of ROS regulation of cancer cell
migration have been proposed; most of which involve alterations of cellular
cytoskeleton and adhesion molecules. For instance, ROS have been reported to
regulate integrin (Chiarugi, Pani et al. 2003; Svineng, Ravuri et al. 2008), small
GTPase Rho family proteins (Alexandrova, Kopnin et al. 2006; Tobar, Caceres et
al. 2008), focal-contact forming proteins (Chiarugi, Pani et al. 2003), and
extracellular matrix-degrading enzymes such as matrix metallo proteinases
(MMPs) (Nelson and Melendez 2004; Lee, Hwang et al. 2008; Svineng, Ravuri et
al. 2008).
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Caveolin-1 (Cav-1) is an essential structural protein component of the
plasma membrane micro domains called caveolae. It has been shown to
function in vesicular trafficking, signal transduction, and tumor progression. Cav1 interacts with several signaling molecules including Ha-Ras, Src-family tyrosine
kinases, G protein α subunits, and protein kinase C (Oka, Yamamoto et al. 1997;
Grande-Garcia, Echarri et al. 2007; Joshi, Strugnell et al. 2008; Park and Han
2009). Increased expression of Cav-1 has been observed in lung
adenocarcinoma and prostate cancer, which are associated with their
invasiveness (Ho, Huang et al. 2002; Yoo, Park et al. 2003; Williams, Hassan et
al. 2005). In lung carcinoma, the elevated Cav-1 expression is also associated
with an increase in metastatic capacity and poor survival of patients (Yoo, Park et
al. 2003; Moon, Lee et al. 2005; Cassoni, Daniele et al. 2009). On the other
hand, Cav-1 has been shown to have a suppressive effect on pancreatic and
breast cancer cell motility (Payne, Bonnefous et al.; Fiucci, Ravid et al. 2002;
Sloan, Stanley et al. 2004). Thus, the role of Cav-1 in cancer cell migration and
metastasis remains unclear and appears to be cell type dependent.
Increased oxidative stress and ROS production have also been
associated with many human metastatic tumors including the lung (Chung-man
Ho, Zheng et al. 2001; Misthos, Katsaragakis et al. 2005), breast, prostate, colon
(Szatrowski and Nathan 1991), and ovary (Hileman, Liu et al. 2004). ROS such
as superoxide anion (O2-), hydrogen peroxide (H2O2), and hydroxyl radical (OH⋅)
have been shown to be upregulated in the tumor micro-environment and have
been suggested to play a role in tumor progression and metastasis (Laurent,
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Nicco et al. 2005; Storz 2005). While ROS are likely to affect cancer cell motility
and invasiveness through multiple mechanisms, Cav-1 may play a key role in this
process since Cav-1 is known to be abnormally regulated in invasive tumors and
play a role in cancer cell migration (Ho, Huang et al. 2002; Yoo, Park et al. 2003;
Moon, Lee et al. 2005; Williams, Hassan et al. 2005; Cassoni, Daniele et al.
2009). Cav-1 is also subject to regulation by ROS (Volonte, Zhang et al. 2002;
Esme, Cemek et al. 2008), but the underlying mechanism of regulation and the
specific ROS involved are unclear. In this study, we investigated the roles of
specific ROS including O2-, H2O2, and OH⋅ in Cav-1 expression and cell
migration, and determined the mechanisms of regulation in human lung
carcinoma H460 cells. The following specific questions are addressed: a)
whether Cav-1 plays a role in the cell migration and invasion; b) whether Cav-1 is
regulated by ROS and if so by what mechanism; and c) what specific ROS are
involved and how they affect cell migration and invasion.
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Experimental Procedures
Cells and Reagents: Human lung cancer epithelial H460 cells were obtained from
American Type Culture Collection (ATCC, Manassas, VA). The cells were
cultured in RPMI 1640 medium containing 10% fetal bovine serum (FBS), 2 mM
L-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin in a 5% CO2
environment at 37° C. 3-(4,5-Dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT), 2’,7’-dichlorodihydrofluorescein diacetate (H2DCF-DA), 2,3dimethoxy-1,4-naphthoquinone (DMNQ), 5,5-dimethyl-1-pyrroline-N-oxide
(DMPO), Hoechst 33342, hydrogen peroxide, catalase, ferrous sulfate
heptahydrate, sodium formate, deferoxamine, lactacystin, type IV collagen, and
laminin were obtained from Sigma (St. Louis, MO). Mn(III)tetrakis(4-benzoic
acid)porphyrin chloride (MnTBAP) and concanamycin A were obtained from
Calbiochem (San Diego, CA). Antibodies for Cav-1, ubiquitin, β-actin,
peroxidase-labeled secondary antibodies, and protein-G agarose were obtained
from Abcam Inc. (Cambridge, MA). Antibody for phospho-Akt (Ser-473) was
from Cell Signaling Technology, Inc. (Beverly, MA).

Generation of Stable Cav-1 Overexpressing Cells: H460 cells were seeded in 6well plate until they reached 60% confluence. The cells were then transfected
with caveolin-1 plasmid (pEX_Cav-1-YFP) (ATCC) or control plasmid (pcDNA3)
using Lipofectamine reagent (Invitrogen, Carlsbad, CA) in culture medium in the
absence of serum. After 12 hours of incubation, the medium was replaced with
complete culture medium containing 10% FBS. Approximately 36 hours after the
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beginning of the transfection, the cells were trypsinized and plated onto 75-ml
culture flasks, and cultured for 28 days with neomycin containing medium (800
μg/ml). The pooled stable transfectant was identified by Western blotting of Cav1 and was cultured in neomycin-free RPMI medium for at least two passages
before each experiment.

Inhibition of Cav-1 by RNA Interference: Lentiviral transduction particles carrying
short hairpin RNA (shRNA) sequence against human Cav-1 (5’-CCGGGACGTG
GTCAAGATTGACTTTCTCGAGAAAGTCAATCTTGACCACGTCTTTTT-3’) and
control non-target sequence (5’-CCGGCAACAAGATGAAGAGCACCAACTCGA
GTTGGTGCTCTTCATCTTGTTGTTTTT-3’) were used to knockdown Cav-1
expression in H460 cells. The viral vectors were obtained commercially from
Sigma Chemical Inc. (Cat # NM_001753 and SHC002V, respectively) and were
used according to the manufacturer’s instruction. Briefly, cells were seeded in 6well plates (5x105/well) and incubated with Cav-1 shRNA lentiviral particles or
control particles at the multiplicity of infection (MOI) of 1.5 in the presence of
hexadimethrine bromide (8 μg/ml) for 36 hours. Transfected cells were analyzed
for Cav-1 by Western blotting prior to use.

Cytotoxicity Assay: Cell viability was determined by MTT assay. After specific
treatments, cells in 96-well plate were incubated with 500 µg/ml of MTT for 4
hours at 37° C. The intensity of formazan product was measured at 550 nm
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using a microplate reader. Absorbance ratio of treated to non-treated control
cells was calculated and presented as relative cell viability.

ROS Detection: Cellular ROS was determined by flow cytometry using H2DCFDA as a fluorescent probe and by electron spin resonance (ESR) spectroscopy
using DMPO as a spin trapping agent. For flow cytometric measurements, cells
were incubated with H2DCF-DA (10 μM) for 30 minutes at 37° C, after which they
were washed and resuspended in phosphate-buffered saline (PBS) and analyzed
for fluorescence intensity using a 485-nm excitation beam and a 538-nm bandpass filter (FACSort, Becton Dickinson, Rutherford, NJ). The mean fluorescence
intensity was quantified by CellQuest software (Becton Dickinson) analysis of the
recorded histograms. For ESR measurements, cells were incubated with DMPO
(100 mM) for 10 minutes at 37° C in the presence or absence of ROS
modulators. ESR signals were measured using a Bruker EMX spectrometer
(Bruker Instruments, Billerica, MA) and a flat cell assembly. Hyperfine couplings
were measured (to 0.1 G) directly from magnetic field separation using
potassium tetraperoxo-chromate and 1,1-diphenyl-2-picrylhydrazyl as reference
standards. An Acquisit program (Bruker Instruments) was used for data
acquisition and analysis.

Migration Assay: Cell migration was determined by wound or scratch assay.
Monolayer of cells was cultured in 24-well plate, and then a wound space was
made with 1 mm width tip. After rinsing with PBS, the cell monolayers were

103

treated with specific ROS modulators and allowed to migrate for 24 hours.
Micrographs were taken under a phase-contrast microscope (100X) (Olympus
DP70, Melville, NY) and wound spaces were measured from ten random fields of
view using an Olympus DP controller software. Quantitative analysis of cell
migration was performed by using an average wound space from those random
fields of view, and the percentage of change in the wound space was calculated
using the formula: % change = (average space at time 0 hours) - (average space
at time 24 hours) / (average space at time 0 hours) x 100. Relative cell migration
was calculated by dividing the percentage change in the wound space of treated
cells by that of the control cells in each experiment.

Invasion Assay: Invasion assay was performed using a 24-well Transwell unit
with polycarbonate (PVDF) filters (8 μm pore size). The membrane was coated
with a mixture of laminin (50 μg/ml), type IV collagen (50 μg/ml), and gelatin
solution (2 mg/ml in 10 mM glacial acetic acid). Cells at the density of 2 X 104
cells per well were seeded into the upper chamber of the Transwell unit in serumfree medium. The lower chamber of the unit was added with a medium
containing 10% FBS. After incubation with specific test agents for 24 hours at
37° C, the medium in the upper chamber was sucked out and the cells on the
upper side of membrane were removed with a cotton swab. Cells that invaded to
the underside of the membrane were stained with 10 μg/ml Hoechst 33342 for 10
minutes and visualized and scored under a fluorescence microscope.
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Western Blot Analysis: After specific treatments, cells were incubated in lysis
buffer containing 20 mM Tris-HCl (pH 7.5), 1% Triton X-100, 150 mM sodium
chloride, 10% glycerol, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 100
mM phenylmethylsulfonyl fluoride, and a commercial protease inhibitor mixture
(Roche Molecular Biochemicals) at 4° C for 20 minutes. Cell lysates were
collected and determined for protein content using the Bradford method (Bio-Rad
Laboratories, Hercules, CA). Proteins (40 μg) were resolved under denaturing
conditions by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred onto a nitrocellulose membrane. The membranes
were blocked for 1 hour in 5% nonfat dry milk in TBST (25 mM Tris-HCl, pH 7.4,
125 mM sodium chloride, 0.05% Tween 20) and incubated with appropriate
primary antibodies at 4° C for 1 hour. Membranes were washed twice with TBST
for 10 minutes and incubated with horseradish peroxidase-labeled isotypespecific secondary antibodies for 1 hour at room temperature. The immune
complexes were then detected by enhanced chemiluminescence detection
system (Amersham Biosciences, Piscataway, NJ) and quantified using
analyst/PC densitometry software (Bio-Rad Laboratories, Hercules, CA).

Immunoprecipitation: After specific treatments, cells were washed with PBS and
lysed in lysis buffer at 4° C for 20 minutes. Cell lysates were collected and
determined for protein content using the Bradford method. Lysate proteins (60
μg) were incubated with Cav-1 antibody for 14 hours at 4° C, followed by a 4hour incubation with protein G-conjugated agarose at 4° C. The immune
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complexes were washed 6 times with cold lysis buffer and resuspended in 2X
Laemmli sample buffer. The immune complexes were separated by 10% SDSPAGE and analyzed by Western blotting as described.

Quantitative Real-Time PCR: Total RNA was extracted with Trizol reagent
(Invitrogen). One microgram of extracted RNA was reverse-transcribed in a 100μl reaction mixture containing 500 μM dNTP, 125 units of MultiScribe Reverse
Transcriptase (Applied Biosystems, Foster City, CA), 40 units of RNase inhibitor,
2.5 μM oligo(dT), 1X Taq-Man reverse transcriptase buffer, and 5 mM MgCl2 at
48 °C for 40 minutes. The primers used in this study were designed using Primer
Express software (Applied Biosystems): Cav-1 (#AI878826) forward 5’-CGAGAA
GCAAGTGTACGACGC-3’, and reverse 5’-ACCACGTCATCGTTGAGGTG-3’;
glyceralde-hyde-3-phosphate dehydrogenase (GAPDH) forward, 5’-GAAGGTGA
AGGTCGGAGTC-3’, and reverse 5’-GAAGATGGTGATGGGATTTC-3’.
Amplification was performed at the following cycling conditions: 95 °C for 10
minutes followed by 40 cycles at 95 °C for 15 seconds and 60 °C for 1 minute. A
SYBR Green PCR Master Mix (Applied Biosystems) was used with 1 ng of cDNA
and with 100-400 nM primers. A negative control without any cDNA template
was run with every assay. All PCR reactions were performed by using ABI
PRISM 7900 Sequence Detection System (Applied Biosystems). Relative mRNA
levels were determined by using the comparative CT (threshold cycle) method
(40), where the caveolin-1 target is normalized to the control and compared with
a reference sample (assigned a relative value of 1) by the equation: 2-ΔΔCT.
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Statistical Analysis: Data were represented as the means ± S.D. from three or
more independent experiments. Statistical analysis was performed by Student’s
t test at a significance level of p < 0.05.
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Results
Differential Effect of ROS on Cell Migration
ROS have been shown to be involved in several cellular migratory
processes including wound repair, metastasis, and angiogenesis (O'Toole, Goel
et al. 1996; Steiling, Munz et al. 1999; Urbich, Dernbach et al. 2002; Ushio-Fukai
and Alexander 2004; Novo, Marra et al. 2006; Kumar, Koul et al. 2008).
However, the role of specific ROS and regulatory mechanisms are not well
understood. We tested whether ROS play a role in the migration of lung
carcinoma H460 cells and determined the specific ROS involved. Cells were
treated with various known inducers and scavengers of ROS, and their effect on
cell migration was determined by wound migration assay. Fig. 1A shows that
treatment of the cells with MnTBAP, a superoxide dismutase (SOD) mimetic and
scavenger of O2-, stimulated the migration of cells across the wound space,
whereas treatment of the cells with DMNQ, a known inducer of O2- (Ishihara,
Shiba et al. 2006; Herr, Zhou et al. 2007), had an opposite effect. Likewise,
treatment of the cells with catalase (CAT) (H2O2 scavenger) promoted cell
migration, whereas treatment with H2O2 inhibited the migration. These results
indicate the inhibitory role of O2- and H2O2 in the migration of H460 cells during
wound healing. In contrast to the above findings, treatment of the cells with
sodium formate (NaFM), a known OH⋅ scavenger (Dokka, Shi et al. 2001; Wang,
Leonard et al. 2004), inhibited the migration, while the OH⋅ generator ferrous
sulfate (FeSO4) promoted this effect. These results suggest the differential roles
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of ROS in the regulation of cancer cell migration with OH⋅ playing a promoting
role and O2- and H2O2 having an inhibitory role.
To ensure that the observed inhibitory and stimulating effects of ROS
modulators was not caused by a cytotoxic effect, cells were treated with the
same concentrations of the test modulators and their effect on cell viability was
determined by MTT assay. The results show that none of the treatments caused
a significant effect on cell viability as compared to non-treated control (Fig. 1B).

Detection of Cellular ROS
To provide supporting evidence for the role of ROS in cell migration,
cellular ROS in response to the above treatments were determined by flow
cytometry and electron spin resonance (ESR). Flow cytometric analysis was
performed using H2DCF-DA as a fluorescent probe. H2DCF-DA is a general
oxidative probe that can detect multiple ROS. The probe enters the cells and is
cleaved by cellular esterases to yield a non-fluorescent product,
dichlorofluorescin (DCFH), which is trapped inside the cells. Upon oxidation by
ROS, DCFH is converted to the fluorescent product DCF which is detected by
flow cytometry. Fig. 2A shows that the ROS inducers DMNQ, H2O2, and FeSO4
were able to increase the cellular DCF fluorescence intensity over control level,
whereas the ROS scavengers MnTBAP, CAT, and NaFM decreased the
fluorescence intensity, indicating multiple ROS generation and scavenging by the
treatments.
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To confirm the formation of ROS in the treated cells, ESR measurements
were performed using DMPO as a spin trapping agent to aid the detection of
short-lived oxygen free radicals. Fig. 2B shows a typical ESR spectrum
generated by incubating H460 cells in culture medium with DMPO. A weak ESR
signal consisting of a 1:2:2:1 quartet which is a characteristic of DMPO-OH⋅
adduct was observed, indicating the formation of OH⋅ radicals. Addition of the
Fenton catalyst and OH⋅ generator FeSO4 to the cells intensified this signal,
supporting the generation of OH⋅ radicals. Addition of the OH⋅ scavenger NaFM
to the FeSO4-treated cells inhibited the ESR signal, indicating the specificity of
OH⋅ detection and their scavenging by NaFM under the test conditions. Neither
H2O2 nor O2- was detectable in this study since the former is not a free radical
and the latter does not form a stable adduct with the spin trapping agent DMPO.

Caveolin 1 Promotes Cell Migration and Invasion
Cav-1 has been shown to modulate cell migration in different cell types
(Oka, Yamamoto et al. 1997; Fiucci, Ravid et al. 2002; Ho, Huang et al. 2002;
Williams, Hassan et al. 2005; Grande-Garcia, Echarri et al. 2007; Joshi, Strugnell
et al. 2008; Park and Han 2009). We tested whether Cav-1 can regulate the
migration and invasion of lung carcinoma H460 cells. The cells were stably
transfected with Cav-1 or control plasmid, and their effects on Cav-1 expression,
cell migration and invasion were determined. Western blot analysis of Cav-1
expression shows a substantial increase in the expression in Cav-1-transfected
cells as compared to vector-transfected control (Fig. 3A). Wound migration
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assay shows that the Cav-1-transfected cells exhibited an increase in migratory
activity as compared to control-transfected cells (Fig. 3B). Transwell invasion
assay similarly indicates an increase in cell invasiveness of the Cav-1
overexpressing cells as compared to control-transfected cells (Fig. 3C).
To confirm the role of Cav-1 in cell migration and invasion, Cav-1
expression was inhibited by RNA interference using shRNA against Cav-1
(shCav-1). H460 cells were treated with shCav-1 viral particles or control shRNA
(shCon) particles, and their effects on cell migration and invasion were
determined. Fig. 3D shows that Cav-1 expression was substantially reduced in
shCav-1-treated cells as compared to shCon-treated cells (left panel). Rescue
experiment was performed on the shCav-1 knockdown cells to exclude the offtarget effect of shCav-1 (right panel). Figs. 3E and 3F show that shCav-1 cells
exhibited reduced migratory and invasive activities as compared to shCon cells,
and that over-expression of Cav-1 in these cells reversed the migratory and
invasive activities. These results support the promoting role of Cav-1 in
migration and invasion of H460 cells.
To determine whether the effects of ROS on cell migration and invasion
are dependent on Cav-1 expression, shCav-1 and shCon cells were treated with
DMNQ, H2O2, and FeSO4 and their effects on cell migration and invasion were
determined. Figs. 4A and 4B show that DMNQ and H2O2 inhibited cell migration
and invasion in shCon cells but not in shCav-1 cells. FeSO4 increased cell
migration and invasion in shCon cells but had minimal effects in shCav-1 cells.
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These results indicate the role of Cav-1 in the ROS effects on cell migration and
invasion.
Cav-1 has been shown to regulate cell migration through a PI3K/Aktdependent mechanism (Ravid, Maor et al. 2005; Li, Ren et al. 2009). We tested
whether knockdown of Cav-1 affects Akt activity by analyzing phosphorylated Akt
(pAkt) levels in shCav-1 and shCon cells. Fig. 4C shows that pAkt level was
substantially reduced in shCav-1 cells as compared to shCon cells. This result is
consistent with our previous report showing the induction of Akt activation by
Cav-1 overexpression (Chanvorachote, Nimmannit et al. 2009). We also
investigated Akt activity in H460 cells in response to specific ROS. Fig. 4D
shows that DMNQ and H2O2 caused a decrease in pAkt level, whereas FeSO4
promoted it. These results are consistent with the observed effects of specific
ROS on Cav-1 expression and cell motility, supporting the role of Cav-1 in the
migratory process through Akt signaling.

ROS Regulate Cav-1 Expression
Cav-1 may be regulated by ROS which may represent a key mechanism
of cell migratory regulation by ROS. To test this possibility, cells were treated
with various ROS modulators and their effect on Cav-1 expression was
determined by Western blotting. Fig. 5A shows that treatment of the cells with
DMNQ or H2O2 substantially down-regulated the expression of Cav-1, whereas
treatment with FeSO4 up-regulated the expression. Consistent with the inhibitory
role of O2- and H2O2, the scavengers of these ROS (MnTBAP and CAT
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respectively) promoted the Cav-1 expression (Fig. 5B). In contrast, the OH⋅
scavenger NaFM inhibited the expression, supporting the positive regulatory role
of OH⋅ in Cav-1 expression. This latter result was confirmed by the observation
that deferoxamine (DFX), a known metal chelator and inhibitor of OH⋅, also
inhibited Cav-1 expression (Fig. 5B).

Role of Specific ROS in Cell Migration, Invasion, and Cav-1 Expression
To further determine the relationship between Cav-1 expression and cell
motility regulation by different ROS, cells were treated with various
concentrations of ROS modulators and their effects on cell migration, invasion,
and Cav-1 expression were determined. Figs. 6A and 6D show that DMNQ
caused a dose-dependent and parallel decrease in both cell migration and Cav-1
expression. Addition of MnTBAP reversed both of these effects of DMNQ,
indicating the role of O2- in the processes and their association. Similar to
DMNQ, H2O2 caused a dose-dependent and concomitant decrease in cell
migration (Fig. 6B) and Cav-1 expression (Fig. 6E), both of which were inhibited
by catalase. In contrast to O2- and H2O2, OH⋅ promoted cell migration (Fig. 6C)
and Cav-1 expression (Fig. 6F) as indicated by their positive responses to FeSO4
treatment and their inhibition by NaFM co-treatment, which were shown to induce
and inhibit respectively the formation of OH⋅ radicals (Fig. 2B). Together, these
results indicate the positive regulatory role of OH⋅ and the opposing role of O2and H2O2 in cell migration through Cav-1 expression. A similar finding was
observed with regard to the role of different ROS in cell invasion (Fig. 6G).
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Superoxide and Hydrogen Peroxide Downregulate Cav-1 by UbiquitinProteasomal Degradation
To investigate the mechanism of Cav-1 down-regulation by O2- and H2O2,
cells were treated with DMNQ and H2O2, and analyzed for Cav-1 mRNA
expression by quantitative real-time RT-PCR. Although causing a substantial
decrease in Cav-1 protein expression (Fig. 6A), treatment of the cells with DMNQ
and H2O2 did not cause a corresponding decrease in Cav-1 mRNA expression
(Fig. 7A). In fact, a slight increase was observed, possibly due to stress
induction. Thus, O2- and H2O2 appear to regulate Cav-1 protein expression
through a transcription-independent mechanism.
Since many proteins are regulated by ROS through protein degradation,
we tested the potential role of degradation in ROS-mediated Cav-1 downregulation. Degradation of endogenous proteins normally occurs through two
major pathways, proteasomal and lysosomal. We therefore tested the effect of
proteasome inhibitors, lactacystin and MG132, and lysosome inhibitor,
concanamycin A, on ROS-induced Cav-1 down-regulation. Figs. 7B and 7C
show that lactacystin and MG132, but not concanamycin A, inhibited Cav-1
down-regulation by DMNQ and H2O2, suggesting proteasomal degradation as a
primary mechanism of Cav-1 down-regulation by ROS.
Because proteins are targeted for proteasomal degradation via
ubiquitination, we tested whether ROS modulators induce ubiquitination of Cav-1
protein. Cells were treated with DMNQ and H2O2, and cell lysates were prepared
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and immunoprecipitated by anti-Cav-1 antibody. The resulting immune
complexes were then analyzed for ubiquitination by Western blots using antiubiquitin antibody. Figures 7D and 7E show that both DMNQ and H2O2 were
able to induce ubiquitination of Cav-1 and that these effects were inhibited by cotreating the cells with MnTBAP and catalase, respectively. Together, these
results indicate ROS-mediated down-regulation of Cav-1 through ubiquitinproteasomal degradation.

ROS Regulate Migration and Invasion of Cav-1 Overexpressing H460 cells and
Melanoma G361 Cells
To substantiate the role of ROS in cell migration and invasion,
experiments were performed in Cav-1 overexpressing H460 cells described
earlier and in melanoma G361 cells to determine cell type-specific effects of
ROS. The cells were treated with the ROS modulators DMNQ, H2O2, and
FeSO4, and their effects on cell migration and invasion were examined. The
results show that DMNQ and H2O2 had similar inhibitory effects on cell migration
and invasion in these cells, while FeSO4 had opposite effects (Fig. 8). These
results are consistent with the earlier findings in H460 cells (Fig. 6) and suggest
the generality of the observed ROS effects on cell migration and invasion.
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Discussion
The role of ROS in the regulation of cell migration and invasion has been
described (Laurent, Nicco et al. 2005; Storz 2005), but the role of specific ROS
and their regulatory mechanisms have not been well investigated. We report
here that different ROS have different effects on cell migration and invasion in
human lung carcinoma H460 cells and melanoma G361 cells. O2- and H2O2
suppress the migration and invasion of the cells, whereas OH⋅ promotes the cell
motility activities. Since several ROS are generated during oxidative stress
which has been linked to tumor progression, the results of this study further
indicate that depending on the type and abundance of specific ROS generated,
oxidative stress conditions may promote or suppress tumor progression by
affecting cell migration and invasion.
The present study also demonstrates the role of Cav-1 as a key target of
ROS regulation of cell motility. Cav-1 has been shown to be involved in cancer
cell motility and tumor progression (Fiucci, Ravid et al. 2002; Sloan, Stanley et al.
2004; Williams and Lisanti 2004; Joshi, Strugnell et al. 2008). However, its
precise role and regulatory mechanisms are still unclear as both promoting and
inhibitory roles of Cav-1 have been reported. In pancreatic cancer cells, Cav-1
was shown to inhibit cell migration and invasion through the inactivation of RhoC
GTPase and Erk-MMP signaling pathways (Han and Zhu; Lin, DiVito et al. 2005).
A similar inhibitory effect of Cav-1 was observed in breast cancer MTLn3 and
MCF-7 cells (Zhang, Razani et al. 2000; Fiucci, Ravid et al. 2002). In contrast,
Cav-1 has been reported to promote lung cancer cell invasion by mediating
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filopodia formation (Ho, Huang et al. 2002). Furthermore, Cav-1 expression is
associated with the tumor grade and metastasis of non-small cell lung cancer
(NSCLC) (Kato, Miyamoto et al. 2004; Moon, Lee et al. 2005). Consistent with
the tumor promoting role of Cav-1, we found that Cav-1 promotes the migration
and invasion of NSCLC H460 cells. The function of Cav-1 is closely associated
with its expression level. Although the difference in Cav-1 expression may result
from various factors such as cell type and stage of cancer (Shatz and Liscovitch
2008), the tumor microenvironment and oxidative status seem to play a key role.
Several ROS have been shown to be up-regulated in the tumor
microenvironment and have been implicated in the aggressive behaviors of
tumor cells (Laurent, Nicco et al. 2005; Storz 2005). However, the mechanisms
by which ROS regulate Cav-1 and tumor cell migration and invasiveness have
not been thoroughly explored. In the present study, we demonstrate that ROS
play an important role in regulating Cav-1 expression and cell migratory functions
in human lung cancer H460 cells. We also show the positive correlation between
Cav-1 expression and cell motility in these cells. More importantly, we
demonstrate the differential roles of individual ROS in Cav-1 expression and cell
migration with O2- and H2O2 having a negative regulatory role, and OH⋅ playing a
positive role.
The results of this study also indicate that the effect of ROS on cell
migratory functions is dependent on Cav-1 expression and is associated with Akt
activity. Activation of Akt by Cav-1 has been shown to mediate cancer cell
migration (Ravid, Maor et al. 2005; Li, Ren et al. 2009; Park and Han 2009) and
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is likely to play an important role in the ROS-induced effects on cell motility
alterations. ROS may also regulate cell motility through other Cav-1-dependent
mechanisms. For example, recent studies have shown that oxidative stress
induced Cav-1 phosphorylation at tyrosine 14 (Chen, Li et al. 2005; Sun, Hu et al.
2009), which has been proposed to play a role in cancer cell migration through
the regulation of focal adhesion (Joshi, Strugnell et al. 2008).
The expression of Cav-1 is tightly regulated at various levels, including
transcriptional and post-transcriptional [for review, see (Williams and Lisanti
2004)]. We found that the down-regulation of Cav-1 by O2- and H2O2 was not
due to transcriptional inactivation since Cav-1 mRNA expression was not downregulated but slightly increased by the O2- inducer DMNQ and H2O2, possibly due
to stress induction. Instead, such down-regulation was shown to be mediated by
protein degradation via the ubiquitin-proteasome pathway. The negative
regulatory roles of O2- and H2O2 in Cav-1 expression and cell motility were
confirmed by the observations that the scavengers of O2- and H2O2 (MnTBAP
and catalase) were able to reverse the effects of DMNQ and H2O2. These results
are consistent with human clinical data showing an increase in MnSOD and
catalase activities in patients with NSCLC (Chung-man Ho, Zheng et al. 2001).
Such increases may result in decreased O2- and H2O2 levels and elevated Cav-1
and migratory activities.
The promoting role of OH⋅ in cancer cell migration and Cav-1 expression
is unexpected and suggests the potential important role of this oxidative species
in tumor progression and metastasis. To our knowledge, this is the first
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demonstration of the positive regulatory role of OH⋅ in cancer cell motility and
Cav-1 expression. This finding also suggests that elevated OH⋅ levels may
increase the risk of cancer metastasis. OH⋅ is a highly reactive free radical
generated primarily via a biologic Fenton reaction. In addition to its known ability
to induce lipid peroxidation and DNA damage, recent studies suggest that it may
exert its cellular effects through the alterations of several key proteins such as
p53 and MMPs (Jiang, Wei et al. 2007). The mechanisms of OH⋅ regulation of
cancer cell migration and invasiveness are not known and likely involve several
signaling pathways. Our study provides initial evidence that this regulation is
mediated, at least in part, through Cav-1 up-regulation.
In conclusion, we demonstrate that Cav-1 plays an important role as a
positive regulator of cancer migration and invasion in human lung carcinoma
H460 cells. Our results also reveal the differential roles of individual ROS in
cancer cell motility and Cav-1 expression, which could be important in
understanding tumor progression and metastasis. Our results also provide
evidence supporting the role of OH⋅ as a key determinant and positive regulator
of cancer cell invasiveness. This new finding suggests a linkage between
elevated OH⋅ formation and increased risk of tumor formation and metastasis.
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FIGURE 1. ROS regulate migration of human lung epithelial H460 cells. A,
confluent monolayers of H460 cells were wounded and the cells were allowed to
migrate for 24 hours in the presence or absence of various ROS modulators,
including MnTBAP (50 μM), DMNQ (5 μM), CAT (7,500 U/ml), H2O2 (100 μM),
NaFM (5 mM), and FeSO4 (50 μM). Wound space was visualized under a phasecontrast microscope and analyzed by comparing the relative change in wound
space of the treated over non-treated cell monolayers. Representative
micrographs from four independent experiments are shown. B, effect of ROS
modulators on cell viability. Cell monolayers were similarly treated with the
indicated concentrations of ROS modulators and analyzed for cell viability after
24 hours by MTT assay. Data are the mean ± S.D. (n = 4). *, p < 0.05 versus
non-treated control.
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FIGURE 2. Effect of ROS modulators on cellular ROS. A, H460 cells were
treated with the indicated concentrations of ROS modulators as shown in Figure
1 and analyzed for ROS levels by flow cytometry using H2DCF-DA as a
fluorescent probe. Data shown are relative fluorescence intensities over control
level determined at 2 hours post-treatment. B, ESR detection of ROS. H460 cells
(1x106 cells/ml) were incubated in culture medium containing the spin trapper
DMPO (100 mM) with or without FeSO4 (50 μM) and NaFM (5 mM). ESR spectra
were recorded 10 minutes after the addition of the test agents. The spectrometer
settings were as follows: receiver gain at 2.5x104, time constants at 0.04
seconds, modulation amplitude at 1.0 G, scan time at 42 seconds, magnetic field
at 3475 ± 100 G. Data are the mean ± S.D. (n = 3). *, p < 0.05 versus nontreated control.
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FIGURE 3. Effects of Cav-1 overexpression and knockdown on cell
migration and invasion. H460 cells were stably transfected with Cav-1 or
control plasmid as described under “Materials and Methods”. A, Cav-1
expression in the control and Cav-1-transfected cells was determined by Western
blotting. Cell extracts were prepared and separated on 10% polyacrylamide-SDS
gels, transferred, and probed with Cav-1 antibody. β-actin was used as a loading
control. B, effect of Cav-1 overexpression on cell migration. Cav-1 and controltransfected cells were cultured in 24-well plates and analyzed for cell migration at
24 hours by wound assay. C, effect of Cav-1 overexpression on cell invasion.
Cav-1 and control-transfected cells were added to extracellular matrix-coated
inserts in a Transwell chamber and incubated for 24 hours. Invading cells were
counted under a fluorescence microscope after staining with Hoechst 33342 and
the average number of cells was scored in each case. D-F, Cav-1 knockdown
experiments were performed using H460 cells treated with Cav-1 shRNA (shCav1) viral particles or control shRNA (shCon) particles as described under
“Materials and Methods”. D, Cav-1 expression in shCav-1 and shCon-treated
cells determined by Western blotting at 36 hours post-treatment (left panel).
Rescue experiment was performed in shCav-1-treated cells by transfecting the
cells with Cav-1 plasmid as described above and analyzed for Cav-1 expression
by Western blotting (right panel). E and F, migration and invasion of shCon,
shCav-1, and rescued cells determined by wound and Transwell assays,
respectively. Data are the mean ± S.D. (n = 3). *, p < 0.05 versus control
transfection; #, p < 0.05 versus shCav1control.
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DMNQ (5 μM), H2O2 (100 μM), and FeSO4 (50 μM) for 24 hours and analyzed for
cell migration and invasion. C, shCav-1 and shCon cells were analyzed for Akt
phosphorylation by Western blotting. Blots were probed with phospho-Akt Ser473 antibody and reprobed with β-actin antibody. D, H460 cells were treated with
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DMNQ (5 μM), H2O2 (100 μM) and FeSO4 (50 μM), and analyzed for Akt
phosphorylation at 6 hours post-treatment. Data are the mean ± S.D. (n = 3). *, p
< 0.05 versus control cells.
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(50 μM) for 24 hours, and cell lysates were prepared and analyzed for Cav-1
expression by Western blotting. B, cells were treated with various ROS
scavengers or inhibitors, including MnTBAP (50 μM), CAT (7,500 U/ml), NaFM (5
mM), and DFX (0.5 mM), and Cav-1 expression was determined after 24 hours.
Blots were reprobed with β-actin antibody to confirm equal loading of samples.
The immunoblot signals were quantified by densiometry, and mean data from
three independent experiments (one of which is shown here) was normalized to
the result obtained in control cells. Data are the mean ± S.D. (n = 3). *, p < 0.05
versus non-treated control.
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and invasion. Western blot analysis of Cav-1 expression in H460 cells treated
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after the treatment with D, DMNQ and MnTBAP; E, H2O2 and CAT; and F, FeSO4
and NaFM. G, cell invasion determined 24 hours after the treatment with DMNQ
(5 μM), H2O2 (100 μM), and FeSO4 (50 μM). Data are the mean ± S.D. (n = 3). *,
p < 0.05 versus non-treated control.
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FIGURE 7. Effects of ROS on Cav-1 mRNA expression and protein
degradation. A, H460 cells were either left untreated or treated with DMNQ (5
μM), H2O2 (100 μM), or FeSO4 (50 μM) for 24 hours. Cav-1 and GAPDH mRNA
expression were then determined by quantitative real-time PCR. The relative
mRNA expression was determined by using the comparative CT method as
described under “Materials and Methods.” B and C, H460 cells were pretreated
with proteasome inhibitor lactacystin (LAC) (10 μM), MG132 (25 μM), or with
lysosome inhibitor concanamycin A (CMA) (1 μM) for 1 hour and then treated
with DMNQ (5 μM) or H2O2 (100 μM) for 24 hour. Cav-1 expression was
determined by Western blots using anti-Cav-1 antibody. D and E, cells were
treated with DMNQ (5 μM) in the presence or absence of MnTBAP (50 μM), or
with H2O2 (100 μM) in the presence or absence of CAT (7,500 U/ml). Cell lysates
were immunoprecipitated with anti-Cav-1 antibody and the immune complexes
were analyzed for ubiquitin by Western blots using anti-ubiquitin antibody.
Analysis of ubiquitin was performed at 2 hours post-treatment where
ubiquitination was found to be maximal. Immunoblot signals were quantified by
densiometry, and mean data from three independent experiments (one of which
is shown here) was normalized to the result obtained in control cells. Data are
the mean ± S.D. (n = 3). *, p < 0.05 versus non-treated control; #, p < 0.05 versus
treated control.
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hours after the treatment with DMNQ (5 μM), H2O2 (100 μM), and FeSO4 (50
μM). Experiments were performed using wound assay and Transwell assay,
respectively. C and D, experiments were repeated using melanoma G361cells.
Data are the mean ± S.D. (n = 3). *, p < 0.05 versus non-treated control.
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Chapter 4. General Discussion and Conclusions

Overview

The overall objective of this dissertation was to examine the effects of NO
and ROS on different cellular signaling pathways that enhance tumorigenesis.
Oxidative stress responses are part of normal physiological cellular processes of
proliferation, senescence and cell death (Schrader and Fahimi 2006). However,
chronic oxidative stress which occurs during prolonged inflammatory signaling
can advance tumorigenesis (Bubici, Papa et al. 2006). NO and ROS are
normally produced at low levels within the cell, however high levels are detected
in cancer cells and within the tumor microenvironment (Pelicano, Carney et al.
2004). Hypoxia, increased iNOS activity, mitochondrial dysfunction and chronic
cytokine and inflammatory signaling all lead to these increases. Additionally,
many cancer therapeutics induce ROS production. The roles of anti- versus prooxidant therapies are widely debated throughout the clinical cancer field (Wang
and Yi 2008), however the sub-lethal signaling effects or both NO and ROS are
exceedingly important as they impact known tumorigenic pathways.
We were most interested in the effects of NO and ROS on existing tumor
cells where aberrations in their signaling profiles are already noted. In chapter 2,
we examined NO changes on the antiapoptotic protein FLIP which is highly
upregulated in chemotherapy-resistant cancers. In chapter 3, we examined the
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effects of different ROS species on Cav-1-dependent migration in NSCLC cells.
Our results indicate that redox species play a vital role in known signaling
pathways important in cancer cell behavior.

S-nitrosylation of FLIP moderates its function

S-nitrosylation is a PTM that modifies the activity of more than 100 target
proteins (Hess, Matsumoto et al. 2005). Chapter 2 contains the details of our
first study examining the effects of S-nitrosylation of FLIP residues 254 and 259.
This project is especially novel since it demonstrates crosstalk between cell
death and proliferative pathways involving FLIP, which is frequently upregulated
in cancer. Many groups have shown that FLIP is a potent inhibitor of caspase-8mediated apoptosis when abundantly expressed, as seen in cancer (Igney and
Krammer 2002). Our laboratory previously reported that S-nitrosylation of FLIP
prevents ubiquitination and subsequent degradation promoting a more potent
inhibition of Fas-mediated apoptosis (Chanvorachote, Nimmannit et al. 2005). In
this study, we found that FLIP-mediated apoptotic resistance to DR-ligandinduced apoptosis is also dependent on the S-nitrosylation of FLIP at residues
254 and 259 (chapter 2, figure 3).
Additionally, FLIP has been reported to interact with proliferative,
migratory and inflammatory pathways such as JNK, MAPK and NF-κB. We
found that S-nitrosylation of FLIP mediates NF-κB activation, however we also
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demonstrate FLIPS (which lacks the S-nitrosylation residues) is capable of
inducing NF-κB activity (chapter 2, figure 2). This is consistent with other groups
(Golks, Brenner et al. 2006). Taken together, these results indicate FLIP
mediates NF-κB activation via multiple signaling pathways. FLIP S-nitrosylation
moderated the ability to bind NF-κB upstream activator RIP1 but not TRAF2
(chapter 2, figures 4, 5).
FLIP has been reported to be a substrate of caspase-8 following Fas
stimulation (Niikura, Nonaka et al. 2002). Additionally, many proteins are known
to be regulated by truncation. We found that S-nitrosylation of FLIP at residues
254 and 259 mediates processing into shorter forms (chapter 2, figure 6) further
indicating potential functional effects of this PTM. Understanding the complete
signaling profiles of potent antiapoptotic proteins that are frequently upregulated
in cancer will help us to determine which proteins are most in need of targeting
for effective drug therapies.

Varying effects of ROS species on Cav-1-dependent migration in NSCLC
cells

A modest amount of ROS can promote cell proliferation and differentiation
(Boonstra and Post 2004), whereas excessive amounts of ROS cause oxidative
damage to lipids, proteins and DNA (Perry, Raina et al. 2000). These differences
are the result of ROS acting as a secondary signaling molecule at low levels.
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Using specific ROS inhibitors and donors we were able to selectively modulate
ROS species in cells (chapter 3, figure 2) while remaining under toxicity
thresholds (chapter 3, figure 1). Other studies have selectively shown H2O2
modulates tumor cell behavior through migration (Reineke, Liu et al.), NF-κB
signaling (Shin, Zhao et al.), premature senescence (Yoshizaki, Fujiki et al. 2009)
and apoptosis (Han, Hanawa et al. 2006) to name a few. Additionally, O2- has
been implicated in cancer, however most studies consider activity and
expression levels of MnSOD. We found that H2O2 and O2- inhibited Cav-1dependent migration and invasion in NSCLC cells via destabilization of Cav-1
through the ubiquitin-proteosome pathway, however the exact mechanism is still
unclear (chapter 3, figures 1, 5, 7). Conversely we found that highly reactive OH⋅
promoted migration and invasion through the potential stabilization or
upregulation of Cav-1. The most common connections of OH⋅ with tumorigenesis
are attributed to its potent oxidizing capacity. We demonstrate for the first time
the association between OH⋅ and Cav-1-dependent migration in cancer cells
further indicating that specific imbalanes in redox biology within the cell can have
dramatically divergent effects on cellular function.

Future directions and recommendations

Future studies examining the effects of ROS and NO on pathways in
tumorigenesis are desperately needed. Countless pathways have been
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implicated in the pathogenesis of cancer and are nearly all subject to oxidative
modification and both ROS and NO targeting. Unfortunately, redox biology is
exceptionally difficult to manipulate and study in vivo and therefore cell culture
experimentation with ROS and NO modification has been widely practiced.
However, this largely neglects the contribution of ROS and NO from the tumor
microenvironment commonly reported (i.e. chronic inflammatory signaling from
TAMs). To date, assaying the amount of SNO in human patient tissue has not
yet been described. Additionally, we are experimentally unable to elucidate
redox effect on signaling pathways in a clear and mechanistic way. There are,
however, several iNOS and ROS modified transgenic mouse models available,
i.e. SOD G93A (Henriques, Pitzer et al.), constitutive iNOS (Takamura, Kato et
al. 1998), and iNOS knockout (dos Santos, Gattas et al.); that could be used to
further delineate which NO/ROS species are the most important in different
signaling pathways.
Our current experimental protocol did not include examination of FLIP
recruitment to the DISC. Although we determined cellular localization of FLIP we
did not coimmunoprecipitate other proteins of the DISC or TNFR signaling
complex. Such experiments would further highlight the DR-mediated interactions
dependent on S-nitrosylation. Additionally, we did not specifically investigate if
the FLIP 2CM harbored any structural modifications or changes in protein folding
which could potentially account for signaling differences through domain
availability and steric hindrance. Supplementary experiments determining iNOS
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localization following DR-stimulation could also be examined as a potential
endogenous NO regulator.
Migratory processes in metastasis are multifactorial and
complicated; however in our second study, we clearly demonstrate different ROS
species effects on migration and invasion in NSCLC cells. Although we
determined these results were Cav-1-dependent, we failed to examine the
localization of Cav-1 by confocal microscopy to resolve any potential changes in
polarization or caveolae formation that ROS may have incurred. Additionally,
PI3K/Akt signaling has been described for Cav-1-dependent migration reported
by us and others [Appendix, Study 3; (Shack, Wang et al. 2003; Chanvorachote,
Nimmannit et al. 2009)], we did confirm that Akt phosphorylation was altered.
However, we did not utilize any of the widely available pathway inhibitors (i.e.
LY294002, wortmannin) to further demonstrate the ROS-dependent effects.
The role of Cav-1 in tumor promotion and suppression has been widely
debated and has largely been suggested to be cell type-dependent
(Burgermeister, Liscovitch et al. 2008). We found that different ROS species
elicited opposing results with the most reactive ROS species, OH⋅, promoting
both migration and invasion. This finding is incredibly important since OH⋅ is
generated via radiation (Halpern, Yu et al. 1995) and chemotherapy treatment
(Sinha, Katki et al. 1987). TNF-α, which is highly abundant in the tumor
microenvironment, has also been reported to increase OH⋅ (Yamauchi, Kuriyama
et al. 1989). Increases in OH⋅ levels are noted to induce cell death in tumor cells
(Ren, Xia et al. 2001) however chemotherapy-resistant breast cancer cell lines
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appeared to be immune to this induction (Sinha, Katki et al. 1987). This could
possibly be attributed to the upregulation of anti-apoptotic proteins (i.e. FLIP and
cIAPs) in the DR pathway that are frequently seen in treatment-resistant cancers.
Therefore, tumor cells that have acquired significant apoptotic-resistance that
exist in a chronic inflammatory microenvironment could be subjected to high
levels of OH⋅ (as well as other ROS and NO), leading them to have increased
migratory signaling, such as what we report in our second study.
In conclusion, our studies have presented the effects of NO and ROS on
two separate pathways frequently implicated in cancer progression. We are
certain that redox biology will become increasingly important in determining the
mechanisms of disease and hope that further studies will be pursued. The
understanding of redox signaling in the context of pathology could help lead to
novel therapeutic targets and clinical breakthroughs in cancer, as well as many
other diseases.
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Caveolin-1 (Cav-1),3 a 21–24-kDa structural protein component of the plasma membrane microdomains termed caveolae
has been shown to function in vesicular trafficking, signal transduction, and cancer progression (1– 4). Although up-regulation
of this protein normally occurs in a variety of terminally differentiated cells including fibroblasts, adipocytes, smooth muscle
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cells, endothelial cells, and epithelial cells (5), Cav-1 is greatly
reduced in most oncogenically transformed and cancer cells
(6 –10). Thus, Cav-1 was first explained to function as a tumor
suppressor protein (11–13). In contrast, increasing evidence
indicates its role as a tumor and metastatic promoter as overexpression or re-expression of Cav-1 was found in many
advanced stage and metastatic cancer cells. Up-regulation of
Cav-1 was shown to render Rat1A cells more resistant to apoptosis (14). Moreover, antisense-induced down-regulation of
Cav-1 caused human prostate cancer cells more sensitive to
apoptosis (15, 16). Therefore, the role of Cav-1 in cancer progression remains controversial.
Metastasis is a multistep process composed of cancer cell
detachment, migration, extravasation, and adhesion of the
detached cells to other target sites. A key mechanism in the
regulation of metastasis is anoikis or detachment-induced apoptosis. Previous studies have shown that Cav-1 acts as a negative regulator of anoikis (17, 18), and its elevated expression in
lung carcinoma is closely associated with the increased metastasis capacity and poor survival of the patients (19). Likewise,
elevated NO and NO synthase levels have been associated in
many human metastatic cancers including the lung (20 –24),
breast (25), colon (26), and cancers of the central nervous system (27). However, the role of NO and its mechanism of metastasis regulation in association with Cav-1 are not well understood. Because resistance to anoikis is a key step in metastasis
development and because Cav-1 has been implicated in this
process, we investigated the potential regulation of Cav-1 by
NO and studied its role in anoikis of human lung carcinoma
cells.
NO has been reported to have both pro- and anti-apoptotic
effect on cells, depending on a variety of factors, including cell
type, cellular redox status, and the flux and dose of local NO (28,
29). In human lung carcinoma cells, we previously reported that
NO plays a suppressive role in apoptosis induced by a variety of
agents, including Fas death ligand (30), chemotherapeutic
agent cisplatin (31), and the metal carcinogen chromium (32).
However, the role of NO in cell anoikis and its potential regulation of Cav-1 have not been well investigated. Using molecular and pharmacological approaches, we report here that NO
plays an important role in Cav-1 regulation and anoikis function of human lung cancer H460 cells. We also demonstrate for
the first time that Cav-1 is down-regulated during cell anoikis
through the ubiquitin-proteasomal degradation pathway and
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Anoikis, a detachment-induced apoptosis, is a principal
mechanism of inhibition of tumor cell metastasis. Tumor cells
can acquire anoikis resistance which is frequently observed in
metastatic lung cancer. This phenomenon becomes an important obstacle of efficient cancer therapy. Recently, signaling
mediators such as caveolin-1 (Cav-1) and nitric oxide (NO)
have garnered attention in metastasis research; however, their
role and the underlying mechanisms of metastasis regulation
are largely unknown. Using human lung carcinoma H460 cells,
we show that NO impairs the apoptotic function of the cells after
detachment. The NO donors sodium nitroprusside and diethylenetriamine NONOate inhibit detachment-induced apoptosis,
whereas the NO inhibitors aminoguanidine and 2-(4-carboxyphenyl) tetramethylimidazoline-1-oxyl-3-oxide promote this
effect. Resistance to anoikis in H460 cells is mediated by Cav-1,
which is significantly down-regulated after cell detachment
through a non-transcriptional mechanism involving ubiquitinproteasomal degradation. NO inhibits this down-regulation by
interfering with Cav-1 ubiquitination through a process that
involves protein S-nitrosylation, which prevents its proteasomal
degradation and induction of anoikis by cell detachment. These
findings indicate a novel pathway for NO regulation of Cav-1,
which could be a key mechanism of anoikis resistance in tumor
cells.

NO Regulates Caveolin-1 and Anoikis
that NO regulates this process by inducing S-nitrosylation of
the protein which inhibits its ubiquitination and proteasomal
degradation. Thus, our study reveals the existence of a novel
mechanism of anoikis regulation, which might be exploited in
metastasis and cancer therapy.
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MATERIALS AND METHODS
Cells and Reagents—Human lung epithelial NCI-H460 cells
were obtained from the American Type Culture Collection
(Manassas, VA). The cells were cultured in RPMI 1640
medium supplemented with 5% fetal bovine serum, 2 mM
L-glutamine, and 100 units/ml penicillin and streptomycin.
Cell cultures were maintained in a humidified atmosphere of
5% CO2 at 37 °C. Cells were passaged at preconfluent densities using a solution containing 0.05% trypsin and 0.5 mM
EDTA. The NO donors sodium nitroprusside (SNP) and
diethylene triamine (DETA) NONOate and the NO inhibitors
2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl3-oxide (PTIO) and aminoguanidine (AG) were obtained from
Sigma. These NO modulators are water-soluble and were prepared in a sterile culture medium before use. Diaminofluorescein diacetate (DAF-DA) and Hoechst 33342 were obtained
from Molecular Probes, Inc. (Eugene, OR). Monoclonal antibody against Cav-1 and protein A-agarose were from Santa
Cruz Biotechnology (Santa Cruz, CA). Antibodies against Akt
and phospho-Akt Ser-473 and Thr-308 were from Cell Signaling Technology, Inc. (Beverly, MA). Antibodies for ubiquitin,
S-nitrosocysteine, ␤-actin, and peroxidase-conjugated secondary antibodies were from Sigma. The transfecting agent Lipofectamine 2000 was from Invitrogen. All other chemicals and
reagents including annexin V-fluorescein isothiocyanate
(FITC), propidium iodide (PI), dithiothreitol (DTT), lactacystin, and LY294002 were from Sigma.
NO Detection—Cellular NO production was determined by
flow cytometry using DAF-DA as a fluorescent probe and by
Griess assay, which measures the stable nitrite byproduct of NO
in the culture medium. After detachment, cells (1 ⫻ 106/ml)
were collected and incubated with 10 M DAF-DA for 30 min at
37 °C. The cells were then washed, resuspended in phosphatebuffered saline, and analyzed for fluorescence intensity using
FACSCaliber (BD Biosciences). Signals were obtained using a
488-nm excitation beam and a 538-nm band-pass filter. In
some experiments cells were visualized for fluorescence intensity using a fluorescence microscope (Carl Zeiss Axiovert, Göttingen, Germany). For the Griess assay, cell supernatants were
collected, and aliquots (100 l) were mixed with 100 l of
Griess reagent (1% sulfanilamide, 0.1% naphthyl ethylenediamine dihydrochloride, 2% phosphoric acid) in a 96-well plate.
After incubation for 10 min at 25 °C, the absorbance at 550 nm
was measured on a microplate reader.
Plasmid and Transfection—Caveolin-1 plasmid (pEX_Cav1-YFP) was obtained from the American Type Culture Collection (Manassas, VA). Stable transfectant of Cav-1 was generated by culturing H460 cells in a 6-well plate until they reached
60% confluence. One microgram of cytomegalovirus-neo vector and 15 l of Lipofectamine reagent with 2 g of Cav-1 or
control pcDNA3 plasmid were used to transfect the cells in the
absence of serum. After 12 h the medium was replaced with

culture medium containing 5% fetal bovine serum. Approximately 36 h after the beginning of the transfection, the cells
were digested with 0.03% trypsin, and the cell suspensions were
plated onto 75-ml culture flasks and cultured for 24 –28 days
with G418 selection (600 g/ml). The pooled stable transfectant was identified by Western blot analysis of Cav-1 and was
cultured in G418-free RPMI 1640 medium for at least two passages before each experiment.
Anoikis Assays—Adherent H460 cells in culture were trypsinized into a single cell suspension and then seeded in 12-well
tissue culture plates coated with 200 l (6 mg/ml in 95% ethanol) of poly-2-hydroxyethylmethacrylate (poly-HEMA; Sigma)
at the density of 1 ⫻ 105 cells/ml. Suspended cells were incubated at 37 °C for various times up to 24 h. Cells were then
harvested, washed, and stained with annexin V-FITC and analyzed for fluorescence intensity by flow cytometry and fluorescence microscopy. For Hoechst 33342 apoptosis assay, cells
were incubated with 10 M the Hoechst dye for 30 min at 37 °C,
and the apoptotic cells having intensely condensed chromatin
and/or fragmented nuclei were visualized under a fluorescence
microscope. For cell survival assay, cells were similarly treated,
harvested, washed, and incubated with 20 M sodium 2,3-bis(2methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) for 4 h at 37 °C. Optical density was then determined by V-max photometer (Molecular Devices, Inc., Menlo
Park, CA) at a wavelength of 450 nm.
Western Blot Analysis—Cell extracts were performed by
incubating the cells in lysis buffer containing 20 mM Tris-HCl,
pH 7.5, 1% Triton X-100, 150 mM sodium chloride, 10% glycerol, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 100
mM phenylmethylsulfonyl fluoride, and a protease inhibitor
mixture (Roche Applied Science) for 30 min on ice. Cell lysates
were collected and assayed for protein content using the Bradford method (Bio-Rad). Equal amount of proteins per sample
(40 g) were resolved on a 10% SDS-polyacrylamide gel electrophoresis and transferred onto 0.45-m nitrocellulose membranes (Pierce). The transferred membranes were blocked for
1 h in 5% nonfat dry milk in Tris-buffered saline/Tween 20 (25
mM Tris-HCl, pH 7.4, 125 mM NaCl, and 0.05% Tween 20) and
incubated with the appropriate primary antibodies at 4 °C overnight. Membranes were washed 3 times with Tris-buffered
saline, Tween 20 for 10 min and incubated with peroxidaselabeled secondary antibodies for 1 h at room temperature. The
immune complexes were detected by chemiluminescence
(Supersignal West Pico; Pierce) and quantified by imaging densitometry using analyst/PC densitometry software (Bio-Rad).
Immunoprecipitation—Cells were washed after treatments
and lysed in lysis buffer for 30 min on ice. Cell lysates were
collected and determined for protein content. Equal amounts
of proteins per sample (60 g) were immunoprecipitated with
anti-Cav-1 antibody for 6 h at 4 °C. The immune complexes
were washed with 30 volumes of lysis buffer, resuspended in 2⫻
Laemmli sample buffer, and boiled at 95 °C for 5 min. The
immune complexes were separated by 10% SDS-PAGE and
analyzed by Western blotting as described above.
Measurements of Cav-1 S-Nitrosylation—Cells were lysed
and immunoprecipitated with anti-Cav-1 antibody as described above. The immunoprecipitated protein was analyzed
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stained with ToPro-3 (Invitrogen), and the actin cytoskeleton
was stained with Alexa Fluor 546-conjugated phalloidin
(Invitrogen). Cells were cytospun onto a glass slide and
mounted using the anti-fade reagent Fluoromont-G (Southern
Biotech, Birmingham, AL). Images were acquired by confocal
laser scanning microscopy (Zeiss LSM 510).
Statistical Analysis—Data were represented as the means ⫾
S.D. from three or more independent experiments. Statistical
analysis was performed by Student’s t test at a significance level
of p ⬍ 0.05.

RESULTS
Nitric Oxide Inhibits Detachment-induced Apoptosis of H460
Cells—NO has been shown to play an important role in the
regulation of cancer cell metastasis; however, the underlying
mechanism of this regulation is unclear. To test whether NO
might regulate this process by inhibiting detachment-induced
apoptosis or anoikis, which is a crucial step in the metastasis of
cancer cells, we first investigated anoikis of human lung cancer
H460 cells in response to various specific NO donors and inhibitors. Anoikis was induced by detaching the cells and incubating them in attachment-resistant poly-HEMA-coated plates for
various times and analyzed for cell viability by XTT assay. Fig.
1A shows that detachment of the cells caused a time-dependent
decrease in cell viability with ⬃55 and 15% of the cells remaining viable after 6 and 12 h, respectively. Analysis of cell apoptosis by flow cytometry using FITC-labeled annexin V antibody
shows a significant increase in annexin V-associated cellular
fluorescence as early as 6 h after the detachment and reached a
maximum at about 18 h (Fig. 1B). In contrast, analysis of cell
necrosis using PI as a probe shows no significant increase in the
PI signal over a 24-h period. These results suggest that apoptosis is the primary mode of cell death after detachment of H460
cells. Morphologic analysis of apoptotic cell death by fluorescence microscopy using Hoechst 33342 and annexin V-FITC
further confirms the results (Fig. 1E).
To investigate the role of NO in detachment-induced apoptosis, detached H460 cells were treated with various concentrations of NO donors and inhibitors, and their effect on cell
survival was determined by XTT assay. Fig. 1C shows that treatment of the cells with NO donor, SNP, or DETA NONOate
caused a dose-dependent decrease in cell death, whereas treatment of the cells with NO inhibitor, AG, or PTIO had an opposite effect. Analysis of cell apoptosis by annexin V-FITC and
Hoechst 33342 assays similarly shows the inhibitory and promoting effect of the NO donors and inhibitors, respectively, on
detachment-induced cell death (Fig. 1, D and E). The NO
donors and inhibitors, when used at the indicated concentrations, had no significant effect on cell necrosis as determined by
PI assay (Fig. 1D).
Effect of NO Modulators on Cellular NO Level—To provide a
relationship between cell death and NO modulation induced by
the test agents, we analyzed cellular NO levels in response to
various NO modulator treatments by colorimetric Griess assay
and by flow cytometric and microscopic assays using DAF-DA
as a fluorescent probe for NO. Fig. 2A shows the result of the
Griess assay which measures the stable nitrite breakdown product of NO. Both NO inhibitors AG and PTIO significantly
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for S-nitrosylation by Western blot using anti-S-nitrosocysteine antibody and by fluorometric measurements as previously
described (32). Briefly, immunoprecipitates were incubated
with 200 M HgCl2 and 200 M diamino naphthalene in 500 l
of phosphate-buffered saline for 0.5 h at room temperature followed by the addition of 1 M NaOH. The fluorescent triazole
product generated from the reaction between diamino naphthalene and NO released from S-nitrosylated Cav-1 was quantified by fluorometry at the excitation and emission wavelengths of 375 and 450 nm, respectively.
Reverse Transcription-PCR—Total RNA was extracted with
Trizol (Invitrogen), and reverse transcription-PCR was performed with Access RT-PCR System (Promega, Madison, WI)
according to the manufacturer’s instructions. Sequences of the
PCR primers were: Cav-1 forward, 5⬘-CGTAGACTCGGAGGGACATC-3⬘, and reverse, 5⬘-TTTCGTCACAGTGAAGGTGG-3⬘; for glyceraldehyde-3-phosphate dehydrogenase,
forward, 5⬘-GCTGAGAACGGGAAGCTTGT-3⬘, and reverse,
5⬘-GCCAGGGGTGCTAAGCAG-3⬘. Reaction products were
analyzed after 30 amplification cycles, each of which involved
consecutive 1-min steps at 94, 55, and 72 °C. The PCR products
were electrophoresed in a 1.5% agarose gel, stained with
ethidium bromide, and photographed.
The results obtained by conventional RT-PCR were verified
by quantitative real-time PCR. One microgram of Trizolextracted RNA was reverse-transcribed in a 100-l reaction
mixture containing 500 M dNTP, 125 units of MultiScribe
Reverse Transcriptase (Applied Biosystems, Foster City,
CA), 40 units of RNase inhibitor, 2.5 M oligo(dT), 1⫻ TaqMan reverse transcriptase buffer, and 5 mM MgCl2 at 48 °C
for 40 min. The primers used in this study were designed
using Primer Express software (Applied Biosystems): Cav-1
(#AI878826) forward 5⬘-CGAGAAGCAAGTGTACGACGC3⬘, and reverse 5⬘-ACCACGTCATCGTTGAGGTG-3⬘; glyceraldehyde-3-phosphate dehydrogenase forward, 5⬘-GAAGGTGAAGGTCGGAGTC-3⬘, and reverse 5⬘-GAAGATGGTGATGGGATTTC-3⬘. Amplification was performed at the
following cycling conditions: 95 °C for 10 min followed by 40
cycles at 95 °C for 15 s and 60 °C for 1 min. A SYBR Green PCR
Master Mix (Applied Biosystems) was used with 1 ng of cDNA
and with 100 – 400 nM primers. A negative control without any
cDNA template was run with every assay. All PCR reactions
were performed by using ABI PRISM 7900 Sequence Detection
System (Applied Biosystems). Relative mRNA levels were
determined by using the comparative CT (threshold cycle)
method (33), where the caveolin-1 target is normalized to the
control and compared with a reference sample (assigned a relative value of 1) by the equation: 2⫺⌬⌬CT.
Immunofluorescence—Cells (0.5 ⫻ 106/well) were seeded in
6-well poly-HEMA-coated plates and treated with NO modulators as described under “Results.” After treatment, the cells
were fixed in 3.7% formaldehyde for 10 min at room temperature and then permeabilized and blocked in a solution containing 0.5% saponin, 1% bovine serum, and 1.5% goat serum for 30
min. After primary antibody incubation with Cav-1 monoclonal antibody (BD Biosciences) at 1:100 dilution for 1 h, cells
were washed and incubated with Alexa Fluor 488-conjugated
secondary antibody (Invitrogen) for 30 min. Cell nucleus was
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and evaluated their effect on
detachment-induced cell death.
Transfected cells were detached,
suspended in poly-HEMA-coated
plates, and analyzed for cell survival
at various times by XTT assay. Fig.
3A shows that Cav-1-transfected
cells exhibited resistance to detachment-induced cell death as compared with control-transfected
cells. Western blot analysis of Cav-1
expression in the transfected cells
shows an increased expression of
Cav-1 protein in the Cav-1-transfected cells compared with controltransfected cells (Fig. 3B). These
results indicate the role of Cav-1 as a
negative regulator of detachmentinduced cell death in lung epithelial
H460 cells. Because Cav-1 has been
shown to regulate cell death and
survival through a PI3K/Akt-dependent mechanism (16, 35, 36), we
tested the effect of Cav-1 overexpression on Akt activity and examined its effect on detachment-induced cell death. Our results show
that Cav-1 overexpression induced
Akt activation as indicated by the
increased phosphorylation of Akt
(Thr-308 and Ser-473), whereas it
had no effect on total Akt level (Fig.
3C). The induction of Akt phosphorylation was inhibited by the
PI3K inhibitor LY294002, suggesting that this induction was mediated
through the PI3K pathway. Analysis
FIGURE 1. Detachment-induced apoptosis and its inhibition by NO. A, effect of cell detachment on cell
survival determined by XTT assay. Lung epithelial H460 cells were detached as described under “Materials and of apoptosis shows that Cav-1 overMethods” and suspended in HEMA-coated plates for various times (0 –24 h). B, effect of cell detachment on expression decreased detachmentapoptosis and necrosis determined by flow cytometry using annexin V-FITC (An V-FITC) and PI assays. C, effect
of NO modulators on detachment-induced cell death. Detached cells were treated with various concentrations induced cell death and that this
of NO donor, SNP (10, 50, 100 M), or DETA NONOate (10, 50, 100 M) or with NO inhibitor, AG (100, 200, 300 effect was inhibited by the PI3K
M), or PTIO (10, 50, 100 M) for 12 h. Cell survival was then determined by XTT assay. CNTL, control. D, effects inhibitor LY294002 (Fig. 3D). These
of NO modulators on detachment-induced apoptosis and necrosis. Detached cells were treated with SNP (50
M), DETA NONOate (50 M), AG (300 M), or PTIO (50 M) for 12 h, and cell apoptosis and necrosis were results suggest that Cav-1 exerts its
determined as described above. E, upper panel, effect of NO modulators on detachment-induced apoptosis anti-apoptotic effect during cell
determined by Hoechst 33342 nuclear fluorescence staining. Lower panel, effect of NO modulators on detachment-induced apoptosis determined by annexin V-FITC fluorescence microscopy. Data are the mean ⫾ S.D. detachment through a mechanism
that is dependent on PI3K/Akt
(n ⫽ 3). *, p ⬍ 0.05 versus non-treated control.
activation.
Cav-1 Overexpression Alters Cell Growth and Morphology of
inhibited cellular nitrite production, whereas the NO donors
SNP and DETA NONOate increased the production as com- H460 Cells—Fig. 3E shows that under a normal growth conpared with non-treated control. These results were con- dition that allows cell attachment, Cav-1-overexpressing
firmed by flow cytometric and microscopic assays of NO cells exhibited an increased growth rate over control-trans(Fig. 2, B and C), which show the induction and inhibition of fected cells. The lag phase before cell growth was significellular NO levels by the NO donor SNP and NO inhibitor cantly reduced in Cav-1-overexpressing cells. As compared
with control-transfected cells, which grew as an epithelial
PTIO, respectively.
Cav-1 Overexpression Renders H460 Cells Resistant to monolayer, Cav-1-overexpressing cells formed cell mounds
Detachment-induced Apoptosis—The role of Cav-1 in the reg- and grew as multilayer epithelial cells (Fig. 3F). This multiulation of cancer cell anoikis is unclear. We studied this role by layer growth pattern is consistent with the increased growth
stably transfecting H460 cells with Cav-1 or control plasmid rate of Cav-1-overexpressing cells. These results suggest that
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FIGURE 2. Effect of NO modulators on cellular NO and nitrite levels. H460
cells were detached and either left untreated or treated with SNP (50 M),
DETA NONOate (50 M), AG (300 M), or PTIO (50 M) for 2 h. A, nitrite production determined by the Griess assay. B and C, NO production determined
by flow cytometry and fluorescence microscopy using DAF-DA as a probe.
Data are the mean ⫾ S.D. (n ⫽ 3). *, p ⬍ 0.05 versus non-treated control.

Cav-1 may function as a tumor promoter by enhancing cell
growth.
Detachment Induces Cav-1 Down-regulation through a Nontranscriptional Proteasome-dependent Mechanism—Having
demonstrated the role of Cav-1 as a negative regulator of cell
anoikis in H460 cells, we next investigated the expression profile of Cav-1 after cell detachment. Detached cells were suspended in attachment-resistant plates for various times and
analyzed for Cav-1 protein and mRNA expression by Western
blotting and RT-PCR, respectively. Fig. 4A shows that Cav-1
protein levels were significantly reduced in cells after detachment in a time-dependent manner. The reduction was strongly
inhibited by lactacystin, a specific proteasome inhibitor, suggesting that detachment-induced Cav-1 down-regulation was
mediated through proteasomal degradation. This result was
confirmed by the observation that another proteasome inhibitor, MG132, also inhibited the decrease in Cav-1 protein
expression (data not shown). Analysis of Cav-1 mRNA levels
by RT-PCR shows that Cav-1 transcripts were relatively
unchanged after cell detachment (Fig. 4B), whereas the protein
levels were substantially reduced. The RT-PCR result was confirmed by quantitative real-time RT-PCR, which shows no significant changes in the Cav-1 mRNA level after cell detachment
(Fig. 4C). Thus, cell detachment appears to cause Cav-1 protein
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reduction through a transcription-independent mechanism.
These results along with subsequent data showing the effect of
cell detachment on Cav-1 ubiquitination support the role of
ubiquitin-proteasomal degradation as an important mechanism of Cav-1 down-regulation induced by cell detachment.
Nitric Oxide Prevents Detachment-induced Cav-1 Down-regulation—We further investigated the potential regulation of
Cav-1 by NO. Cells were detached and suspended in HEMAcoated plates in the presence or absence of NO donors and
inhibitors. Cav-1 protein expression was then determined by
Western blotting. Fig. 4D shows that the NO donors SNP and
DETA NONOate strongly inhibited detachment-induced
Cav-1 down-regulation at the concentrations shown to induce
an increase in cellular NO levels (Fig. 2). In contrast, the NO
inhibitors AG and PTIO promoted this down-regulation (Fig.
4D). These results were confirmed by confocal immunofluorescence microscopy which shows that Cav-1 fluorescence intensity was reduced after cell detachment and that the NO donor
SNP was able to inhibit this reduction, whereas the NO inhib-
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FIGURE 3. Cav-1 overexpression increases cell death resistance and Akt
phosphorylation, alters growth pattern, and increases growth rate.
A, H460 cells were stably transfected with Cav-1 or control plasmid as
described under “Materials and Methods.” Transfected cells were grown in
culture medium and analyzed for cell survival at various times after detachment using XTT assay. Attached cells showed no significant apoptosis during
the test period of 24 h (data not shown). B, Western blot analysis of Cav-1
expression in control and Cav-1-transfected cells. Cell extracts were prepared
and separated on 10% polyacrylamide-SDS gels, transferred, and probed with
Cav-1 antibody. ␤-Actin was used as a loading control. CNTL, control. C, effect
of Cav-1 overexpression on Akt phosphorylation. Transfected cells were
detached and incubated in HEMA-coated plates for 12 h in the presence or
absence of LY294002 (10 M). Cell lysates were prepared and analyzed for Akt
phosphorylation by Western blotting. Blots were probed with antibodies specific to phospho-Akt (Ser-473 and Thr-308) and Akt. D, apoptosis of the
treated cells was analyzed by Hoechst 33342 assay and expressed as the ratio
of apoptotic nuclei to total nuclei. E, effect of Cav-1 overexpression on cell
proliferation. Cav-1 and control-transfected cells were grown in normal tissue
culture plates and analyzed for cell proliferation at various times by hemocytometry. F, morphology of control and Cav-1-transfected cells in culture. Data
are the mean ⫾ S.D. (n ⫽ 3). *, p ⬍ 0.05 versus vector-transfected control.
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role of NO in detachment-induced
Cav-1 down-regulation. Analysis of
the fluorescence pattern in the
treated and control cells shows no
apparent changes in the cellular
localization of Cav-1, which is
largely membrane-bound.
Detachment Induces Cav-1 Ubiquitination and Its Inhibition by NO—
The observation that detachmentinduced Cav-1 down-regulation
was inhibited by proteasome inhibitors suggests that this down-regulation could be mediated by protein ubiquitination and subsequent
degradation by the proteasome.
Because ubiquitination of Cav-1 has
not been reported, we examined
whether cell detachment could
induce Cav-1 ubiquitination and
whether or not this process is regulated by NO. Cells were detached
and suspended in HEMA-coated
plates in the presence or absence of
NO donors for various times. Cell
lysates were prepared and immunoprecipitated with anti-Cav-1 antibody, and the resulting immune
complexes were analyzed for ubiquitin by Western blotting. Fig. 5A
shows that Cav-1 was rapidly ubiquitinated as early as 1 h after cell
detachment and peaked at about
3 h. The NO donors SNP and DETA
NONOate strongly inhibited this
ubiquitination, suggesting that NOmediated inhibition of protein ubiquitination could be a key mechanism of Cav-1 stabilization by NO,
and our subsequent study supports
this notion.
NO-mediated S-Nitrosylation of
Cav-1 as a Potential Mechanism of
FIGURE 4. Effect of cell detachment on Cav-1 expression and its regulation by NO. A, H460 cells were Protein Stability Regulation—Previdetached and seeded in HEMA-coated plates for various times (0 –24 h) in the presence or absence of lactacystin
(LAC) (10 M). Cells extracts were prepared and analyzed for Cav-1 protein expression by Western blotting. Blots ous studies have shown that NO
were reprobed with ␤-actin antibody to confirm equal loading of samples. The immunoblot signals were quantified induced S-nitrosylation of some
by densitometry, and mean data from independent experiments (one of which is shown here) were normalized to
apoptosis regulatory proteins, such
the results in control cells at 0 h. B, RT-PCR analysis of Cav-1 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA expression at various times (0 –24 h) after cell detachment. C, relative Cav-1 mRNA expression as c-FLIP and Bcl-2, and prevented
determined by quantitative real-time PCR. The relative mRNA expression was determined by using the compar- their ubiquitination and degradaative CT method as described under “Materials and Methods.” D, detached cells were treated with NO inhibitor,
AG (300 M) or PTIO (50 M), or with NO donor, SNP (50 M), or DETA NONOate (50 M) for 12 h, after which they tion by the proteasome (30 –32). To
were analyzed for Cav-1 expression by Western blotting. E, detached cells were either left untreated or treated test whether S-nitrosylation could
with SNP (50 M) or AG (300 M) for 12 h and analyzed for Cav-1 by immunofluorescence confocal microscopy. be involved in the regulation of
Cells were also stained with Alexa Fluor 546-conjugated phalloidin and ToPro-3 to aid visualization of actin
cytoskeleton and nucleus. Data are the mean ⫾ S.D. (n ⫽ 3). *, p ⬍ 0.05 versus attached cell control; #, p ⬍ 0.05 Cav-1 by NO, we performed immuversus the indicated control or 12-h detached cell control.
noprecipitation experiments examining the effect of NO on Cav-1
itor AG further reduced the signal intensity (Fig. 4E). Although S-nitrosylation and protein expression. The results show that
these results are non-quantitative, they support the Western treatment of the cells with NO donors, SNP, and DETA
blot data and provide additional evidence for the suppressive NONOate induced S-nitrosylation of Cav-1 as determined by
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FIGURE 5. Effects of NO modulators on Cav-1 ubiquitination and S-nitrosylation. A, H460 cells were detached and either left untreated or treated
with SNP (50 M) or DETA NONOate (50 M) in the presence or absence of DTT
(1 mM) in HEMA-coated plates. Cells lysates were prepared and immunoprecipitated (IP) with anti-Cav-1 antibody. The resulting immune complexes
were then analyzed for ubiquitin by Western blotting (WB) at various times.
Maximum ubiquitination of Cav-1 was observed at ⬃3 h after cell detachment. Lysate input was determined by probing ␤-actin. CNTL, control.
B, detached cells were similarly treated with the test agents, and Cav-1 S-nitrosylation was determined by immunoprecipitation using anti-Cav-1 antibody followed by Western blot analysis of the immunoprecipitated protein
using anti-S-nitrosocysteine antibody. Densitometry was performed to determine the relative S-nitrosocysteine/␤-actin levels. C, Cav-1 S-nitrosylation was
determined by fluorometry. Immunoprecipitates from above were incubated
with 200 M HgCl2 and 200 M diaminonaphthalene in phosphate-buffered
saline. NO released from S-nitrosylated Cav-1 was quantified at 375/450 nm.
Plots are the mean ⫾ S.D. (n ⫽ 3). *, p ⬍ 0.05 versus non-treated control; #, p ⬍
0.05 versus the indicated treatment controls.

Western blot analysis of the immunoprecipitated protein using
S-nitrosocysteine antibody (Fig. 5B). Similar results were
obtained when the immunoprecipitated protein was analyzed
for S-nitrosylation by fluorometric measurements of the
released NO product (Fig. 5C). Cav-1 S-nitrosylation by the NO
donors was inhibited by DTT, a known inhibitor of S-nitrosylation (37, 38) (Fig. 5, B and C), supporting the specificity of
S-nitrosylation detection. To test whether S-nitrosylation of
Cav-1 affects its stability, we analyzed the effect of NO donors
and DTT on Cav-1 protein expression. Fig. 6A shows that the
NO donors SNP and DETA NONOate were able to stabilize the
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protein after cell detachment and that the S-nitrosylation
inhibitor DTT inhibited the stabilizing effect of NO donors.
Together, these results indicate that NO regulates Cav-1
expression at least in part by inducing protein S-nitrosylation which interferes with its ubiquitination and subsequent
degradation by the proteasome. This new finding provides a
mechanistic insight into the regulation of Cav-1 by NO,
which could be important in the control of cancer cell
anoikis and metastasis.
Nitric Oxide Induces Anoikis Resistance and Multilayer Formation—To provide supporting evidence for the role of NO in the
regulation of cell anoikis through protein S-nitrosylation, H460
cells were detached and incubated with NO donors in the presence or absence of DTT. Cell viability was then determined
after 12 h using XTT assay. Fig. 6B shows that the NO donors
SNP and DETA NONOate significantly increased cell viability
after detachment and that DTT inhibited this effect of NO
donors. In the earlier study we showed that cells overexpressing
Cav-1 exhibited multilayer formation. Because NO up-regulates Cav-1 expression, we examined whether NO could induce
a similar multilayer formation in H460 cells. Cells were grown
in culture plates in the presence or absence of NO donors, and
cell morphology was examined by microscopy after 24 h. Fig. 6B
shows that the NO donors SNP and DETA NONOate were able
to induce multilayer formation of H460 cells as compared with
non-treated control. Because multilayer formation is a key
characteristic of malignant tumor cells, this finding suggests
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FIGURE 6. NO inhibits detachment-induced Cav-1 down-regulation and
cell death. A, H460 cells were detached and either left untreated or treated
with SNP (50 M) or DETA NONOate (50 M) in the presence or absence of DTT
(1 mM) in HEMA-coated plates. A, cell lysates were prepared and analyzed for
Cav-1 protein expression by Western blotting after 12 h. Densitometry was
performed to determine the relative levels of Cav-1 after reprobing the membranes with ␤-actin antibody. B, cells survival was determined by XTT assay
after 12 h. C, morphology of cells treated with SNP (50 M) or DETA NONOate
(50 M) for 12 h. Data are the mean ⫾ S.D. (n ⫽ 3). *, p ⬍ 0.05 versus nontreated control; #, p ⬍ 0.05 versus the indicated treatment controls.
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that NO may regulate tumorigenesis by promoting malignant
transformation through Cav-1 up-regulation.
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DISCUSSION
Lung cancer is the leading cause of cancer mortality worldwide, and most death is associated with tumor metastasis. To
metastasize, a malignant cell must detach from its primary
tumor, invade the nearby circulatory or lymph system, and
establish itself in a new site. Once in the bloodstream, most of
the cells die by anoikis, which is an important mechanism that
prevents metastasis. However, some cancer cells develop resistance to anoikis and consequently survive to establish new
metastases. Several anoikis-regulatory proteins including
Cav-1 have been investigated in recent years. However, the role
of Cav-1 in metastatic cancer progression and the underlying
mechanisms are unclear. Both pro- and anti-carcinogenic
effect of Cav-1 have been described. Recombinant Cav-1 overexpression was shown to inhibit cell proliferation by inducing
cell cycle arrest at G0/G1 phase (1). Genomic analysis of Cav1⫺/⫺ null mice and human breast cancer mutations (P132L)
supported the role of Cav-1 as a negative regulator of cell transformation and tumorigenesis (39). Likewise, stable expression
of Cav-1 in human breast cancer MCF-7 cells attenuated cell
proliferation and inhibited anchorage-independent growth
(17). In contrast to its suppressive role in cancer cell growth, an
elevated expression of Cav-1 has been reported in several
human tumors including prostate, colon, and breast (23, 24).
Overexpression of Cav-1 also prevented detachment-induced
apoptosis and p53 activation in cancer cells (18). Furthermore,
in lung cancer cells Cav-1 overexpression promoted metastasis
(19). Consistent with the pro-survival role of Cav-1, we found
that Cav-1 positively regulated cell growth and inhibited
detachment-induced apoptosis of lung cancer H460 cells (Fig.
3). The anti-apoptotic effect of Cav-1 was found to be associated with its ability to activate PI3K/Akt because inhibition of
Akt activation by the PI3K inhibitor LY294002 abrogated this
effect. Cav-1 has been shown to interact with and inhibit serine/
threonine protein phosphatases PP1 and PP2A, leading to sustained Akt activation and inhibition of apoptosis by thapsigargin in prostate cancer cells (16). Cav-1 has also been shown to
interact with PI3K and regulate ceramide-induced cell death in
fibroblasts (35). Likewise, Cav-1 overexpression in fibroblasts
and HeLa cells induces Akt activation; however, such activation
promotes cell death induced by arsenite (36). Thus, although
there is a general agreement that Cav-1 can activate PI3K/Akt,
its consequence on cell death can be different and is dependent
on cellular context, cell type, and apoptotic stimuli used.
In this study we observed that Cav-1 is rapidly down-regulated after cell detachment and that overexpression of Cav-1 or
stabilization of the protein by NO protected the cells from apoptosis (Figs. 3 and 6). NO induction and Cav-1 overexpression
also promoted cell transformation facilitating multilayer formation (Figs. 3 and 6). The expression of Cav-1 is tightly regulated at various levels, including transcriptional and post-transcriptional (for review, see Ref. 40). Although the importance of
transcriptional regulation of Cav-1 has been emphasized in
numerous studies, post-translational modifications such as
ubiquitination and phosphorylation have emerged as impor-

tant regulators of protein stability and function (for reviews, see
Refs. 29 and 41). In the present study we found that Cav-1 was
rapidly ubiquitinated and degraded by the proteasome after cell
detachment in concomitant with anoikis (Figs. 4 and 5). Cav-1
transcripts were relatively unchanged during this process (Fig.
4), indicating a non-transcriptional regulation of Cav-1 expression after cell detachment. These results support the ubiquitinproteasomal degradation as a primary mechanism of detachment-induced Cav-1 down-regulation. This finding adds Cav-1
to the growing list of cellular proteins that are subjected to
regulation by the ubiquitin-proteasomal degradation pathway.
The results of this study also demonstrated that Cav-1 stability and function is regulated by NO. NO has been shown to
regulate apoptosis under various physiologic and pathologic
conditions (28, 42, 43); however, its roles in anoikis and metastasis are unclear. Recent evidences suggest that depending on
its expression level, NO can exert either promoting or inhibitory effects on tumor growth and metastasis. The promoting
effects of NO are generally observed at relatively low but sustained levels of NO, whereas the inhibitory effects of NO are
seen at high and acute concentrations that induce tumor cell
death (44 – 46). The results of this study are consistent with
previous reports showing that low (micromolar) levels of NO
inhibited cell death and increased cell migration (47– 49). The
promoting role of NO in tumorigenesis is also supported by the
observations that both inducible and constitutive forms of NO
synthase are elevated in several human tumors (50, 51) and that
human and murine carcinomas expressing NO synthase are
very aggressive when implanted into mice (52). Furthermore,
there seems to be a direct correlation between the expression of
NO synthase and the tumor grade, suggesting a causative role
for NO in promoting metastasis (52).
We showed that NO negatively regulates anoikis of lung
epithelial H460 cells as demonstrated by the ability of NO
donors to suppress detachment-induced apoptosis and the
reversal effect induced by NO inhibitors (Fig. 1). The NO
donors also had a stabilizing effect on detachment-induced
Cav-1 down-regulation, whereas the NO inhibitors showed an
opposite effect (Figs. 4 and 6). These results support NO-mediated stabilization of Cav-1 as a key mechanism of anoikis regulation. The mechanism by which NO stabilizes Cav-1 was
shown to involve inhibition of protein ubiquitination, as the
NO donors inhibited the ubiquitination of Cav-1 by cell detachment (Fig. 5).
Recent evidence indicate that S-nitrosylation is an important
mechanism by which NO modulates the function of cellular
proteins (for reviews, see Refs. 29 and 53). S-Nitrosylation can
either attenuate or accentuate protein functions (34, 54, 55),
and our previous studies have shown that it plays an important
role in stability and function of apoptosis regulatory proteins
such as c-FLIP and Bcl-2 (30 –32). In the present study we
found that Cav-1 was rapidly S-nitrosylated by NO after cell
detachment, and inhibition of this S-nitrosylation by DTT
blocked the effect of NO on Cav-1 ubiquitination (Fig. 5). The
inhibition of S-nitrosylation by DTT also led to a decrease in
Cav-1 protein expression and cell survival (Fig. 6), supporting
the role of S-nitrosylation in Cav-1 stability and function. The
mechanism by which S-nitrosylation promotes Cav-1 stability

NO Regulates Caveolin-1 and Anoikis
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was shown to involve protein ubiquitination inhibition,
although the precise mechanism of this inhibition remains to be
investigated. It is possible that S-nitrosylation of Cav-1 may
alter the protein conformation such that it could not be recognized by the enzyme ubiquitin ligases that serve to tag the protein for subsequent degradation by the proteasome.
In conclusion, we demonstrated that Cav-1 plays an important role as a negative regulator of anoikis in human lung carcinoma H460 cells. We also demonstrated for the first time that
Cav-1 is down-regulated during cell anoikis through a nontranscriptional mechanism involving ubiquitin-proteasomal
degradation. NO regulates this process at least in part through
protein S-nitrosylation, which prevents its ubiquitination and
degradation by the proteasome. In demonstrating the effect of
NO on Cav-1 stability and function, we documented a novel
mechanism of anoikis regulation, which could be important in
the control of cancer metastasis. Because NO and Cav-1 have
been shown to be overexpressed in many human tumors, NOmediated regulation of Cav-1 could be a common mechanism
of anoikis resistance and metastasis. This novel finding of the
regulation of Cav-1 by NO may have important implications in
cancer therapy.
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Abstract PYRIN domain (PYD) proteins have recently
emerged as important signaling molecules involved in the
development of innate immunity to intracellular pathogens
through activation of inflammatory mediator pathways.
ASC is the central adaptor protein, which links pathogen
recognition by PYD-containing pathogen recognition
receptors to the activation of downstream effectors,
including activation of Caspase-1 and NF-jB. The cellular
PYD-only protein 1 (cPOP1) can block the recruitment of
ASC to activated PAN receptors and thereby functions as
an endogenous inhibitor of the PYD-mediated signal
transduction pathway. Here we describe the identification
and characterization of a Shope Fibroma homolog to

cPOP1. Like cPOP1, a Shope Fibroma virus-encoded POP
(vPOP), co-localizes and directly associates with ASC and
inhibits PYD-mediated signal transduction. Poxviruses are
known to encode immune evasive proteins to promote host
cell infection and suppression of the host immune response.
Poxvirus-encoded vPOPs represent a novel class of
immune evasive proteins and impair the host response by
blocking Cryopyrin and ASC inflammasome-mediated
activation of pro-Caspase-1 and subsequent processing of
pro-interleukin (IL)-1b, and expression of vPOPs causes
activation of NF-jB.
Keywords Caspase-1  IL-1b  Inflammasome 
NF-jB  PYRIN domain  Poxvirus

Andrea Dorfleutner and Siera J. Talbott contributed equally to this
work.

Introduction
PYRIN domain (PYD) proteins are important signaling
molecules involved in host defense to pathogens through
activation of inflammatory mediator pathways. Humans
have at least 23 proteins containing a PYD. [1–4]. Pathogens are recognized by the leucine-rich region (LRR) of
PYD-containing pathogen recognition receptors, known as
PYD-NLR, PAN, PYPAF, NALP, Caterpiller, and Nod
proteins. Activation of these proteins is hypothesized to be
achieved through displacement of the intramolecular
interaction of the LRR with the NACHT domain. Activated
PYD-NLR-family proteins recruit and oligomerize the
PYD-containing adapter protein ASC (TMS1) [5, 6] into
cytoplasmic aggregates (‘specks’’), referred to as the inflammasome, where activation of downstream effectors
occurs [7]. Caspase-1-mediated processing of pro-IL-1b
and activation of the transcription factor NF-jB have been
described as effectors of PYD-mediated signal transduction
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5¢-CGGAATTCAAAATGGAGCACCGACCGTCATTA-3¢,
5¢-GCGCCTCGAGATAAAATAACAATTTGCGACATA
CACC-3¢. The complete open reading frame of S013L was
cloned directly from the genome of SFV using the primer
pair 5¢-CGGAATTCTACTTTAAAATGAAGGAAAAT
GACAT-3¢, 5¢-GCGCCTCGAGTTGATAAAACAAACT
TTCACGATA-3¢. Both PCR products were digested with
EcoR1 and Xho1 restriction enzymes and cloned into
pcDNA3 (Invitrogen) expression plasmids modified to
contain an NH2-terminal myc or Flag epitope tag. The
authenticity of S013L and M013L was confirmed by DNA
sequence analysis. Expression constructs for ASC, ASCPYD, ASC-CARD, cPOP1, Cryopyrin (R260W), proIL-1b, and pro-Caspase-1 were described previously
[15, 17, 18].

and enforced oligomerization of ASC is sufficient for
activation of these downstream effectors.
Hereditary mutations in PYD-NLR-family proteins can
cause deregulated recruitment of ASC, which leads to
autoinflammatory disorders, such as periodic fever
syndromes. Specifically, mutations in the PYD-containing
protein Pyrin (Marenostrin) account for familial Mediterranean fever, whereas mutations in the PYD-NLR-family
member Cryopyrin (CIAS1, PYPAF1, NALP3) have been
linked to familial cold auto-inflammatory Syndrome,
Muckle–Wells syndrome, and Chronic infantile neurological cutaneous and articular syndrome [8].
The PYD belongs to the family of death domain fold
(DDF) domains, which also includes the caspase recruitment domain (CARD), the death domain (DD), and the
death effector domain (DED). CARD and DED interactions are also regulated by CARD-only proteins (COPs)
and DED-only proteins, respectively. These small proteins
are just composed of a single CARD or DED and include
the CARD-only proteins COP (Pseudo-ICE), Iceberg and
INCA [9–12], or the DED-only proteins PED (PEA-15),
FLIP-s, and viral (v) FLIP [13, 14]. In general DDF-only
proteins can function as dominant-negative inhibitors for
particular signaling pathways by competing for critical
binding partners, thereby interrupting signal transmission
to downstream effector proteins.
The recruitment of ASC to PYD-NLR-family proteins is
regulated by a PYRIN-only protein 1 (POP1), which
interferes with the PYD-PYD interaction between ASC and
PYD-NLRs, thereby impairing host defense by blocking
downstream effectors [15]. Here we report the identification and characterization of a Shope Fibroma Virus (SFV)
POP homolog, which impairs the host response by blocking PYD-mediated activation of pro-Caspase-1 and subsequent processing of pro-interleukin (IL)-1b. During the
preparation of this manuscript, Johnston et al. characterized
a Myxoma virus-encoded POP, which also functions as an
inhibitor of IL-1b secretion [16]. We continued this study
and show that the Shope Fibroma virus-encoded POP
functions similar to the Myxoma virus-encoded POP, and
that both proteins affect also NF-jB activation.

Cell culture and transfection
HEK293N, HEK293T, and rabbit kidney (RK13) cells
were obtained from the American Type Culture Collection
and cultured in Dulbecco’s modified Eagle’s medium
supplemented with 4 mM L-glutamine, 1.5 g/l sodium
bicarbonate, 0.1 mM non-essential amino acids, 1.0 mM
sodium pyruvate, and 10% fetal bovine serum (HEK293)
and Minimum essential medium (Eagle) with 2 mM
L-glutamine and Earle’s BSS adjusted to contain 1.5 g/l
sodium bicarbonate, 0.1 mM non-essential amino acids,
1.0 mM sodium pyruvate, and 10% fetal bovine serum
(RK13). HEK293 cells were transfected using Polyfect
(Qiagen) or the Calcium precipitation method.
Viral infection
Infection of subconfluent layers of RK13 cells with the
rabbit Fibroma virus (strain Original A) was carried out at a
multiplicity of infection (MOI) of 10 in OPTI minimum
essential medium (Invitrogen) supplemented with 2% fetal
calf serum for 1 h. The inoculum was removed, the cells
were washed with serum-free medium and further grown
for the indicated times.
Reverse transcriptase-polymerase chain (RT-PCR)
reaction

Materials and methods
RK13 cells were infected with the rabbit SFV (strain Original A) at a MOI of 10, as described above. Sixteen hours
(16 h) post-infection, RNA was isolated using the Trizol
reagent (Invitrogen) according to the manufacturer’s
instructions. Five micrograms (5 lg) total RNA was subjected to DNase I (Invitrogen) treatment according to the
manufacturer’s instructions and reverse transcribed using
the Superscript II enzyme (Invitrogen) into first strand
cDNA, followed by PCR amplification with GoTaq poly-

Plasmids and strains
The rabbit Myxoma virus (MV; strain Lausanne) and the
rabbit Shope Fibroma virus (SFV; strain Original A) were
obtained from the American Type Culture Collection. The
complete open reading frame of M013L was cloned
directly from the genome of MV by high fidelity PCR
(PFU Ultra, Stratagene) using the primer pair
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merase (Promega) using the S013L-specific primer pair
5¢-CGGAATTCTACTTTAAAATGAAGGAAAATGAC
AT-3¢, 5¢-GCGCCTCGAGTTGATAAAACAAACTTTCA
CGATA-3¢ (324 bp) and the bACTIN-specific primer pair
5¢-GACGATGATATTGCCGCACT-3¢, and 5¢-GATACCA
CGCTTGCTCTGAG-3¢ (533 bp). A control, in which the
RT was omitted during the RT step, was also performed.
PCR-products were excised from agarose gels and
sequence verified.

following day with expression plasmids as indicated using
Lipofectamine plus (Invitrogen). Where indicated, cells
were infected the following day with SFV (MOI = 10). At
48 and 72 h post-transfection (24 and 48 h post-infection),
cells were fixed in 3.7% formaldehyde, permeabilized with
0.5% Saponin (Sigma), blocked with 0.5% Saponin, 1.5%
BSA, and 1.5% normal goat serum (Zymed), and immunostained with rabbit polyclonal anti-myc antibodies
(1:500, Santa Cruz Biotech), mouse monoclonal anti-Flag
M2 antibodies (1:3,500, Sigma) and secondary Alexa Fluor
488 and 546 conjugated antibodies (1:200, Molecular
Probes) in PBS, supplemented with 0.5% Saponin, 1.5%
BSA, and 1.5% normal goat serum (Zymed). The nucleus
is visualized by incubation with ToPro-3 (Molecular
Probes) and the actin cytoskeleton with Alexa Fluor-conjugated phalloidin. After three washes with PBS, supplemented with 0.5% Saponin, samples were mounted with
Vectashield (Vectorlabs) and images were acquired by
confocal laser-scanning microscopy (Zeiss LSM510).

Co-immunoprecipitation assay
Immunoprecipitation assays were performed following
transient expression of HA-tagged ASC and either myctagged M013L or Myc-tagged gp013L into HEK293T
cells. Thirty-six hours (36 h) post-transfection, cells were
lysed in isotonic lysis buffer (150 mM NaCl, 20 mM Tris–
HCl, pH 7.4, 10% glycerol, 0.2% NP-40), supplemented
with protease and phosphatase inhibitors. Clarified lysates
were subjected to immunoprecipitation using agaroseconjugated anti-HA antibodies (Santa Cruz Biotechnology)
for 4 h at 4C. Following extensive washing in lysis buffer,
bound immune complexes were separated by SDS/PAGE
and analyzed by immunoblotting using directly HRP-conjugated anti-myc antibodies (Santa Cruz Biotechnology) in
conjunction with an ECL detection system (AmershamPharmacia). Where indicated, cell lysates (10% volume)
were included along side immune complexes. Alternatively, lysates were directly analyzed by immunoblotting
after normalization for total protein content.

Luciferase reporter gene assay
About 5 · 104 HEK293N cells cultured in 5% serum in 96well plates were transfected in triplicates with the indicated
expression plasmids using Polyfect transfection reagent
(Qiagen) with a total of 500 ng plasmid DNA (normalized
for total DNA), including 75 ng of pNF-jB-LUC (Stratagene) and 3 ng of a Renilla luciferase gene driven by a
constitutive TK promoter (pRL-TK; Promega). At 36 h
post-transfection, cells were treated where indicated with
20 ng/ml TNFa (Biomol) for 8 h and directly analyzed
using the Dual Glow Luciferase kit (Promega) in a Genios
multimode plate reader (Tecan).

In vitro protein interaction assay
The PYD of ASC was expressed as a GST-fusion protein in
E. coli BL21 cells (Stratagene) and affinity-purified using
GSH-Sepharose (Amersham-Pharmacia). GST-ASC-PYD
or GST control (50 ng) immobilized on 10 ll GSHSepharose were blocked in 142.4 mM KCl, 5 mM MgCl2,
10 mM HEPES pH 7.4, 0.5 mM EGTA, 1 mM EDTA,
0.2% Nonidet P-40, 1 mM DTT, supplemented with protease inhibitors and 1 mg/ml BSA for 30 min at room
temperature. Beads were washed twice and incubated with
in vitro translated and biotinylated (Promega) vPOP proteins overnight at 4C as above, but the buffer was supplemented with protease inhibitors and 0.5 mg/ml BSA.
Bound proteins were washed extensively, separated by
SDS/PAGE, immunoblotted with Streptavidin-HRP and
detected with ECL (Amersham-Pharmacia).

IL-1b secretion assay
HEK293N cells were transiently transfected with the
indicated expression plasmids in 24-well plates using the
Polyfect transfection reagent (Qiagen). Twenty-four hours
(24 h) post-transfection, the culture medium was replenished with 0.5 ml of fresh culture medium. Thirty-six hours
(36 h) post-transfection, IL-1b secreted into the culture
supernatants was measured by ELISA using a commercial
kit (BD Pharmingen), normalizing data for cell number, as
determined by crystal violet assay, and precise culture
volume, and performing assays in triplicates.
Results

Confocal microscopy observations

Poxviruses encode PYD-only proteins

RK13 cells were seeded onto Collagen type I-coated cover
slips in 6-well dishes and transiently transfected the

Viruses are known to interfere with host immune and
apoptosis pathways. Since the PYD emerged recently as a

123
163

688

Virus Genes (2007) 35:685–694

key domain in innate immunity, we performed database
mining to identify potential virus-encoded PYD-containing
proteins. Using this approach, we identified open reading
frames in several poxviruses that encode potential viral
PYD-only proteins (vPOPs) (Fig. 1A). Clustal W alignment of the deduced amino acid sequences of the rabbit
Myxoma virus (MV) POP (M013L) [20], the Shope Fibroma virus (SFV) POP (gene: S013L, protein gp013L)
[21], the Swinepox virus (SPV) POP (SPV14L) [22], the
Yaba-like disease virus (YLDV) POP (18L) [23], and the
Mule deer poxvirus (DpV) POP (DPV83gp024) [24] show
significant homologies to cPOP1 and the PYD of ASC
(Fig. 1B). The M013L and gp013L proteins are only 59.5%
identical (65% conserved) to each other. To verify that
S013L is also transcribed in cells infected with poxviruses,
we performed RT-PCR analysis of S013L, due to the lack
of specific antibodies. Total RNA was isolated from RK13
cells and RK13 cells infected with the SFV for 16 h, and

transcribed into first strand cDNAs. Subsequent PCR
analysis using S013L-specific primers demonstrated the
presence of vPOP-specific transcripts only in SFV-infected
cells, which show the typical cytopathic effects (Fig. 1C,
lane 3). Primer specificity for vPOP versus cPOP is shown
by the absence of PCR product in non-infected cells
(Fig. 1C, lane 2). Viral genomic DNA-contamination was
excluded by omitting cDNA from the reverse transcription
in the PCR reaction, which did not amplify a PCR product
(Fig. 1C, lane 4).
For further studies we amplified the ORF of S013L and
M013L by PCR directly from virus particles, cloned it into
mammalian expression vectors in frame with a myc-epitope tag and sequence verified these vPOPs. Transient
transfection of S013L and M013L in HEK293 cells
resulted in expression of vPOPs of the predicted molecular
weight (Fig. 1D). Myc-tagged cPOP1 was used as a control.

Fig. 1 The Shope Fibroma virus encodes a PYD-only protein.
Comparison of viral and cellular PYD-only proteins. (A) Schematic
representation of Myxoma virus (MV) POP (M013L), the Shope
Fibroma virus (SFV) POP (gp013L), the Swinepox virus (SPV) POP
(SPV14L), the Yaba-like disease virus (YLDV) POP (18L), the Mule
deer poxvirus (DpV) POP (DPV83gp024), cPOP1, and ASC. (B)
Clustal W alignment of M013L, gp013L, SPV14L, 18L,
DPV83gp024, cPOP1 and the PYD of ASC. Black and gray boxes
indicate identical and similar (conserved) amino-acid residues,
respectively. The a-helices, as determined for the PYD of ASC are
marked on top [19]. (C) The presence of S013L-specific transcripts

was determined in RK13 cells before and 16 h post-infection with the
rabbit Fibroma virus (SFV) (MOI = 10) by RT-PCR. RT-PCR was
performed with S013L-specific primers and primers specific for bactin. RT: reverse transcriptase. A representative phase contrast
image of uninfected RK13 cells (top) and RK13 cells infected with
SFV (bottom) is shown. (D) Myc-tagged expression constructs for
cPOP1, SFV gp013L, and MV M013L were transiently transfected
into HEK293T cells. Thirty-six hours (36 h) post-transfection,
normalized cell lysates were separated by SDS/PAGE and analyzed
by immunoblot for expression of myc-tagged proteins
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gp013L co-localizes with the central PYD-containing
adaptor protein ASC

consists of a PYD and a CARD [5, 6]. To map the interaction domain of ASC and SFV gp013L or MV M013L, we
performed in vitro GST-pull down assays. Recombinant
proteins of the PYD or the CARD of ASC were expressed
as GST fusion proteins in E. coli BL21 and affinity purified, whereas SFV gp013L and MV M013L were generated
by in vitro translation. These in vitro interaction studies
further confirmed that SFV gp013L and MV M013L
interact with the PYD of ASC, while no interaction was
observed with the CARD of ASC or the GST control
(Fig. 3B). These results demonstrated that SFV gp013L
and MV M013L directly interact with ASC by PYD-PYD
interaction.

The central adaptor protein ASC binds to activated
PYD-NLR-family proteins and mediates activation of
downstream effectors by PYD-PYD interactions. ASC
frequently localizes to characteristic aggregates, referred to
as specks [6], where ASC interacting proteins such as
cPOP1 are frequently recruited [15]. To investigate whether SFV gp013L co-localizes with ASC similar to cPOP1
and MV M013L, we performed immunofluorescence
analysis of cellular and viral POPs in the absence or
presence of ASC. Myc-tagged SFV gp013L (Fig. 2A-a), or
myc-tagged MV M013L (Fig. 2B-a) alone localized to
diffusively throughout the cytoplasm and the nucleus at
48 h post-transfection. At 72 h post-transfection, SFV
gp013L (Fig. 2A-b) and MV M013L (Fig. 2B-b) localized
to punctuate, vesicular structures in the cytoplasm. To
investigate whether virus infection impacts the localization
of vPOPs, we transiently transfected SFV gp013L into
RK13 cells, followed by infection with SFV. Twenty-four
hours (24 h) post-infection SFV gp013L started to aggregate in the cytoplasm of infected cells (Fig. 2A-c), with
stronger aggregation visible at 48 h post-infection (Fig. 2
A-d).
Also cPOP1 showed cytoplasmic and nuclear localization, and co-expression of cPOP1 and ASC leads to
recruitment of cPOP1 into ASC-formed specks [15].
Therefore, localization of vPOPs to these structures was
investigated. Co-expression of Flag-tagged ASC resulted in
co-localization of SFV gp013L (Fig. 2A-e) and MV
M013L (Fig. 2B-c) proteins with ASC in the characteristic
specks. Infection of RK13 cells with SFV did not impact
the localization of ASC and SFV gp013L, likely because
these proteins already localize to specks (Fig. 2A-f).

gp013L interferes with PYD-mediated activation
of Caspase-1
The best-characterized effector protein downstream of the
PYD signal transduction pathway is Caspase-1. Interaction
of cPOP1 with ASC impairs PYD-mediated activation of
downstream effectors by preventing association with upstream PYD-NLR-family proteins [15]. Since vPOPs share
significant homology with cPOP1, we investigated the effect of SFV gp013L or MV M013L interaction with ASC
on PYD-mediated activation of Caspase-1. The PYD signal
transduction pathway was reconstituted in HEK293N cells,
which are deficient in endogenous components of this
pathway, including ASC. Co-expression of a constitutively
active Cryopyrin R260W (a PYD-NLR-family member),
ASC, pro-Caspase-1, and pro-IL-1b leads to activation of
the PYD-mediated signal transduction pathway, and can be
measured by secretion of bioactive IL-1b. Co-expression of
the disease-associated Cryopyrin mutant R260W interacts
with ASC even in the absence of a ligand, promotes ASC
oligomerization, activation of pro-Caspase-1, and subsequently IL-1b secretion [25]. Co-expression of either SFV
gp013L (Fig. 4A) or MV M013L (Fig. 4B) in this system
impaired ASC-mediated activation of Caspase-1 in a dosedependent manner and reduced activity of Caspase-1 to
baseline, as measured by secretion of bioactive IL-1b,
which is processed from pro-IL-1b into bioactive IL-1b by
Caspase-1. Expression of all proteins, except IL-1b, which
we measured by ELISA, was verified by immunoblot
(Fig. 4C).

gp013L interacts with the central PYD-containing
adaptor protein ASC
cPOP1 co-localizes with ASC into ASC-formed specks and
has been identified as an ASC-binding protein. Since SFV
gp013L, and MV M013L co-localized with ASC, their
capability to interact with each other was investigated.
Myc-tagged SFV gp013L or MV M013L were co-expressed in HEK293T cells with HA-tagged ASC by transient co-transfection. Co-immunoprecipitation experiments
of cleared protein lysates with anti-HA sepharose demonstrated the presence of myc-tagged SFV gp013L or MV
M013L in these immune complexes, further indicating that
SFV gp013L and MV M013L form complexes with ASC
in vivo, reminiscent to cPOP1 (Fig. 3A).
PYD-containing proteins usually associate by PYDPYD interaction. POPs only contain the PYD, but ASC

gp013L promotes activation of the transcription factor
NF-jB
Recruitment of ASC to activated PYD-NLR-family members, such as Cryopyrin, has also been implicated in the
activation of the transcription factor NF-jB, though this
finding is not yet supported by animal studies [17, 26].
cPOP1 can interfere with the interaction of ASC and
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Fig. 2 SFV gp013L co-localizes with ASC. Localization of epitopetagged proteins was analyzed following transient transfection into
RK13 cells. (A) Localization of SFV gp013L. Myc-tagged SFV
gp013L was immunostained with a rabbit polyclonal anti-myc
antibody and visualized with an Alexa Fluor 488-conjugated antirabbit antibody 48 h post-transfection (panel a) and 72 h posttransfection (panel b). Actin was visualized with Alexa Fluor 546conjugated phalloidin and the nucleus was stained with ToPro-3.
Shown is from left to right: Myc-tagged SFV gp013L (green), nucleus
(blue), actin (red), and a merged image. Twenty-four hours (24 h)
post-transfection cells were also infected with SFV (MOI = 10) and
cells were immunostained as described above at 24 (panel c) and 48 h
(panel d) post-infection (48 and 72 h post-transfection). Myc-tagged
SFV gp013L and Flag-tagged ASC were immunostained 72 h posttransfection with rabbit polyclonal anti-myc and mouse monoclonal
anti-Flag antibodies and visualized with Alexa Fluor 488 and 546conjugated anti-rabbit and mouse antibodies, respectively. The
nucleus was stained with ToPro-3. Shown is from left to right:
Myc-tagged SFV gp013L (green), Flag-tagged ASC (red), nucleus

(blue), and a merged image (panel e). Twenty-four hours (24 h) posttransfection cells were also infected with SFV (MOI = 10) and cells
were immunostained as described above at 48 h post-infection (72 h
post-transfection) (panel f). (B) Localization of MV M013L. Myctagged MV M013L was immunostained with a rabbit polyclonal antimyc antibody and visualized with an Alexa Fluor 488-conjugated
anti-rabbit antibody 48 h post-transfection (panel a) and 72 h posttransfection (panel b). Actin was visualized with Alexa Fluor 546conjugated phalloidin and the nucleus was stained with ToPro-3.
Shown is from left to right: Myc-tagged MV M013L (green), nucleus
(blue), actin (red), and a merged image. Myc-tagged MV M013L and
Flag-tagged ASC were immunostained 72 h post-transfection with
rabbit polyclonal anti-myc and mouse monoclonal anti-Flag antibodies and visualized with Alexa Fluor 488 and 546-conjugated antirabbit and mouse antibodies, respectively. The nucleus was stained
with ToPro-3. Shown is from left to right: Myc-tagged MV M013L
(green), Flag-tagged ASC (red), nucleus (blue), and a merged image
(panel c)

Cryopyrin, thereby impairing oligomerization of ASC and
subsequently activation of NF-jB [15]. Therefore, the effect of SFV gp013L and MV M013L on NF-jB activation
was investigated. Expression of SFV gp013L and MV
M013L alone potently activated NF-jB, in contrast to
cPOP1 (Fig. 5A). In contrast to the inhibitory effect of
cPOP1 on NF-jB activation, neither SFV gp013L (Fig. 5

B) nor SFV M013L (Fig. 5C) could impair Cryopyrin
(R260W) and ASC-mediated NF-jB activation, but rather
enhanced activation of NF-jB in a dose-dependent manner.
SFV gp013L and MV M013L also enhanced TNFa-mediated activation of NF-jB (Fig 5D), further confirming
the positive impact of vPOPs on the NF-jB activation
pathway.
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Fig. 3 SFV gp013L associates with ASC. (A) In vivo binding
between ASC and SFV gp013L. HEK293T cells were transiently
transfected with HA-tagged ASC, myc-tagged SFV gp013L, and
myc-tagged MV M013L, as indicated. Thirty-six hours (36 h) posttransfection, clarified and normalized cell lysates were subjected to
co-immunoprecipitation using immobilized anti-HA antibodies (Santa
Cruz Biotechnology). Immune complexes were separated by SDS/
PAGE transferred onto PVDF membranes and probed with anti-myc
antibodies directly conjugated to HRP. Membranes were stripped and
reprobed with anti-HA-HRP antibodies. Ten percent (10%) of the
total lysate was run alongside the immunoprecipitation (IP). WB:
western blot. (B) In vitro binding between ASC and SFV gp013L.

SFV gp013L and MV M013L were in vitro translated, labeled with
biotin, and subjected to in vitro GST-pull down assays using GSTASC-CARD, GST-ASC-PYD, and GST immobilized to GSH
sepharose, as indicated. Protein complexes were separated by SDS/
PAGE, transferred onto PVDF membranes and bound proteins were
visualized by immunoblotting with streptavidin-HRP and ECL-Plus
(Amersham Pharmacia Biotech) detection. A membrane is stained
with coomassie blue to visualize the GST fusion proteins. An asterisk
denotes two degradation products, which is present in the ASC-PYD
GST fusion protein purification, but which is not affecting this assay.
A molecular weight standard is indicated to the right

Fig. 4 SFV gp013L inhibits Caspase-1-mediated processing of proIL-1b. HEK293N cells were transiently transfected in triplicates with
expression constructs for pro-Caspase-1, murine pro-IL-1b, Cryopyrin (R260W), ASC, and SFV gp013L (A) or MV M013L (B), as
indicated. Thirty-six hours (36 h) post-transfection, secreted IL-1b
was measured by ELISA (BD Pharmingen) from normalized culture
supernatants using a standard curve generated with a recombinant IL1b. Data are presented as picograms per milliliter of secreted IL-1b

(mean SD; n = 3). (C) HEK293N cells were transfected with the
indicated expression constructs using the concentrations as used for
the IL-1b assay (A, B), and cleared protein lysates were separated by
SDS/PAGE and immunoblotted with antibodies to detect expression
of pro-caspase-1, Cryopyrin (R260W), ASC, SFV gp013L, and MV
M013L. (+ and ++ indicate the two different expression levels of viral
POPs)

Discussion

(PAMPs) [1–4], and some examples of bacterial and recently viral ligands for PYD-NLRs have been specifically
identified [27–31]. Activation of PYD-NLR-family proteins results in oligomerization and recruitment of the
adaptor protein ASC via PYD-PYD interactions [25, 32].
Subsequently, ASC links pathogen recognition to downstream effector activation, including Caspase-1-mediated
processing and secretion of IL-1b, IL-18, and possibly

PYD-containing proteins are important mediators of
inflammatory responses during host defense. In humans, 16
potential PYD-containing pathogen recognition receptors
(PYD-NLR-family members) have been recognized,
including Cryopyrin. It is hypothesized that these proteins
are activated by pathogen-associated molecular patterns
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Fig. 5 SFV gp013L activates the transcription factor NF-jB.
HEK293N cells were transiently transfected in 96-well plates in
triplicates with the indicated expression constructs, including pNFjB-LUC (Stratagene) and pRL-TK (Promega), keeping the total
amount of DNA constant. (A) Cells were transfected with either a
control plasmid or SFV gp013L or MV M013L expression plasmids,
as indicated. (B) Cells were transfected with a control plasmid or ASC
and Cryopyrin (R260W) in the presence or absence of increasing
amounts of SFV gp013L, or cPOP1. (C) Cells were transfected with a
control plasmid or ASC and Cryopyrin (R260W) in the presence or

absence of increasing amounts of MV M013L, or cPOP1. (D) Cells
were transfected with a control plasmid or SFV gp013L or MV
M013L. Where indicated, 36 h post-transfection, cells were treated
for 8 h with 20 ng/ml recombinant human TNFa. Samples were
analyzed using the Dual Glow Luciferase kit (Promega) in a Genios
multimode plate reader (Tecan). Results are presented as fold
induction of NF-jB relative to control transfected cells not induced
with TNFa, normalized to tymidine kinase (TK) reporter gene activity
(mean SD; n = 3)

IL-33 [27, 33, 34]. NF-jB activation has been proposed as
another effector of PYD signal transduction. The PYDmediated signal transduction pathway can be modulated by
the cPOP1, which impairs the interaction of PYD-NLRfamily members and ASC and subsequent activation of
downstream effectors [15].
In this study, we characterized a poxviral-encoded PYDcontaining protein, which is the product of S013L in the
SFV genome (gp013L). As a control the product of M013L
in the MV genome (M013L) was used. MV M013L has
been recently shown to inhibit IL-1b secretion [16]. The
SFV gp013L and MV M013L proteins are only 59.5%
identical (65% conserved), but nevertheless function
identically with respect to Caspase-1 and NF-jB activation. Poxviruses are large dsDNA containing viruses,
which are well known to encode immune evasive proteins
to impair the host response upon infection [35, 36]. These
immunomodulatory genes usually lack conservation be-

tween poxvirus family members, which may reflect differences in host tropism. Poxviruses are known to hijack
cellular proteins that are then employed to evade immune
recognition and to impair apoptosis of infected host cells.
Many crucial pathways of the cellular and humoral host
defense can be targeted [35, 36] and the fact that poxviruses also target PYD proteins further emphasizes the
significance of this signal transduction pathway for host
defense. SFV and MV encode inhibitors of the PYDmediated signal transduction pathway called PYD-only
proteins, SFV gp013L and MV M013L, respectively.
Additional members were identified in the genome of SPV,
YLDV, and DpV, suggesting that these genes encode a
novel class of common immune evasive proteins. To discriminate the viral and cellular POPs, we propose to
rename POP1 to cPOP1. Like the cellular homolog, vPOPs
interact with ASC, the central adaptor protein of the PYDsignal transduction pathway. The interaction is mediated by
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Expression of vPOPs strongly promoted activation of
NF-jB, which is in contrast to cPOP1 [15]. POPs most
likely impair the PYD-PYD association between ASC and
PYD-NLR-family proteins, thereby disrupting the pathway
leading to the activation of these effectors, which occurs in
the inflammasome. It is therefore surprising that NF-jB
activation is not impaired by vPOPs, suggesting selectivity
for Caspase-1 activation. We recently demonstrated that
ASC can compete with Cardiak (Rip2) for pro-Caspase-1
binding [18], and a recent study suggested that ASC
interaction with Caspase-1 prevents the interaction of
Caspase-1 with Cardiak, and that this interaction is
required for the activation of NF-jB [39]. According to this
model, the disruption of the PYD-NLR-ASC interaction by
vPOPs might also impair the subsequent interaction of
ASC with pro-Caspase-1. As a result, pro-Caspase-1 would
be available to associate with Cardiak to activate NF-jB.
Upon infection, poxviruses, including the MV, potentially
block the NF-jB activation pathway using virus-encoded
conserved ankyrin-containing proteins, such as the critical
virulence factor M150R (MNF), which function analogous
to cellular IjBs [40]. PYD proteins link to the NF-jB
activation pathway at the level of the IKK complex, and
also Caspase-8 has been implicated in this pathway [17, 26,
41, 42]. However, many viruses activate NF-jB, which
establishes a more efficient infection, which promotes viral
replication and prevents virus-induced apoptosis of
infected cells [43]. High and constitutive activation of NFjB has also been linked to tumorigenesis, and MV and
SFV are tumorigenic in their natural hosts, and activation
of NF-jB by virulence factors could support tumor
development by promoting proliferation and impairing the
apoptotic host response [44].
Cryopyrin, one of the PYD-NLR-family proteins for
which ligands have been identified, senses several bacterial-derived PAMPs [27–30]. A very recent report also
provides evidence that Cryopyrin is required for Caspase-1
activation in response to viral infections and recognizes
viral-derived PAMPs, such as dsRNA [31]. The observation that poxviruses encode immune evasive proteins that
target the PYD-signal transduction pathway, further support that viral PAMPs might function as ligands for some
PYD-NLRs. In summary, our data provide evidence for the
existence of a SFV-encoded gp013L, which in spite of the
rather low sequence similarity compared to the MV-encoded M013L, functions identically by inhibiting activation of Caspase-1 and activating NF-jB. Virus-encoded
PYD proteins represent a novel class of conserved immune
evasive proteins, which target the host inflammasome. This
observation further emphasizes the importance of PYD
proteins for host defense and support that viral-derived
PAMPs are recognized by the inflammasome.

PYD-PYD, but not PYD-CARD interaction, as shown by
in vitro GST pull down assays, and it appears that the
binding of SFV gp013L to ASC is slightly stronger than
that of MV M013L to ASC.
ASC frequently localizes to characteristic structures in
the cytoplasm or forms characteristic cytoplasmic aggregates, known as specks, to which ASC-interacting proteins
are frequently recruited. However, the physiological function of specks is not known. Initially vPOPs localize diffusively throughout the cell, and are found inside vesicular
cytoplasmic structures 72 h post-transfection. Interestingly,
infection of RK13 cells with SFV caused aggregation of
SFV gp013L in a time-dependent manner. Co-expression
with ASC caused recruitment of vPOPs into ASC-formed
specks, reminiscent of cPOP1 [15]. cPOP1 localizes to the
cytoplasm and the nucleus, and co-expression with ASC
causes redistribution of cPOP1 into ASC formed specks
[15]. Since SFV gp013L already co-localized with ASC
into specks, infection of RK13 cells with SFV did not alter
their localization.
The best-characterized PYD-activated downstream
effector is Caspase-1. Activation of Caspase-1 is required
for the processing, activation and subsequent secretion of
the proinflammatory cytokines pro-IL-1b, pro-IL-18, and
pro-IL-33 [37, 38]. Activation of Caspase-1 requires prior
activation of PYD-NLR-family proteins by their cognate
ligands, subsequent recruitment of ASC, and formation of
inflammasomes. Both SFV gp013L and MV M013L
impaired Cryopyrin and ASC-mediated activation of Caspase-1, which might be explained by the impaired formation of an inflammasome containing ASC and Cryopyrin in
the presence of vPOPs. The ability of vPOPs to impair
Caspase-1 activation in response to other than Cryopyrin
containing inflammasomes will need further investigation.
Apart from vPOPs, poxviruses are known to encode other
proteins that interfere with the Caspase-1-IL-1b pathway.
Several poxviruses encode soluble IL-1 receptors, which
bind only to IL-1b. The cellular receptor, however, binds
IL-1a, IL-1b and IL-1RA, suggesting that specific inhibition of IL-1b is crucial during poxvirus infection [35, 36].
MV and SFV encode Serp2, which shows similarity to the
cowpox virus crmA, and also inhibits Caspase-1 [35, 36].
Poxviruses acquired mechanisms to impair the generation
and function of IL-1b at three different levels: (1) at the
inflammasome formation and signal transduction leading to
Caspase-1 activation, (2) directly at Caspase-1 activation,
and (3) at the binding of IL-1b to its receptor. Blocking
three key steps by three distinct poxviral-encoded proteins
emphasizes the importance of this cytokine for host
defense. Poxviruses also encode proteins, such as IL18BPs, to interfere with IL-18, a cytokine that also requires
Caspase-1 for processing [35, 36].
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Pyrin domain (PYD) proteins have recently emerged as important signaling molecules involved in the
development of innate immunity against intracellular pathogens through activation of inflammatory mediator
pathways. ASC is the central adaptor protein, which links pathogen recognition by PYD-containing pathogen
recognition receptors, known as PYD-Nod-like receptors (NLR), PAN, PYPAF, NALP, Nod, and Caterpiller
proteins, to the activation of downstream effectors, including activation of caspase-1 and NF-B. Activation of
these effectors occurs when specific protein complexes, known as inflammasomes, are formed. PYD signal
transduction leads to inflammasome assembly and activation of specific effector proteins. It is modulated by
a cellular PYD-only protein (cPOP1), which binds to ASC and interferes with the recruitment of ASC to
activated PYD-NLRs. Here we describe the identification and characterization of a second cellular POP
(cPOP2), which shows highest homology to the PYD of PAN1. cPOP2 binds to ASC and PAN1, thereby blocking
formation of cryopyrin and PAN1-containing inflammasomes, activation of caspase-1, and subsequent processing and secretion of bioactive interleukin-1␤. Existence of a second cPOP provides additional insights into
inflammasome formation and suggests that POPs might be a common regulatory mechanism to “fine-tune” the
activity of specific PYD-NLR family protein-containing inflammasomes.
NF-B have been described as effectors of PYD-mediated
signal transduction, and enforced oligomerization of ASC is
sufficient for their activation.
Hereditary mutations in PYD family proteins can cause dysregulated recruitment of ASC, which leads to autoinflammatory disorders, such as periodic fever syndromes. Specifically,
mutations in pyrin (marenostrin) account for familial Mediterranean fever, whereas mutations in the PYD-NLR family
member cryopyrin (CIAS1, PYPAF1, NALP3, CLR1.1) have
been linked to familial cold autoinflammatory syndrome,
Muckle-Wells syndrome, and chronic infantile neurological cutaneous and articular syndrome (3).
The PYD belongs to the death domain fold (DDF) domain
family, which also includes the caspase recruitment domain
(CARD), the death domain (DD), and the death effector domain (DED). CARD and DED interactions are also regulated
by CARD-only proteins (COPs) and DED-only proteins, respectively. These small proteins are composed of a single
CARD or one or two DED domains and include the CARDonly proteins COP (Pseudo-ICE), ICEBERG and INCA (9,
11, 17, 18), or the DED-only proteins PED (PEA-15), FLIP-s,
and viral FLIP (4, 16). In general, DDF-only proteins can
function as dominant-negative inhibitors for particular signaling pathways by competing for critical binding partners,
thereby interrupting signal transmission to downstream effector proteins. Inflammasome formation, upon pathogen infection, is regulated by cellular and viral pyrin-only proteins
(vPOPs), which interfere with the PYD-PYD interaction between ASC and PYD-NLR family proteins, thereby impairing

Pyrin domain (PYD) proteins are important signaling molecules involved in host defense against pathogens through activation of inflammatory mediator pathways. Humans have at
least 23 proteins containing a PYD (12, 31, 33, 34). Pathogens
are recognized by the leucine-rich region (LRR) of PYDcontaining pathogen recognition receptors, known as PYDNod-like receptors (NLR), pyrin- and NACHT domain-containing proteins (PAN), pyrin domain-containing Apaf1-like
proteins (PYPAF), NACHT-LRR- and pyrin domain-containing proteins (NALP), nucleotide-binding oligomerization domain-containing proteins (Nod), and Caterpiller proteins. Activation of these proteins is hypothesized to be achieved
through displacement of the intramolecular interaction of the
LRR with the NACHT (NAIP, CIITA, HET-E, and TP1)
domain. Activated PYD-NLR family proteins recruit and oligomerize the PYD-containing adaptor protein ASC (apoptosis-associated speck-like protein containing a caspace recruitment domain; TMS1) (5, 24) into cytoplasmic structures,
referred to as the inflammasomes, where downstream effector
activation occurs (22). Caspase-1-mediated processing of prointerleukin (IL)-1␤ and activation of the transcription factor
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host defense by blocking downstream effectors (13, 29; A.
Dorfleutner, S. J. McDonald, N. B. Bryan, K. N. Funya, J. C.
Reed, X. Shi, D. C. Flynn, Y. Rojanasakul, and C. Stehlik,
submitted for publication). Here we report the identification
and characterization of a second cellular POP, cPOP2, which
impairs PYD-mediated activation of pro-caspase-1 and subsequent processing of pro-IL-1␤.
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Direct yeast two-hybrid interaction. The EGY48 strain of Saccharomyces
cerevisiae (MAT trp1 ura3 his leu2::plexApo6-leu2) was maintained in yeast extract-peptone-dextrose medium. cPOP2 and the PYD of several NLR family
proteins, pyrin, and ASC were cloned into pJG4-5 and pGilda yeast expression
vectors under the GAL1 promoter. Plasmids were cotransformed by the LiCl
method with pSH1834, which contains eight repeats of a LexA promoter to drive
expression of the ␤-galactosidase reporter gene, in EGY48. Transformed yeast
cells were plated onto leucine-deficient Burkholder’s minimal medium containing 2% galactose and 1% raffinose and supplemented with appropriate amino
acids, and the interaction of the proteins was scored by leucine complementation-dependent growth. Colonies were then replicated onto Burkholder’s minimal medium plates containing leucine and 2% glucose, and ␤-galactosidase filter
assays were performed and scored according to the time required to yield a blue
color.
Confocal microscopy analysis. HEK293T cells were seeded onto collagen type
I-coated coverslips in six-well dishes and transiently transfected the following day
with pcDNA3 expression plasmids for myc-tagged cPOP2, myc-tagged cPOP1,
Flag-tagged ASC, and HA-tagged PAN1 as indicated, using the calcium phosphate precipitation method. At 36 h posttransfection, cells were fixed in 3.7%
formaldehyde; permeabilized with 0.5% saponin (Sigma); blocked with 0.5%
saponin, 1.5% BSA, and 1.5% normal goat serum (Zymed); and immunostained
with rabbit polyclonal anti-myc antibodies (1:500; Santa Cruz Biotech), mouse
monoclonal anti-Flag M2 antibodies (1:3,500, Sigma), rat polyclonal anti-HA
antibodies (1:2,500; Roche Applied Science), and secondary Alexa Fluor 488 and
546 conjugated antibodies (1:200; Molecular Probes) in phosphate-buffered saline supplemented with 0.5% saponin, 1.5% BSA, and 1.5% normal goat serum
(Zymed). Nuclei were visualized by incubation with ToPro-3 (Molecular Probes),
and the actin cytoskeleton was stained with Alexa Fluor 488- or 546-conjugated
phalloidin. After three washes with PBS, supplemented with 0.5% saponin,
samples were mounted with Vectashield (Vectorlabs), and images were acquired
by confocal laser-scanning microscopy (Zeiss LSM510).
IL-1␤ secretion assay. HEK293N cells were transiently transfected with
pcDNA3 expression plasmids for mouse pro-IL-1␤, myc-tagged pro-caspase-1,
HA-tagged ASC, myc-tagged cryopyrin, untagged PAN1, and Flag-tagged
cPOP2 in 24-well plates using the Polyfect transfection reagent (QIAGEN). At
24 h posttransfection, the culture medium was replenished with 0.5 ml of fresh
culture medium. At 36 h posttransfection, IL-1␤ secreted into the culture supernatants was measured by enzyme-linked immunosorbent assay (ELISA) using a
commercial kit (BD Biosciences–Pharmingen) and a Genios multimode plate
reader (Tecan). Assays were performed in triplicate, and data were normalized
for cell number, as determined by crystal violet assay.

MATERIALS AND METHODS
Plasmids and strains. The complete open reading frame of cPOP2 was cloned
from a pooled cDNA library by high-fidelity PCR (PfuUltra; Stratagene) using
the primer pair 5⬘-GCGAATTCATGGCATCTTCTGCAGAGCTG-3⬘ and 5⬘CCGCCTCGAGTTAAGGTGGGGGCATCACACA-3⬘. The PCR product was
digested with EcoRI and XhoI restriction enzymes and cloned into pcDNA3
(Invitrogen) expression plasmids, which were modified to contain an NH2-terminal myc, hemagglutinin (HA), or Flag epitope tag. The authenticity of cPOP2
was confirmed by DNA sequence analysis. Expression constructs for ASC, ASCPYD, ASC-CARD, cPOP1, cryopyrin (R260W), PAN1, pro-IL-1␤, and procaspase-1 were described previously (2, 28–30).
Cell culture and transfection. HEK293N, HEK293T, and Jurkat cells were
obtained from the American Type Culture Collection and cultured in Dulbecco’s
modified Eagle’s medium (HEK293) and RPMI 1640 medium (Jurkat cells) and
supplemented with 4 mM L-glutamine, 1.5 g/liter sodium bicarbonate, 0.1 mM
nonessential amino acids, 1.0 mM sodium pyruvate, and 10% fetal bovine serum.
HEK293 cells were transfected using Polyfect (QIAGEN) or the calcium precipitation method, and Jurkat cells were transfected using Lipofectamine Plus
(Invitrogen).
Reverse transcriptase PCR (RT-PCR) reaction. RNA was isolated from cells
using the TRIzol reagent (Invitrogen), according to the manufacturer’s instructions. Total RNA (5 g) was subjected to DNase I (Invitrogen) treatment and
reverse transcribed using the Superscript II enzyme (Invitrogen) into first-strand
cDNA, as suggested by the manufacturer, followed by PCR amplification with
GoTaq polymerase (Promega) using the cPOP2-specific primer pair 5⬘-ATGG
CATCTTCTGCAGAGCTG-3⬘ and 5⬘-TTAAGGTGGGGGCATCACACA-3⬘
(294 bp) and the ␤-actin-specific primer pair 5⬘-GACGATGATATTGCCGCA
CT-3⬘, 5⬘-GATACCACGCTTGCTCTGAG-3⬘ (533 bp). A negative-control experiment with pooled RNA samples, in which the RT was omitted during the
RT-PCR step, was also performed. PCR products were excised from agarose
gels, and sequences were verified.
Coimmunoprecipitation assay. Immunoprecipitation assays were performed
following transient expression of the HA-tagged PYD of ASC (ASC-PYD) and
the myc-tagged cPOP2; the myc-tagged PYD of PAN1 (PAN1-PYD) and the
Flag-tagged cPOP2; and PAN1 and the myc-tagged cPOP2 into HEK293T cells.
At 36 h posttransfection, cells were lysed in isotonic lysis buffer (150 mM NaCl,
20 mM Tris-HCl [pH 7.4], 10% glycerol, 0.2% NP-40) supplemented with protease and phosphatase inhibitors. Clarified lysates were subjected to immunoprecipitation using agarose-conjugated anti-myc or anti-Flag antibodies (Santa
Cruz Biotechnology) for 4 h at 4°C. Following extensive washing in lysis buffer,
bound immune complexes were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed by immunoblotting using
horseradish peroxidase (HRP)-conjugated anti-HA (Santa Cruz Biotechnology)
and anti-myc (Santa Cruz Biotechnology) antibodies or anti-PAN1 antibodies
(Imgenex) in conjunction with an ECL detection system (Amersham-Pharmacia). Where indicated, cell lysates (5% volume) were included alongside immune
complexes. Alternatively, lysates were directly analyzed by immunoblotting after
normalization for total protein content.
In vitro protein interaction assay. cPOP2 was expressed as a glutathione
S-transferase (GST) fusion protein in Escherichia coli BL-21 cells (Stratagene)
and affinity purified using glutathione (GSH)-Sepharose (Amersham-Pharmacia). GST-cPOP2 or the GST control (50 ng) immobilized on 10 l GSHSepharose was blocked in a mixture containing 142.4 mM KCl, 5 mM MgCl2, 10
mM HEPES (pH 7.4), 0.5 mM EGTA, 1 mM EDTA, 0.2% Nonidet P-40, and 1
mM dithiothreitol and supplemented with protease inhibitors and 1 mg/ml bovine serum albumin (BSA) for 30 min at room temperature. Beads were washed
twice and incubated with in vitro-translated and biotinylated (Promega) ASC and
PAN1-PYD proteins overnight at 4°C as described above, except that the buffer
was supplemented with protease inhibitors and 0.5 mg/ml BSA. Bound proteins
were washed extensively, separated by SDS-PAGE, immunoblotted with streptavidin-HRP, and detected with ECL-Plus (Amersham-Pharmacia).

RESULTS
Identification of a second cellular PYD-only protein. We
recently characterized human POP1, which is highly similar to
the PYD of ASC, and showed that it interferes with the PYDPYD interaction between ASC and cryopyrin to block activation of NF-B (29). POP1 represents the first endogenous
regulator of the PYD signal transduction pathway. More recently, we and others identified poxviral POP homologues that
impair host defense by preventing inflammasome formation,
which prompted us to suggest renaming POP1 to cPOP1 (7a,
13). Poxviruses are large double-stranded DNA viruses, which
encode virulence factors that enable them to evade the host
immune responses upon infection, and are known to frequently hijack proteins from the host (25, 27).
We mined the human genome for additional cellular POPs.
Since cPOP1 is most homologous to the PYD of ASC (29), we
applied the PYD of other PYD-containing proteins for the
database mining. Using the PYD of PAN1 (PYPAF2, NALP2,
NBS1, CLR19.9) (a PYD-NLR protein), we identified a potential PYD-containing open reading frame, carried on a single
exon on chromosome 3q28, which recently was also predicted
by NCBI using GNOMON (accession no. XR_001234). The
deduced amino acid sequence revealed a potential POP, similar to cPOP1 and several poxviral POPs, which all bind to ASC
172
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FIG. 1. The human genome encodes a second cellular PYD-only protein. (A) Schematic domain representation of cPOP2 and other known
viral and cellular POPs, ASC, and PYD-NLR family proteins. Myxoma virus (MV; M013L), rabbit Shope fibroma virus (SFV; gp013L), swinepox
virus (SPV; SPV14L), Yaba-like disease virus (YLDV; 18L), mule deer poxvirus (DPV; DPV83gp024). (B) Clustal W alignment of cPOP2 and the
most similar PYD of PAN1 (PYPAF2, NALP2, NBS1, CLR19.9). (C) cPOP2 and the PYDs of the three most similar PYD-containing proteins,
PAN1, PAN 7 (PYPAF3, NALP7, NOD12, CLR19.4), and ASC. (D) cPOP2 with other known POPs. Dark gray and light gray shading indicates
identical and similar (conserved) amino acid residues, respectively. The ␣-helices, as determined for the PYD of ASC, are marked above the
sequences (e.g., H1, H2, etc.) (19).

eral conserved amino acid residue patches are present in all
known POPs (Fig. 1D).
cPOP2 is expressed in human cells. Because we predicted
cPOP2 from the human genome, we investigated whether
cPOP2 is actually expressed in human cells. Due to the lack of

by PYD-PYD interaction (Fig. 1A). This protein, which we
named cPOP2, shows 68% sequence similarity (61% sequence
identity) to the PYD of PAN1 (Fig. 1B). High sequence similarity of cPOP2 to the PYD of PAN7 (PYPAF3, NALP7,
NOD12, CLR19.4) and ASC (Fig. 1C) is also detectable. Sev173

VOL. 75, 2007

INFLAMMASOME REGULATION BY cPOP2

1487

detectable between ASC and the PYD of PAN1 with the GST
control, demonstrating the specificity of these interactions
(Fig. 3A).
We next investigated whether the interaction between
cPOP2 and ASC or PAN1 can also occur in vivo. The HAtagged PYD of ASC (ASC-PYD) was coexpressed with myctagged cPOP2 (or as a control, cPOP1) in HEK293T cells by
transient cotransfection. Coimmunoprecipitation experiments
of cleared protein lysates with anti-myc Sepharose demonstrated the presence of HA-tagged ASC-PYD in immune complexes containing myc-tagged cPOP1 or cPOP2 but not in
control immune complexes. These findings indicated that
cPOP2 can form complexes with ASC in vivo, reminiscent of
cPOP1 (Fig. 3B). To test the interaction between cPOP2 and
PAN1, we first coexpressed the myc-tagged PYD of PAN1
(PAN1-PYD) and Flag-tagged cPOP2 into HEK293T cells.
Coimmunoprecipitation experiments of cleared protein lysates
with anti-Flag Sepharose demonstrated the presence of myctagged PAN1-PYD in immune complexes containing Flagtagged cPOP2 but not in control immune complexes (Fig. 3C).
Similarly, coexpression of untagged full-length PAN1 with
myc-tagged cPOP2 in HEK293T cells followed by coimmunoprecipitation of cleared protein lysates further confirmed specific binding of cPOP2 to PAN1 (Fig. 3D). To test the interaction of cPOP2 and PAN1 also under endogenous conditions,
we transiently transfected large and small amounts of myctagged cPOP2 into Jurkat cells, because no antibody specific
for cPOP2 is currently available and Jurkat cells express PAN1
(2). Coimmunoprecipitation of myc-containing immune complexes from cleared protein lysates demonstrated the presence
of endogenous PAN1 in a dose-dependent manner (Fig. 3E).
These experiments demonstrated that cPOP2 is capable of
binding to ASC and PAN1 and that the binding is mediated by
PYD-PYD interaction.
POPs can impair PYD-mediated signal transduction by
binding to the PYD of ASC but may also block the PYD of
PYD-NLR family proteins, such as PAN1, to prevent recruitment of ASC by PYD-PYD interaction. To investigate this
possibility, we performed direct yeast two-hybrid interactions
between cPOP2 and several PYD-NLR family proteins. cPOP2
was fused to the DNA-binding domain of LexA, whereas the
PYDs of PYD-NLR family proteins were fused to the activation domain of B42, because we expect that the interaction will
occur between the PYDs of PYD-NLRs and cPOP2, as shown
for ASC and PAN1 (Fig. 3F). Results were confirmed by performing a reciprocal experiment. This screen identified several
PYD-NLR family proteins as potential binding partners of
cPOP2. cPOP2 displays highest sequence similarity to the PYD
of PAN1 (Fig. 1B), which consistently conferred the strongest
growth of yeast on selective plates and yielded the highest
␤-galactosidase activity. Also, the PYDs of PAN2 (PYPAF4,
NALP4, CLR19.5), PAN6 (PYPAF7, NALP12, Monarch-1,
CLR19.3), NALP1 (NAC, CARD7, DEFCAP, CLR17.1), and
ASC, which all show significant similarities to cPOP2, were
identified as potential cPOP2-interacting proteins. The PYDs
of pyrin, cryopyrin (CIAS1, PYPAF1, NALP3, CLR1.1),
PAN5 (NALP10, PYNOD, NOD8, CLR11.1), and PAN10
(PYPAF6, NALP11, NOD17, CLR19.6) did not interact with
cPOP2 under these conditions, demonstrating the specificity
and selectivity of the identified cPOP2 interactions.

FIG. 2. cPOP2 is expressed in human cell lines. cPOP2-specific
transcripts were detected in several human cell lines by RT-PCR,
which was performed with cPOP2-specific primers and primers specific
for ␤-actin. RT-PCR was also performed using pooled RNA from
THP-1 cells treated with 600 ng/ml LPS (E. coli serotype O111:B4) for
2, 4, 6, 12, and 24 h (THP-1 ⫹ LPS). A cPOP1 expression plasmid
(pcDNA3-myc-cPOP1) was included as a negative control, and a
cPOP2 expression plasmid (pcDNA3-myc-cPOP2) was used as a positive control. Pooled RNA not incubated with reverse transcriptase
during the RT-PCR step was also used as a negative control.

a specific antibody, we performed RT-PCR analysis using
cPOP2-specific primers and RNA isolated from various human
cell lines. The presence of a cPOP2-specific transcript of 294 bp
in several cell lines confirmed that cPOP2 is indeed transcribed
and that it encodes a predicted protein of approximately 11 kDa
(Fig. 2). Since cPOP2 is encoded on a single exon, we ensured
that all potential genomic DNA contamination of the isolated
RNA was removed by treatment of the RNA with DNase I, prior
to cDNA synthesis. We also performed a negative-control cDNA
synthesis reaction from THP-1 RNA in the absence of the RT,
which did not yield a cPOP2-specific PCR product, verifying that
no genomic DNA contamination had occurred. We performed a
PCR using as a template a plasmid-encoding cPOP1 for a negative control and a plasmid-encoding cPOP2 for a positive control.
Because cPOP2-specific transcripts were not found in all cell lines
tested, we also verified the quality of the cDNA template by
performing the PCR using ␤-actin-specific primers, which
amplified a 533-bp product. PCR products were excised from
agarose gels and confirmed by DNA sequencing to correspond
to cPOP2.
cPOP2 interacts with ASC and PAN1. cPOP1 and vPOPs
regulate the activation of PYD-dependent immune effectors by
PYD-PYD interaction with the central adaptor protein ASC.
cPOP2 further shows highest sequence similarity to the PYD
of PAN1, a PYD-NLR protein. The ability of cPOP2 to bind to
ASC and PAN1 was therefore investigated by an in vitro glutathione S-transferase pull-down assay using ASC and PAN1
as prototypical examples. A recombinant cPOP2 protein was
expressed as a GST fusion protein in E. coli BL21 and affinity
purified, whereas the PYDs of PAN1 and ASC were generated
by in vitro translation. These in vitro interaction studies confirmed that cPOP2 is capable of interacting not only with ASC
but also with the PYD of PAN1 (Fig. 3A). No interaction was
174

1488

INFECT. IMMUN.

DORFLEUTNER ET AL.

FIG. 3. cPOP2 associates with ASC and PYD-NLR family proteins. (A) In vitro binding between cPOP2, ASC, and PAN1. ASC and the PYD
of PAN1 were in vitro translated, labeled with biotin, and subjected to in vitro GST pull-down assays using GST-POP2 and a GST control
immobilized on GSH-Sepharose, as indicated. Protein complexes were separated by SDS-PAGE and transferred onto polyvinylidene difluoride
(PVDF) membranes, and bound proteins were visualized by immunoblotting with streptavidin-HRP and ECL-Plus (Amersham Pharmacia
Biotech) detection. The recombinant GST-cPOP2 and GST proteins are visualized by Coomassie blue staining. The asterisk denotes several
degradation products of cPOP2, which did not affect this assay. (B) In vivo binding between cPOP2 and ASC. HEK293T cells were transiently
transfected with the HA-tagged PYD of ASC (ASC-PYD), myc-tagged cPOP1, and myc-tagged cPOP2, as indicated. At 36 h posttransfection,
clarified and normalized cell lysates were subjected to coimmunoprecipitation, using immobilized anti-myc antibodies (Santa Cruz Biotechnology).
Immune complexes were separated by SDS-PAGE, transferred onto PVDF membranes, and probed with anti-HA antibodies directly conjugated
to HRP and detected with ECL (Amersham Pharmacia Biotech). Membranes were stripped and reprobed with anti-myc-HRP antibodies. Five
percent of the total lysate was also immunoblotted with HA-HRP antibodies to control for ASC-PYD expression. IP, immunoprecipitation; WB,
Western blot. (C, D, E) In vivo binding between cPOP2 and PAN1. HEK293T cells were transiently transfected with the myc-tagged PYD of PAN1
(PAN1-PYD) and Flag-tagged cPOP2 (C) or full-length, untagged PAN1 and myc-tagged cPOP2 (D), as indicated. At 36 h posttransfection,
clarified and normalized cell lysates were subjected to coimmunoprecipitation, using immobilized anti-Flag antibodies (Sigma) (C) or immobilized
anti-myc antibodies (Santa Cruz Biotechnology) (D). Immune complexes were separated by SDS-PAGE, transferred onto PVDF membranes, and
probed with anti-myc antibodies directly conjugated to HRP (Santa Cruz Biotechnology) (C) or with anti-PAN1 antibodies (Imgenex) and
secondary anti-rabbit antibodies conjugated to HRP (Amersham Pharmacia Biotech) and detected with ECL and ECL-Plus (Amersham
Pharmacia Biotech) (D). Membranes were stripped and reprobed with anti-Flag-HRP antibodies (Sigma) (C) or anti-myc HRP antibodies (D).
Jurkat cells were transiently transfected with small (⫹) and large (⫹⫹) amounts of myc-tagged cPOP2, and cleared lysates were coimmunoprecipitated at 36 h posttransfection, using immobilized anti-myc antibodies (Santa Cruz Biotechnology) (E). Immune complexes were separated by
SDS-PAGE, transferred onto PVDF membranes and probed with anti-PAN1 antibodies (Imgenex) and secondary anti-rabbit HRP antibodies
(Amersham Pharmacia), and detected with ECL-Plus (Amersham Pharmacia Biotech). Membranes were stripped and reprobed with anti-myc-
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NLR family member), ASC, pro-caspase-1, and pro-IL-1␤
leads to activation of the PYD-mediated signal transduction
pathway, which can be measured by secretion of bioactive
IL-1␤. The disease-associated cryopyrin mutant R260W interacts more efficiently with ASC and promotes ASC oligomerization, activation of pro-caspase-1, and subsequently IL-1␤
secretion, even in the absence of a ligand (8). Coexpression of
cPOP2 with ASC and cryopyrin (R260W) impaired ASC-mediated activation of caspase-1 in a dose-dependent manner, as
measured by secretion of bioactive IL-1␤, which is processed
from pro-IL-1␤ by caspase-1 (Fig. 5A). As previously reported,
coexpression of ASC and PAN1 also induces activation of
pro-caspase-1 (1, 2). Coexpression of cPOP2 with ASC and
PAN1 also impaired activation of caspase-1 by the PAN1containing inflammasome in a dose-dependent manner (Fig.
5B). These results demonstrate a potential role for cPOP2 in
modulating activation of caspase-1 by specific inflammasomes.

cPOP2 colocalizes with PAN1 and the central PYD-containing adaptor protein ASC. cPOP1 and vPOPs show a distinct
intracellular localization to punctate structures in the cytoplasm
and to the nucleus (7a, 13, 29). When coexpressed with the central
adaptor protein ASC, cPOP1 is recruited into ASC-formed
specks. In contrast, this redistribution into specks was not observed with vPOPs, which instead colocalized with ASC in
smaller, cytoplasmic vesicular structures (7a, 29). Because cPOP2
is capable of binding to ASC and PAN1, we used immunofluorescence to investigate whether cPOP2 can also colocalize with
ASC or PAN1, upon transient coexpression in HEK293 cells.
cPOP2 localized primarily to vesicular cytoplasmic structures and
the nuclei of cells (Fig. 4A). Coexpression with ASC (Fig. 4C)
resulted in partial colocalization of cPOP2 with ASC to these
vesicular structures in the cytoplasm (Fig. 4B).
ASC forms inflammasomes, which require activation of a specific PYD-NLR family member by pathogen-associated molecular patterns. cPOP2 shows highest similarity to the PYD of PAN1,
which is one of the PYD-NLRs that recruits ASC to form a
specific inflammasome (1, 2). Transient expression of PAN1 in
HEK293 cells showed a very similar localization to punctate cytoplasmic structures and the nucleus (Fig. 4D). Coexpression with
cPOP2 resulted in efficient colocalization of both proteins to
these punctate cytoplasmic structures, but neither of the proteins
localized any longer to the nucleus (Fig. 4E).
ASC can also form characteristic cytoplasmic structures, referred to as specks, which are large, perinuclear aggregates
(24). ASC-interacting proteins, including cPOP1 and vPOPs,
are frequently recruited into these structures (7a, 29). cPOP2
was not recruited into ASC-formed specks but was excluded
from these structures (Fig. 4F). Also, PAN1 was not recruited
into ASC-formed specks under these conditions (data not
shown). In contrast, cPOP1 efficiently colocalized with ASC to
these specks (Fig. 4G).
cPOP2 interferes with PYD-mediated activation of
caspase-1. The best-characterized effector protein downstream
of the PYD signal transduction pathway is caspase-1. Procaspase-1 is activated upon recruitment to inflammasomes by
CARD-CARD interactions mediated by ASC. Interaction of
cPOP1 and vPOPs with ASC impairs PYD-mediated activation
of downstream effectors by preventing association with upstream PYD-NLR family proteins (7a, 29). Because cPOP2
associates with inflammasome-associated proteins, we investigated the effect of cPOP2 interaction with ASC or PAN1 on
PYD-mediated activation of caspase-1. The PYD signal transduction pathway was reconstituted in HEK293N cells, which
are deficient in endogenous components of this pathway. Coexpression of a constitutively active cryopyrin (R260W) (an

DISCUSSION
PYD-containing proteins have emerged as important mediators of inflammatory responses during host defense. The PYD
signal transduction pathway is triggered by the recognition of
specific pathogen-associated molecular patterns by PYD-containing pathogen recognition receptors (PYD-NLR family
proteins). Active PYD-NLRs recruit the adaptor protein
ASC to form specific inflammasomes, where activation of
pro-caspase-1 occurs (1, 22). To date, 16 human PYD-NLR
family members that form inflammasomes, including NALP1,
cryopyrin, and PAN1, have been recognized (31). However,
the exact molecular mechanism is currently poorly understood.
Specific ligands have thus far been identified only for cryopyrin
and NALP1 (1, 14, 15, 21–23, 32). Activation of PYD-NLR
family proteins results in oligomerization and recruitment of
the adaptor protein ASC via PYD-PYD interactions (22). Subsequently, ASC links pathogen recognition to downstream effector activation, including caspase-1-mediated processing and
secretion of IL-1␤, IL-18, and possibly IL-33 (20, 32, 35). Due
to the key role of the proinflammatory cytokine IL-1␤, its
generation and receptor binding are regulated at several key
areas in mammalian cells, including CARD-only proteins
(COPs) and IL-1RA (6, 7).
Our identification of cPOP2 in the present study is the first
indication of an endogenous inhibitor that controls generation
of IL-1␤ at the initiating step, directly at the level of inflammasome formation. Many of the PYD-containing proteins are
inducibly expressed in response to proinflammatory stimuli,
which is consistent with their proinflammatory function. Also,

HRP antibodies (Santa Cruz Biotechnology). (F) Direct interaction screen in yeast between cPOP2, ASC, and PYD-NLR family proteins. Yeast
two-hybrid assays were performed, scoring for activation of reporter genes encoding leucine (LEU2) and ␤-galactosidase (left panel). Plasmid
combinations that resulted in growth on leucine-deficient media within 4 days were scored as positive (right panel). The ␤-galactosidase activity
of each colony was also tested by filter assay and scored according to the time required to yield a blue color. cPOP2 was fused to the DNA binding
domain of LexA, and the PYD family proteins were fused to the activation domain of B42. The scoring was obtained by considering also the
reciprocal experiments, where cPOP2 was fused to the activation domain of B4, and the PYD family proteins were fused to the DNA binding
domain of LexA. In all cases, there was good agreement between data obtained by both experiments and also between the leucine and the
␤-galactosidase assays. Note that all plasmids contained only the PYD. Results for PAN2 (PYPAF4, NALP4, CLR19.5), PAN5 (NALP10,
PYNOD, NOD8, CLR11.1), PAN6 (PYPAF7, NALP12, Monarch-1, CLR19.3), PAN10 (PYPAF6, NALP11, NOD17, CLR19.6), NAC (CARD7,
DEFCAP, NALP1, CLR17.1), and cryopyrin (CIAS1, PYPAF1, NALP3, CLR1.1) are shown.
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FIG. 4. cPOP2 colocalizes with ASC and PAN1. Localization of epitope-tagged proteins was analyzed following transient transfection into
HEK293T cells. (A) Myc-tagged cPOP2 was immunostained with a rabbit polyclonal anti-myc antibody and visualized with an Alexa Fluor
546-conjugated anti-rabbit antibody. Actin was visualized with Alexa Fluor 488-conjugated phalloidin, and the nucleus was stained with ToPro-3.
Shown from left to right are myc-tagged cPOP2 (red), actin (green), the nucleus (blue), and a merged image. (B) Myc-tagged cPOP2 and
Flag-tagged ASC and were immunostained with rabbit polyclonal anti-myc and mouse monoclonal anti-Flag antibodies and visualized with Alexa
Fluor 546- and 488-conjugated anti-rabbit and anti-mouse antibodies, respectively. The nucleus was stained with ToPro-3. Shown from left to right
are myc-tagged cPOP2 (red), Flag-tagged ASC (green), the nucleus (blue), and a merged image. (C) Flag-tagged ASC was immunostained with
a mouse monoclonal anti-Flag antibody and visualized with Alexa Fluor 488-conjugated anti-mouse antibodies. The nucleus was stained with
ToPro-3. Shown from left to right are Flag-tagged ASC (green), actin (red), the nucleus (blue), and a merged image. (D) HA-tagged PAN1 was
immunostained with a rat polyclonal anti-HA antibody and visualized with Alexa Fluor 488-conjugated anti-rat antibodies. The nucleus was stained
with ToPro-3. Shown from left to right are HA-tagged PAN1 (green), actin (red), the nucleus (blue), and a merged image. (E) Myc-tagged cPOP2
and HA-tagged PAN1 were immunostained with rabbit polyclonal anti-myc and rat polyclonal anti-HA antibodies and visualized with Alexa Fluor
546- and 488-conjugated anti-rabbit and anti-rat antibodies, respectively. The nucleus was stained with ToPro-3. Shown from left to right are
myc-tagged cPOP2 (red), HA-tagged PAN1 (green), the nucleus (blue), and a merged image. (F) Myc-tagged cPOP2 and Flag-tagged ASC were
immunostained as described for panel B, and a representative cell that showed an ASC-formed speck was imaged. Shown from left to right are
myc-tagged cPOP2 (red), Flag-tagged ASC (green), the nucleus (blue), and a merged image. (G) Myc-tagged cPOP1 and Flag-tagged ASC
were immunostained as described above, and a representative cell that showed an ASC-formed speck was imaged. Shown from left to right are
myc-tagged cPOP1 (red), Flag-tagged ASC (green), the nucleus (blue), and a merged image.

other PYD-containing proteins, including pyrin and ASC, on
chromosome 16, cPOP2 is located on chromosome 3q28 alone.
cPOP2 displays 40% similarity with cPOP1. The observation
that cPOP2 also interacts with the PYD of PYD-NLR family
proteins provides additional insights into inflammasome formation and provides evidence that POPs interact not only with

cPOP2 was induced at the mRNA level in THP-1 monocytes in
response to lipopolysaccharide (LPS) stimulation, emphasizing
its role during inflammation. cPOP2 shows high similarity to
several PYD-NLR family proteins and ASC. The highest similarity is found to the PYD of PAN1, and cPOP2 is capable of
interacting with PAN1. Unlike cPOP1, which is clustered with
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to PAN1, and showed by coimmunoprecipitation and GST
pull-down experiments that the binding is mediated by PYDPYD interaction. We also expect that, based on yeast twohybrid assay results, PAN2, PAN6, and NALP1 are capable of
binding to cPOP2. Because we did not test all known PYDcontaining proteins, there might be more potential PYD-containing binding partners of cPOP2 (Table 1).
Binding of ASC to activated PYD-NLR family proteins results
in the formation of inflammasomes, which are required for activation of pro-caspase-1 (1, 22). Activation of pro-caspase-1 is
required for the processing, activation, and subsequent secretion of the proinflammatory cytokines pro-IL-1␤, pro-IL-18,
and pro-IL-33 (10, 26). cPOP2 impaired cryopyrin- and ASCmediated activation of pro-caspase-1, possibly explained by the
impaired formation of a cryopyrin-containing inflammasome
in the presence of cPOP2. cPOP2 also impaired activation of
pro-caspase-1 from a PAN1-containing inflammasome. Assembly of the cryopyrin-containing inflammasome is probably
blocked by binding to the PYD of ASC, whereas the PAN1containing inflammasome could be inhibited by simultaneously
blocking the PYDs of ASC and PAN1, which would impair the
recruitment of ASC to PAN1. The lower secretion of IL-1␤
from PAN1-expressing cells than from cryopyrin (R260W)expressing cells might be due to the higher activity of the
R260W-mutated cryopyrin protein, which is found in patients
with autoinflammatory disorders, as opposed to the wild-type
PAN1 protein (8). The sequence similarity between cPOP2
and cPOP1 is 40% and is 31 to 36% between cPOP2 and
vPOPs. Determination of whether cPOP2 and other POPs
function to “fine-tune” inflammasome assembly, prevent formation of specific inflammasomes, or participate in the termi-

FIG. 5. cPOP2 inhibits caspase-1-mediated processing of pro-IL1␤. HEK293N cells were transiently transfected in triplicate with expression constructs for pro-caspase-1, murine pro-IL-1␤, ASC, cPOP2,
and cryopyrin (R260W) (A) or PAN1 (B) (small dose, ⫹; medium
dose, ⫹⫹; and large dose, ⫹⫹⫹), as indicated. At 36 h posttransfection, secreted IL-1␤ was measured by ELISA (BD Pharmingen) from
normalized culture supernatants using a standard curve generated with
recombinant IL-1␤. Data are presented as picograms per milliliter of
secreted IL-1␤ (mean ⫾ standard deviation; n ⫽ 3). Transfected cells
were also directly lysed in Laemmli buffer and analyzed by SDS-PAGE
immunoblotting for the expression of all constructs, except pro-IL-1␤,
which was measured by ELISA.

TABLE 1. Similarity of cPOP2 to known human
PYD-containing proteinsa
Protein

the adaptor ASC but also directly with PYD-NLR family proteins to regulate activation of pro-caspase-1.
cPOP2 localizes to cytoplasmic vesicular structures but is
also found diffusely throughout the nucleus, similar to cPOP1
(29). ASC localizes to punctate structures in the cytoplasm, or
it forms characteristic cytoplasmic aggregates, referred to as
specks, to which ASC-interacting proteins, including cPOP1,
are frequently recruited. Some colocalization between cPOP2
and ASC can be observed in these vesicular structures in the
cytoplasm, but cPOP2 is not recruited to ASC-containing
specks, and specks are rarely formed when cPOP2 is coexpressed with ASC. One explanation might be that cPOP2 impairs the aggregation of ASC with other proteins that are
essential for speck formation, such as PYD-NLR family proteins. These differences further suggest a distinct functional
mechanism of cPOP1 compared to that of cPOP2. Expression
of PAN1 resulted in localization similar to that observed for
cPOP2, and both proteins efficiently colocalize when coexpressed. Like cPOP1 and vPOPs, cPOP2 also interacts with
ASC, the central adaptor protein of the PYD signal transduction pathway. We identified several PYD-NLR family members as potential binding partners for cPOP2, verified binding

cPOP2
(% sequence similarity)

PAN1.........................................................................................69
PAN7.........................................................................................50
PAN3.........................................................................................43
PAN6.........................................................................................42
PAN2.........................................................................................41
PAN12.......................................................................................40
cPOP1 .......................................................................................40
PAN8.........................................................................................38
AIM2.........................................................................................38
ASC ...........................................................................................37
Pyrin ..........................................................................................37
PAN5.........................................................................................37
IFIX...........................................................................................35
PAN9.........................................................................................34
PAN13.......................................................................................34
Cryopyrin ..................................................................................33
NALP1 ......................................................................................32
PAN10.......................................................................................32
PAN11.......................................................................................30
IFI16..........................................................................................30
PAN14.......................................................................................28
MNDA ......................................................................................27
PAN4.........................................................................................25
a
Separate Clustal W alignments of cPOP2 with the PYD of human PYDcontaining proteins were performed to calculate percent sequence similarity
(identical and conserved amino acid residues).
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nation of caspase-1 activation to prevent systemic inflammation will require further investigation.
In summary, our data provide evidence for the existence of
a second cellular POP, which binds to the PYD of ASC and
PAN1 and potentially to several other PYD-NLR proteins, to
impair inflammasome-mediated activation of pro-caspase-1
and subsequent processing and secretion of the proinflammatory cytokine IL-1␤. The existence of two different cellular
POPs might provide for more versatile regulation of inflammasome assembly and might allow specific PYD-NLR family
proteins to be suppressed and others to be spared.
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